Exercise in chronic kidney disease: impact on immunity and inflammation by J.L. Viana (7237922)
 
 
 
This item was submitted to Loughborough’s Institutional Repository 
(https://dspace.lboro.ac.uk/) by the author and is made available under the 
following Creative Commons Licence conditions. 
 
 
 
 
 
For the full text of this licence, please go to: 
http://creativecommons.org/licenses/by-nc-nd/2.5/ 
 
  
 
 
 
 
 
Exercise in Chronic Kidney Disease: 
Impact on Immunity and Inflammation 
 
 
 
 
 
By 
João Luís Campos Pereira da Cruz Viana 
 
 
 
 
 
A Doctoral Thesis 
 
Submitted in partial fulfilment of the requirements for the award of 
 Doctor of Philosophy of Loughborough University 
 
 
 
September 2011 
 
 
 
© João Luís Campos Pereira da Cruz Viana (2011) 
  
  
iii 
Abstract 
Chronic kidney disease (CKD) is associated with a complex state of immune 
dysfunction characterised by immune depression, which predisposes CKD patients to 
infections, and by immune activation resulting in inflammation, which is associated with 
cardiovascular disease among these patients. It has been suggested that regular 
moderate exercise may enhance immune function and exert anti-inflammatory effects. 
However, such effects are still unclear in CKD. Therefore, we investigated the effects 
of acute and regular (1-month and 6-months) moderate intensity aerobic exercise 
(walking) on measures of immunity and inflammation in pre-dialysis CKD patients. 
A single bout of walking exercise induced an overall immune and inflammatory 
response that was comparable to that observed in healthy individuals, with no 
indication of harmful effects to patients’ underlying state of immune dysfunction. Acute 
exercise induced a normal pattern of mobilisation of immune cells. Concerning immune 
cell function, acute exercise had no effect on T lymphocyte and monocyte activation, 
while it actually improved neutrophil responsiveness to a bacterial challenge in the 
recovery period. In addition, acute exercise induced a systemic anti-inflammatory 
environment, evidenced by the marked elevation in plasma IL-10 levels after exercise, 
which was most likely mediated by the observed increase in plasma IL-6 levels. 
Regular walking exercise exerted anti-inflammatory effects, with no apparent 
detrimental effects to patients’ immune and inflammatory status. Regular exercise led 
to improvements in the systemic inflammatory status (ratio of pro-inflammatory IL-6 to 
anti-inflammatory IL-10 cytokine levels) that were accompanied, and most likely 
mediated, by the observed down-regulation of T lymphocyte (only evident at 6-months) 
and monocyte activation. In addition, a reduction in IL-6 production in PBMC and whole 
blood cultures was also observed (only assessed at 1-month). Regular exercise had no 
effect on circulating immune cell numbers and neutrophil degranulation responses. 
These findings provide compelling evidence that walking exercise is safe from an 
immune and inflammatory perspective and has the potential to be an effective anti-
inflammatory therapy in pre-dialysis CKD patients. 
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2 
1.1. Rationale and structure of the thesis 
Chronic kidney disease (CKD) is associated with profound alterations of both 
innate and adaptive immunity, resulting in a complex and still not entirely 
understood state of immune dysfunction, wherein signs of immune depression 
and activation coexist. While immune depression contributes to the high 
incidence of infectious complications in patients with CKD, persistent immune 
activation leads to a state of chronic inflammation, which is associated with the 
increased risk of cardiovascular disease among these patients. Importantly, 
infection and cardiovascular disease are major causes of morbidity and 
mortality in CKD. Hence, the immune dysfunction that accompanies CKD 
represents a major target for therapeutic interventions aiming to improve 
outcome in CKD. Exercise has the potential to be one of such therapies. It has 
been suggested that regular engagement in moderate intensity exercise may 
enhance certain aspects of the immune function and may exert anti-
inflammatory effects, which is believed to contribute, at least in part, to the lower 
risk of infection and cardiovascular disease that is observed in physically active 
individuals in comparison with their sedentary counterparts. However, the 
impact of exercise on immune and inflammatory parameters has been poorly 
investigated in CKD. Apart from the potential benefits, given that exercise is 
being advocated into the routine clinical care of patients with CKD, it is also 
paramount to determine if exercise is safe to their underlying compromised 
immunity and inflammatory status. Therefore, this thesis focuses on the effects 
of acute and regular moderate intensity aerobic exercise on measures of 
immunity and inflammation in pre-dialysis CKD patients. 
In the present chapter, the relevant background information that supports this 
research is presented. Chapter 2 outlines the research design and describes 
the methods that were common to the main experimental research. Chapter 3 
presents a preliminary study conducted in healthy volunteers. The following 3 
chapters include the main research studies of this thesis. In Chapter 4, the 
effects of acute exercise are presented. Chapters 5 and 6 address the effects of 
regular exercise, reporting the findings from a 1-month uncontrolled trial and a 
6-months controlled trial, respectively. Finally, Chapter 7 provides a summary of 
the main findings of this thesis as well as their possible implications.  
  
3 
1.2. Background 
Chronic kidney disease: definition and classification 
CKD is a general term for heterogeneous disorders affecting the structure and 
function of the kidney. The variation in disease expression is related partially to 
cause and pathology, severity, and rate of progression (Levey & Coresh, 2011). 
CKD is defined as either kidney damage (proteinuria, haematuria or anatomical 
abnormality) or glomerular filtration rate (GFR)1 < 60 ml/min/1.73m2 present on 
at least 2 occasions for ≥ 3 months and it is classified into 5 stages as shown in 
Table 1.1 (National Collaborating Centre for Chronic Conditions, 2008). Stages 
3 to 5 may be defined solely by GFR, while stages 1 and 2 also require the 
presence of persistent proteinuria, albuminuria, haematuria or structural 
abnormalities. Established renal failure (stage 5), often called end-stage renal 
disease (ESRD), is an irreversible, long-term condition that may require renal 
replacement therapy (RRT), such as regular dialysis treatment or kidney 
transplantation, to maintain life. 
  
                                            
1 GFR is the best overall index of kidney function. Normal values, which are related to age, 
gender, and body size, are approximately 130 ml/min/1.73 m2 in young men and 120 
ml/min/1.73 m2 in young women. In the clinical setting, GFR is generally estimated (eGFR) 
based on serum creatinine and demographic data (age, gender and ethnic origin) with the 
Cockcroft-Gault or MDRD (modification of diet in renal disease) equations (Stevens et al., 
2006). The use of the abbreviated MDRD equation (Levey et al., 2000) is currently 
recommended in the UK to estimate GFR (National Collaborating Centre for Chronic 
Conditions, 2008). 
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Table 1.1. Stages of chronic kidney disease. Adapted from National Collaborating Centre for 
Chronic Conditions (2008)2. 
Stage* GFR 
ml/min/1.73 m2 
Description 
1 ≥ 90 Normal or increased GFR, with other evidence of kidney damage 
2 60 - 89 Slight decrease in GFR, with other evidence of kidney damage 
3A 45 - 59 
Moderate decrease in GFR, 
with or without other evidence of kidney damage 
3B 30 - 44 
4 15 - 29 Severe decrease in GFR, with or without other evidence of kidney damage 
5 < 15 (or dialysis) Established renal failure 
*Use the suffix (p) to denote the presence of proteinuria3 when staging CKD 
  
                                            
2 The 5-stage classification system for CKD was initially proposed by the US National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guidelines (National 
Kidney Foundation, 2002; Levey et al., 2003). This was adopted internationally (Levey et al., 
2005), including in the UK (Burden et al., 2005; Department of Health, 2005). However, the 
current UK National Institute for Health and Clinical Excellence (NICE) guidelines (National 
Collaborating Centre for Chronic Conditions, 2008) introduced some relevant modifications 
(subdivision of stage 3 CKD into 3A and 3B; adoption of a “(p)” suffix to denote proteinuria at all 
stages of CKD). In fact, the definition and classification for CKD has been subject of extensive 
debate over the last decade. Recently, Kidney disease: Improving Global Outcomes (KDIGO) 
hosted a conference on the topic and, based on data from collaborative meta-analysis 
examining the relationship between eGFR and albuminuria with mortality (all-cause and 
cardiovascular) and kidney outcomes (ESRD, acute kidney injury and progressive CKD) in 
diverse populations, it was recommended to retain the current definition and to modify the NFK-
KDOQI classification by adding albuminuria stage, subdivision of stage 3, and emphasizing 
clinical diagnosis (Levey et al., 2011). The CKD staging system is therefore expected to evolve 
in the very near future. 
3 Urinary albumin:creatinine ratio ≥ 30 mg/mmol or protein:creatinine ratio ≥ 50 mg/mmol. 
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Chronic kidney disease: prevalence 
Many countries have surveillance systems to monitor ESRD treated by RRT. 
Incidence and prevalence vary because of differences in underlying disease 
rates and treatment availability. In 2008, incidence was as high as 200 per 
million population (pmp) in many countries, and it was nearing 400 pmp in the 
US, Taiwan and some regions of Mexico. Of note, diabetes was the most 
common cause of ESRD is most countries, accounting for more than 40% of 
incident ESRD patients in several countries (US Renal Data System, 2010). In 
the UK, the number of adult patients starting RRT in 2008 was 108 pmp, with 
24% of these patients having diabetes as the primary renal diagnosis (Byrne et 
al., 2010a). Prevalence has been increasing worldwide. By the end of 2008, 
Taiwan and Japan continued to report the greatest rates, at 2,311 and 2,126 
pmp, respectively, followed by the US, at 1,752 pmp (US Renal Data System, 
2010). In the UK, there were 47,525 adult patients receiving RRT at the end of 
2008, equating to a prevalence of 774 pmp. This represents an annual increase 
in prevalence of approximately 4.4%, which has been fairly consistent over the 
last 10-15 years (Byrne et al., 2010b). Of note, over 2% of the total UK National 
Health Service (NHS) budget is spent on RRT, with costs of around £30,000 per 
year for each patient (Feehally et al., 2008).  
Whilst these numbers clearly show the importance of early identification of CKD 
and, where possible, the prevention of progression to ESRD, they do not 
illustrate the total burden of CKD because patients with CKD are more likely to 
die than to progress to ESRD. For example, Keith et al. (2004) followed a 
representative population of 27,998 patients who had eGFRs < 90 ml/min/1.73 
m2, and found that over a 5-year observation period, 1.1%, 1.3%, and 19.9% of, 
respectively, stage 2, 3, and 4 CKD patients progressed to RRT, while 19.5%, 
24.3%, and 45.7% died. It is also important to highlight that data from the 
number of people undergoing RRT cannot even been seen as a surrogate of 
the number of people with stage 5 CKD, which can be illustrated by the fact that 
the mean eGFR at initiation of RRT in 2008 in the UK was 8.6 ml/min/1.73 m2 
(Byrne et al., 2010a). 
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Estimates of the prevalence of early CKD have only started to emerge over the 
last decade. A systematic review of 26 population-based studies across 
Europe, Asia, North America, and Australia showed a median prevalence of 
CKD (defined as eGFR < 60 ml/min/1.73 m2) of 7.2% in patients older than 30 
years and a prevalence ranging from 23.4% to 35.8% in those older than 64 
years (Zhang & Rothenbacher, 2008). In the UK, a large primary care study 
suggested an age-standardised prevalence of stages 3-5 CKD (i.e., eGFR < 60 
ml/min/1.73 m2) of 8.5% (10.6% in females and 5.8% in males). In these 
patients, the age- and gender-adjusted odds ratio for hypertension, diabetes 
and cardiovascular disease were respectively, 2.1, 1.33, and 1.69. The 
prevalence of CKD rose dramatically with age (Stevens et al., 2007). It is 
noteworthy that these studies do not account for stages 1 and 2 CKD. Data 
from the National Health and Nutrition Examination Survey (NHANES) in the US 
not only provide estimates of the overall population prevalence of CKD (based 
on persistent albuminuria and decreased eGFR), but also indicate that the 
prevalence is increasing. Comparison of the prevalence of stages 1-4 CKD in 
NHANES 1998-1994 with NHANES 1999-2004 showed an increase in the 
population prevalence from 10.0 to 13.1%; the ageing population and increased 
prevalence of diabetes, hypertension, and obesity seem to account partially for 
this increase (Coresh et al., 2007). Although the estimates of the prevalence of 
CKD might be limited by selection bias, the criteria used to define CKD, and the 
methods used to estimate GFR and define kidney damage, they certainly raise 
much concern. CKD is now increasingly recognised as global public health 
problem (Levey et al., 2007). 
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Chronic kidney disease: causes and consequences 
CKD has many potential pathologic causes, which can be grouped into diabetic 
and non-diabetic diseases. The latter can be further subdivided into vascular, 
glomerular, tubulointerstitial and cystic diseases. Some selected examples of 
causes of CKD are provided in Figure 1.1. A variety of kidney injuries may 
eventually progress to CKD. Disease may start in the tubules and interstitium 
(tubulointerstitial diseases), in the glomeruli (glomerular diseases) or in the 
renal vascular tree (vascular diseases), as a consequence of (i) systemic 
diseases such as diabetes and hypertension, (ii) autoimmune reactions and 
renal transplant rejection, (iii) the action of drugs, toxins and metals, (iv) 
infections, (v) mechanical damage, (vi) ischemia, (vii) obstruction of the urinary 
tract, (viii) primary genetic alterations, and (ix) undetermined causes. Yet, a 
number of conditions, like genetic cystic diseases, affect renal structures and 
function through mostly unspecific mechanisms, progressing into CKD for 
undetermined reasons. Whether started as glomerular, tubular or vascular 
damage, chronic progression eventually converges into common renal 
histological and functional alterations affecting most renal structures, which lead 
to progressive and generalized fibrosis and glomerulosclerosis. Once initiated, 
kidney injury gradually aggravates even in the absence of the triggering insult. 
Consistently with a common chronic phenotype, CKD can be diagnosed 
independently from the knowledge of its cause. 
Diabetes and hypertension are the most common causes of CKD, and therefore 
major risk factors for the development and progression of CKD. According to 
the current UK NICE clinical guidelines, other risk factors for the development of 
CKD include: cardiovascular disease (ischaemic heart failure, peripheral 
vascular disease and cerebral vascular disease); structural renal tract disease, 
renal calculi or prostatic hypertrophy; multisystem diseases with potential kidney 
involvement (e.g. systemic lupus erythematosus); family history of stage 5 CKD 
or hereditary kidney disease. It is noteworthy that although age, gender, and 
ethnicity (South Asian and African Caribbean) might be associated with 
increased risk of CKD, their use as risk markers to test people for CKD is not 
recommended in the absence of the above risk factors. Likewise, in the 
absence of metabolic syndrome, diabetes or hypertension, obesity alone is not 
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recommended as a risk marker to test people for CKD (National Collaborating 
Centre for Chronic Conditions, 2008). 
 
Figure 1.1. Classification and selected examples of causes of chronic kidney disease. 
Reproduced from James et al. (2010). 
Although ESRD is traditionally considered the most serious outcome of CKD, 
complications of CKD can occur at any stage and often lead to death with no 
progression to ESRD. Epidemiological studies have consistently shown that 
people with diagnosed CKD have a far greater likelihood of cardiovascular 
death than progression to ESRD (Drey et al., 2003; Keith et al., 2004; John et 
al., 2004; Go et al., 2004; Foley et al., 2005). Hence, cardiovascular disease is 
regarded as the most frequent complication of CKD. Nevertheless, progressive 
deterioration of the excretory and endocrine functions of the kidney leads to 
complex disorders, which collectively constitute the uraemic syndrome. The 
clinical manifestations of uraemia are rather non-specific and may involve any 
system of the body. The principal clinical features of uraemia are summarised in 
Table 1.2. 
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Table 1.2. Principal clinical features of uraemia. Adapted from Almeras & Argilés (2009). 
Central nervous system 
Diurnal somnolence, night insomnia,  
disorders of the memory and the concentration, asthenia, 
headache, confusion… 
Peripheral nervous system Polyneuritis, restless legs, cramps 
Gastrointestinal Anorexia, nausea, gastroparesia, parotiditis, stomatitis 
Hematologic Anaemia, haemostasis disorders  
Cardiovascular Hypertension, atherosclerosis, coronary artery disease 
Skin Itching, skin dryness, calciphylaxis 
Endocrinology Growth impairment, impotence, infertility, sterility 
Osteoarticular Secondary hyperparathyroidism, osteomalacia,  β2-microglobulin amyloidosis 
Nutrition Malnutrition, weight loss, muscular catabolism 
Immunity Low response to vaccination, increased sensitivity to infectious diseases 
Biochemical Metabolic acidosis, hyperphosphatemia, hyperkaliemia 
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Immune dysfunction in chronic kidney disease 
CKD is associated with profound alterations in both branches of the immune 
system, innate and adaptive immunity, resulting in a complex state of immune 
dysfunction (Cohen et al., 1997; Girndt et al., 2001a; Pesanti, 2001; Amore & 
Coppo, 2002; Descamps-Latscha et al., 2002; Stenvinkel et al., 2005; 
Chonchol, 2006; Eleftheriadis et al., 2007; Hauser et al., 2008; Kato et al., 
2008). Research in this area is vast and the available data suggest that, in 
general, no aspect of the immune system is unaffected. An in-depth review of 
the literature on the immunological disturbances associated with CKD is beyond 
the scope of this thesis. Overall, the most striking observation is that patients 
with CKD paradoxically present signs of immune depression and immune 
activation. The aim of this section is to illustrate this, providing examples that 
are related to the measurements made in this thesis. In addition, the potential 
role of the immune dysfunction that accompanies CKD as an underlying cause 
of morbidity and mortality in these patients in emphasised. 
It should be acknowledged that a great part of the research in this area was 
conducted in ESRD, particularly haemodialysis, patients. Nevertheless, cross-
sectional studies that have included both patient groups have commonly 
reported intermediate disturbances in pre-dialysis patients in comparison with 
healthy subjects and haemodialysis patients. Moreover, the available 
correlational evidence between immunological alterations and kidney function 
further support this. Accordingly, it is well accepted that the immune alterations 
observed in CKD are multifactorial in origin and causes may include uraemia 
and its consequences and treatment, altered renal metabolism of 
immunologically active proteins, as well as specific effects of RRT, such as 
dialysis procedures. 
Historically, the observation that uraemic patients showed extended survival of 
skin grafts (Dammin et al., 1957) is often quoted as the first evidence of 
impaired host defences in CKD.  Subsequently, several clinical manifestations, 
including increased susceptibility for infections (discussed below), cutaneous 
anergy in delayed-type hypersensitivity reactions to a broad panel of antigens 
and poor responses to vaccination, have established that CKD is clearly 
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associated with an immunodeficient state (Cohen et al., 1997; Girndt et al., 
2001a; Pesanti, 2001; Eleftheriadis et al., 2007). 
Given the central role of the neutrophils in the host defence against infections, 
their defective function has been well characterised in the context of CKD, and 
neutrophil chemotaxis, adhesion, migration, phagocytosis and bactericidal 
activities (including degranulation), have all been shown to be impaired (Cohen 
et al., 1997; Pesanti, 2001). On the other hand, neutrophils from CKD patients 
show clear signs of activation (e.g. elevated plasma elastase levels) and are 
know to exist in a primed state, which is associated with the chronic state of 
inflammation and oxidative stress that accompanies the disease (Sela et al., 
2005; Costa et al., 2008; Caimi et al., 2009; Pereira et al., 2010; Polańska et al., 
2010). 
T lymphocyte functional defects have also been widely reported in patients with 
CKD. These include reduced proliferation, reduced production of interleukin 
(IL)-2 and interferon-ɣ and altered type 1/type 2 T helper cell balance (Girndt et 
al., 2001a; Stenvinkel et al., 2005; Eleftheriadis et al., 2007). On the other hand 
T lymphocytes from CKD patients show increased expression of early activation 
markers (e.g. CD69 and CD25) and heightened apoptotic turnover (Stachowski 
et al., 1991; Meier et al., 2000; Ankersmit et al., 2001; Meier et al., 2002; Moser 
et al., 2003; Meier et al., 2005; Litjens et al., 2006; Meier et al., 2007; 2008). 
It is currently recognised that the altered T lymphocyte function observed in 
CKD can be attributed to the defective interaction between the antigen-
presenting cell (APC), such as the monocyte, and the T lymphocyte (Girndt et 
al., 2001a; Eleftheriadis et al., 2007; Kato et al., 2008), because T cell activation 
is normal in the presence of APCs from healthy donors (Meuer et al., 1987; 
Girndt et al., 1993). T cell activation requires at least two signals. The 
interaction between major histocompatibility complex (MHC)-antigen peptide 
complex on the APC with the T cell receptor provides the first signal, while the 
second signal occurs through the interaction between co-stimulatory cell 
surface molecules (CD80/86) on the APC and CD28 on the T cell membrane. In 
the absence of co-stimulatory signalling, T cells fail to respond effectively and 
are rendered anergic (Sharpe & Freeman, 2002). The finding that the addition 
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of heterologous APCs or stimulating antibodies against CD28 led to a 
normalised proliferative function of T lymphocytes from haemodialysis patients 
indicated that a disturbance in the co-stimulatory signalling between 
CD80/CD86 and CD28 could be responsible for the impaired T lymphocyte 
responses in CKD patients (Girndt et al., 1993). Latter, flow cytometry revealed 
reduced monocyte CD86 expression in haemodialysis patients, which was 
associated with the clinical immune defect (lower levels in non-responders than 
responders to hepatitis B vaccination), as well as with the in vitro lymphocyte 
proliferative response. Importantly, monocyte CD86 expression was not 
reduced in pre-dialysis patients (Girndt et al., 2001b). On the other hand, 
monocytes from CKD patients are “pre-activated” and overproduce pro-
inflammatory cytokines, such as tumour necrosis factor (TNF)-α, IL-1β, IL-6 and 
IL-8 (Girndt et al., 1995; Higuchi et al., 1997; Morita et al., 1997; Girndt et al., 
1998; Sardenberg et al., 2004), which contributes to further impairment of the 
immune response (Girndt et al., 1995) but also to the chronic inflammation state 
that accompanies CKD (Stenvinkel et al., 2005; Carrero et al., 2008). 
At the systemic level, markers of a chronically activated immune system, such 
as pro-inflammatory cytokines and acute-phase proteins (e.g. C-reactive protein 
(CRP)), are a constant finding in patients with CKD and it is now well 
established that CKD is associated with persistent inflammation (Carrero & 
Stenvinkel, 2010). Several causes may contribute to the chronic inflammatory 
state of patients with CKD but the increased production of cytokines (immune 
activation) coupled with their reduced renal clearance (the kidney is the major 
site for elimination of many cytokines) are likely to play a prominent role. In 
addition, recurrent infections (reflecting immune depression) further activate the 
immune system and induce inflammation. Importantly, this chronic inflammation 
state is associated with cardiovascular disease and other uraemic 
complications, such as protein energy wasting (Stenvinkel et al., 1999; 2005; 
Carrero et al., 2009; Carrero & Stenvinkel, 2009). 
Cardiovascular disease is extremely prevalent and is the leading cause of death 
in CKD (Foley et al., 1998; Parfrey & Foley, 1999; Vanholder et al., 2005; 
Tonelli et al., 2006; Saran & DuBose, 2008; Stenvinkel, 2010). In fact, CKD is a 
risk factor for cardiovascular disease (Sarnak et al., 2003) and the presence of 
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CKD worsens outcomes of cardiovascular disease (Weiner et al., 2004; Herzog 
et al., 2011). The risk of cardiovascular events is already elevated at early 
stages of CKD and it increases continuously as kidney function deteriorates (Go 
et al., 2004). The involvement of immunity and inflammation in cardiovascular 
disease is well documented (Libby, 2002; Hansson, 2005; Libby et al., 2009; 
Hansson & Hermansson, 2011; Libby et al., 2011). In CKD, this association has 
also been subject of great interest. It is noteworthy that the cardiovascular 
disease risk factor profile appears to be different in CKD compared with the 
general population. While “traditional” risk factors only partially explain the 
increased cardiovascular disease risk, the “novel” risk factors, which include 
inflammation markers, are not only highly prevalent in CKD but also more 
strongly associated with cardiovascular disease in these patients than in the 
general population (Stenvinkel et al., 2008). Of interest, it has been recently 
shown that plasma IL-6 concentration independently predicted overall and 
cardiovascular mortality in a cohort of patients at different CKD stages with 
greater prediction power than CRP, TNF-α, and albumin (Barreto et al., 2010). 
This confirms the view that IL-6 is a better prognostic tool compared with other 
commonly measured markers of inflammation and oxidative stress previously 
reported in haemodialysis patients (Tripepi et al., 2005; Honda et al., 2006; 
Zoccali et al., 2006; Pachaly et al., 2008; Wetmore et al., 2008). 
Although having received considerably less attention than cardiovascular 
disease, infectious complications are also a major cause of morbidity and 
mortality in CKD (Naqvi & Collins, 2006; Levey et al., 2007; Foley, 2007; 2008; 
Dalrymple & Go, 2008). Infection has consistently ranked second to 
cardiovascular disease in causes of death in ESRD patients treated by dialysis. 
In the UK, infection and cardiovascular disease accounted, respectively, for 
17% and 29% of deaths in the prevalent dialysis population in 2008 (Ansell et 
al., 2010). Mortality rates secondary to sepsis and pneumonia are markedly 
higher in dialysis patients compared with the general population (Sarnak & 
Jaber, 2000; 2001). The epidemiology of infections at earlier stages of CKD has 
been less investigated but there is also evidence that pre-dialysis CKD are at 
increased risk for infections. Data from the US Renal Data System indicates 
that patients with diagnosed CKD have substantially higher rates of 
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hospitalisation for pneumonia, bacteraemia/sepsis and urinary tract infections, 
compared with patients without diagnosed CKD. In addition, patients with CKD 
have longer lengths of hospital stay during infection-related admissions 
compared with patients without CKD (Naqvi & Collins, 2006; Dalrymple & Go, 
2008). Recent studies have confirmed the higher risk of infection-related 
hospitalisation and mortality among pre-dialysis CKD patients, and as expected 
it appears that the risk increases as kidney function decreases (James et al., 
2008; 2009; Wang et al., 2011). Various factors may predispose patients with 
CKD to infectious complications (Dalrymple & Go, 2008) but the alterations in 
the immune system (discussed above) are the obvious major culprit. On the 
other hand, infections are typical inflammatory states, and accumulating 
evidence indicates that they are a common antecedent of new cardiovascular 
events in dialysis patients (Stenvinkel et al., 2002a; Zoccali et al., 2003; Ishani 
et al., 2005; Foley, 2006; Schiavoni et al., 2010; Dalrymple et al., 2011). The 
association between infection and cardiovascular disease is also documented 
in the general population (Kiechl et al., 2001; Nieto, 2002; Smeeth et al., 2004). 
In summary, CKD is associated with a complex state of immune dysfunction. 
While immune depression contributes to the high risk of infection, immune 
activation leads to a state of chronic inflammation that contributes to the high 
risk of cardiovascular disease. In addition, recurrent infections also contribute to 
cardiovascular disease (probably through inducing chronic inflammation). On 
the other hand, persistent immune activation further worsens the already 
compromised immune response. Remarkably, infection and cardiovascular 
disease are major causes of morbidity and mortality in CKD. In this context it is 
worth mentioning a unique study in haemodialysis patients that, although not 
addressing the specific mortality causes, demonstrated that higher levels of 
circulating pro-inflammatory cytokines were associated with mortality, while 
immune parameters reflecting improved T cell function were associated with 
survival, independent of other medical risk factors (Kimmel et al., 1998). Clearly, 
the immune dysfunction that accompanies CKD represents a major target for 
therapeutic interventions aiming to improve outcome in CKD.  
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Can regular exercise help? 
Physically active individuals are at lower risk of infection, particularly of the 
upper respiratory tract, in comparison with their sedentary counterparts 
(Matthews et al., 2002; Kostka & Praczko, 2007; Kostka et al., 2008; Nieman, 
2011; Fondell et al., 2011). It should be acknowledged, however, that most of 
these studies rely on subject self-reported infection symptoms and only focus 
on upper respiratory tract infections. Evidence from studies of diagnosed and 
more severe infection is less compelling but also suggests that physical activity 
might confer some protection (Baik et al., 2000; Leveille et al., 2000; Neuman et 
al., 2010). Although a direct link still remains to be determined, the lower risk of 
infection in physically active individuals has been attributed, at least in part, to 
the effects of regular exercise on the immune system because several cross-
sectional studies (physically active vs. sedentary) and some limited evidence 
from longitudinal studies (exercise intervention) support the idea that regular 
moderate intensity exercise may enhance certain aspects of immune function 
(Woods et al., 2002; Kohut & Senchina, 2004; Senchina & Kohut, 2007; 
Haaland et al., 2008; Martin et al., 2009; Nieman, 2011). 
It is well established that physical activity or physical fitness are associated with 
reduced cardiovascular disease risk (Berlin & Colditz, 1990; Erikssen, 2001; 
Wannamethee & Shaper, 2001; Blair et al., 2001; Tanasescu et al., 2002; Batty 
& Lee, 2004; Blair & Morris, 2009). Large cohort studies consistently show an 
inverse association between markers of systemic inflammation and physical 
activity or fitness, and data from several exercise intervention studies support 
that regular moderate intensity exercise reduces inflammation (Kasapis & 
Thompson, 2005; Bruunsgaard, 2005; Plaisance & Grandjean, 2006; Nicklas & 
Brinkley, 2009; Beavers et al., 2010). Thus, it is now widely accepted that 
regular moderate intensity exercise reduces the risk of cardiovascular disease, 
in part because exercise exerts anti-inflammatory effects (Petersen & Pedersen, 
2005; Wilund, 2007; Handschin & Spiegelman, 2008; Gleeson et al., 2011). 
Hence, regular exercise has the potential to counteract the immune dysfunction 
state that accompanies CKD and in this way contribute to a reduced risk of 
infection and cardiovascular disease.  
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Has this already been investigated in chronic kidney disease? 
Although the potential anti-inflammatory effects of regular exercise in CKD 
patients have been recognised, research in this area is currently very limited, 
particularly in pre-dialysis CKD patients (Bronas, 2009). Published exercise 
intervention studies reporting effects of regular exercise on markers of systemic 
inflammation in patients with CKD are listed in Table 1.3. Only 2 studies have 
focused on pre-dialysis patients (Castaneda et al., 2004; Leehey et al., 2009). 
Castaneda et al. (2004) reported that 12-weeks of resistance exercise training 
reduced CRP and IL-6 levels, while Leehey et al. (2009) reported that 24-weeks 
of aerobic exercise training had no effect on CRP levels. Studies on 
haemodialysis patients have also yielded conflicting results. Exercise training 
reduced CRP levels in 5 studies (Załuska et al., 2002; Nindl et al., 2004; 
Cheema et al., 2007a; Afshar et al., 2010; 2011), while the other 3 reports have 
found no effect (Kopple et al., 2007; Toussaint et al., 2008; Wilund et al., 2010). 
Besides the lack of effect on CRP levels, Kopple et al. (2007) reported no effect 
of approximately 21-weeks of aerobic (intradialytic) or resistance (before 
dialysis) training or both on IL-6 and TNF-α levels, whilst Wilund et al. (2010) 
also reported no effect of 4-months of intradialytic aerobic exercise on IL-6 
levels. However, in the study of Kopple et al. (2007) a trend for a reduction in 
CRP and IL-6 levels was apparent following aerobic exercise training but not 
after resistance exercise training or a combination of both regimens. 
Intriguingly, Cheema et al. (2011) have recently reported that 12-weeks of 
intradialytic progressive resistance training had no effect on TNF-α, IL-1β, IL-6, 
IL-8, IL-10 and IL-12 levels, while a reduction in CRP levels had been 
previously reported (Cheema et al., 2007a). Differences between the studies 
described above, including the length of the intervention, and the exercise 
regimen used make comparisons difficult, but is important to highlight that most 
of these studies had small sample sizes and systemic inflammatory markers 
have been secondary study outcomes. Apart from inflammatory markers, there 
is only a single report addressing the impact of regular exercise on immune 
parameters in haemodialysis patients (Daniilidis et al., 2004). These authors 
investigated the effects of a 6-months, mostly aerobic, exercise programme on 
some serum immunoglobulins (Igs), complement factors and ILs, as well as T 
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lymphocyte subsets (exercise group n=18 vs. control group n=14). Although the 
authors noted a few non-significant differences, the only significant difference 
reported in immune parameters was a reduction in serum IgA in the exercise 
group. In addition, it was found that patients in the exercise group had fewer 
upper respiratory tract infections than patients in the control group over the 
study period (6 out 18 patients in the exercise group vs. 8 out 14 patients in the 
control group, P < 0.05). The authors attributed the reduction in serum IgA to 
this low incidence of upper respiratory tract infection. Data from this study is 
obviously very limited.  
Clearly, the impact of regular exercise on immune and inflammatory parameters 
in patients with CKD still remains uncertain. 
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Table 1.3. Exercise intervention studies reporting effects of regular exercise on markers 
of systemic inflammation in pre-dialysis and haemodialysis patients. 
Study details Outcome 
Pre-dialysis 
(Castaneda et al., 2004)  
12-weeks resistance training (n=14) or control (n=12) ↓ CRP 
↓ IL-6 
(Leehey et al., 2009)  
24-weeks aerobic training (n=7) or control (n=4) NS CRP 
Haemodialysis 
(Załuska et al., 2002)  
6-months intradialytic cycling (n=10) ↓ CRP 
(Nindl et al., 2004)  
12-weeks resistance training (n=10) ↓ CRP 
(Cheema et al., 2007a)*  
12-weeks intradialytic resistance training (n=24) or control (n=25) ↓ CRP 
(Cheema et al., 2011)*  
12-weeks intradialytic resistance training (n=13) or control (n=12) 
 
NS TNF-α 
NS IL-1β 
NS IL-6 
NS IL-8,  
NS IL-10 
NS IL-12 
(Kopple et al., 2007)  
21-weeks intradialytic cycling (n=10) or resistance training (n=15) or 
intradialytic cycling + resistance training (n=12) or control (n=14) 
NS CRP 
NS TNF-α 
NS IL-6 
(Toussaint et al., 2008)  
3-months intradialytic cycling + 3-months control (crossover; n=9+10) NS CRP 
(Wilund et al., 2010)  
4-months intradialytic cycling (n=8) or control (n=9) NS CRP 
NS IL-6 
(Afshar et al., 2010)  
8-weeks intradialytic cycling (n=7) or intradialytic resistance training 
(n=7) or control (n=7) 
↓ CRP 
(Afshar et al., 2011)  
8-weeks intradialytic cycling (n=14) or control (n=14) ↓ CRP 
*Same study but different number of samples assayed CRP: C-reactive protein 
IL: interleukin 
TNF: tumour necrosis factor 
 
  
 
 
 
 
 
 Chapter 2
General Methods 
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2.1. Research design 
The studies reported in this thesis were part of a collaborative research project 
between Loughborough University and Leicester General Hospital entitled “the 
effect of acidosis correction and exercise on tissue wasting and immune 
function in renal patients”, which received prior approval by the UK National 
Health Service Research Ethics Committee. Originally this project was divided 
in three parts as follows: 1) pilot study of 1-month duration in patients receiving 
renal replacement therapy (RRT) by peritoneal dialysis (PD); 2) pilot study of 1-
month duration on patients with chronic kidney disease (CKD) who have not yet 
started RRT by dialysis; 3) main study of 6-months duration on PD patients or 
pre-dialysis CKD patients (depending on the outcome of studies 1 and 2). 
However, due to difficulties in recruiting PD patients the two pilot studies were 
merged into a single pilot study of 1-month duration for which both PD and pre-
dialysis CKD patients were recruited. In addition, the main study of 6-months 
duration was conducted on pre-dialysis CKD patients. 
Patient recruitment was conducted by a nephrologist. Exercise testing and 
prescription were conducted by myself and another PhD student (whose 
research focused on muscle physiology). Blood sampling was carried out by 
myself or a nephrologist. All the analytical procedures reported in this thesis 
(including the methods development) were conducted by myself alone. 
All patients were recruited from Nephrology Outpatient clinics at Leicester 
General Hospital. Exclusion criteria were age <18 years, pregnancy, and 
orthopaedic or cardiovascular disability that severely limited exercise capacity. 
Potential participants were fully informed both verbally and in writing about the 
purpose of the study and the experimental procedures to be performed, and 
were given at least 24 h to reach a decision. Patients willing to participate were 
then asked to provide written informed consent and underwent a medical 
examination to ensure their ability to participate in the study. 
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1-month uncontrolled study (Chapter 5) 
Both PD patients and pre-dialysis CKD patients were recruited for the 1-month 
study. Thirty-three patients, including 7 PD patients and 26 pre-dialysis CKD 
patients, provided written informed consent to participate. A total of 25 patients, 
including 4 PD patients, completed the study. However, for the purpose of 
sample homogeneity, patients on PD were excluded from the analysis 
presented in this thesis. Therefore a total of 21 pre-dialysis patients were 
included in this study. All patients were assigned to an exercise programme of 
1-month duration as detailed below. In addition, 10 of the patients included in 
this study were randomised to receive sufficient additional oral bicarbonate to 
raise plasma bicarbonate to approximately 29 mmol/l, while the others 
continued with their usual bicarbonate therapy (target plasma bicarbonate 24 
mmol/l). Investigating the effect of the additional bicarbonate therapy is however 
beyond the scope of this thesis and therefore data from all the patients that 
participated in this study were pooled together. Nevertheless, a potential 
confounding effect from this therapy is addressed and data from patients on 
standard vs. additional bicarbonate therapy were also examined separately. 
All patients performed an exercise test as described below at baseline and after 
1-month of regular exercise. Resting venous blood samples were obtained on 
both occasions. Patients were asked to refrain from exercise during the 
preceding 24 h. 
6-months controlled study (Chapter 6) 
Forty pre-dialysis CKD patients were recruited for the 6-months study. The first 
20 patients recruited were assigned to an exercise programme of 6-months 
duration as detailed below (15 of these patients were kept from the 1-month 
study, i.e. engaged in an additional period of 5-months of exercise training), 
while the other 20 patients continued with their habitual physical activity. In 
addition, 10 patients on each group were randomised to receive additional oral 
bicarbonate (target plasma bicarbonate 29 mmol/l) or to continue with their 
usual bicarbonate therapy (target plasma bicarbonate 24 mmol/l). Therefore, 
patients were assigned to four groups as follows: 1) control group (no exercise 
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and no additional bicarbonate therapy); 2) additional bicarbonate therapy only 
(no exercise); 3) exercise only (no additional bicarbonate therapy); and 4) 
exercise and additional bicarbonate therapy. However, as the scope of this 
thesis is to investigate the effect of exercise, the groups were collapsed 
irrespective of the additional bicarbonate therapy to form one exercise group 
and one non-exercise control group. Nevertheless, a potential confounding 
effect from the additional bicarbonate therapy was addressed by examining the 
data from patients in the exercise group as standard vs. additional bicarbonate 
therapy.  
All patients performed an exercise test as described below at baseline and after 
6-months. Resting venous blood samples were obtained on both occasions. 
Patients were asked to refrain from exercise during the preceding 24 h. 
Acute study (Chapter 4) 
In addition to the above studies, the effect of acute exercise was also 
investigated. For this purpose two further venous blood samples were collected 
immediately after and 1 h after the baseline exercise test from all the patients 
that participated in the 1-month study but analysis were only conducted on 
patients that completed the study. However, patients on PD (n=4) and patients 
on immunosuppressive therapy (n=5) were excluded. In addition, 1 further 
patient was excluded because blood samples were not obtained following 
exercise. Therefore, a total of 15 pre-dialysis patients were included in this 
study. 
Pilot study (Chapter 3) 
Before conducting the studies in patients with CKD, a preliminary investigation 
was conducted in healthy volunteers. However, as some procedures were still 
in development at that time, there are relevant disparities in relation to the 
procedures described here. Therefore, a full description of the methods used in 
that study is included in the respective individual chapter for clarity. 
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2.2. Exercise testing 
At baseline, the exercise test consisted of 30 min walking on a motorised 
treadmill at a 1% gradient and at a speed that elicited a rating of perceived 
exertion (RPE) in the range of 12-14 (“somewhat hard”) according to Borg 
(1982). RPE was recorded every 2 min and the treadmill speed was adjusted to 
maintain the RPE in the target range. The treadmill speed was also recorded 
every 2 min. At the end of each study (1-month or 6-months), the exercise test 
was repeated using exactly the same treadmill speed profile (i.e. same absolute 
exercise intensity) and the RPE response was recorded every 2 min. 
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2.3. Exercise programme 
All patients that participated in the 1-month study and patients in the exercise 
group from the 6-months study were prescribed a home-based exercise 
programme, which consisted of at least 30 min walking, 5 times per week at a 
RPE in the range of 12-14 (“somewhat hard”) for the total duration of the 
respective study (1-month or 6-months). As most CKD patients receive β-
blocker therapy an overall heart rate (HR) range could not be used to prescribe 
the exercise intensity. Nevertheless, an individual HR range was established 
during the baseline exercise test by recording the HR response at the required 
RPE target range and this was also provided to each patient in conjunction with 
an HR monitor. For monitoring purposes, patients were asked to keep exercise 
diaries where they recorded the duration and the overall RPE of each exercise 
session. In addition, patients were requested to attend the hospital gym once 
per month for a supervised exercise session to ensure compliance and to make 
any necessary adjustments to the exercise programme. 
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2.4. Blood sampling, handling and analysis 
All venous blood samples, approximately 20 ml each, were collected by 
venepuncture from an antecubital vein using a 21 g butterfly needle cannula 
and a dry syringe, and immediately dispensed into two separate tubes as 
follows: approximately 7.5 ml into one S-Monovette tube (Sarstedt, Leicester, 
UK) containing K3EDTA (1.6 mg/ml) and approximately 12.5 ml into one 
universal tube containing heparin (16 units/ml). 
Haematology 
For the following analysis K3EDTA-treated whole blood was used. Haemoglobin 
concentration was determined in duplicate using the cyanmethaemoglobin 
method. Haematocrit was determined by measuring packed cell volumes in 
triplicate on a microhaematocrit centrifuge. Plasma volume of resting blood 
samples was estimated from the haematocrit values. Plasma volume changes 
in post-exercise blood samples were estimated from the haemoglobin and 
haematocrit values according to Dill & Costill (1974) and all cell counts and 
plasma measurements were corrected for these changes relative to the resting 
blood sample in the acute study only (Chapter 4). Total and differential 
leukocyte counts were determined using an automated haematology analyser 
(Coulter Ac·T 5diff OV, Beckman Coulter, High Wycombe, UK). 
Plasma lactate 
Duplicate 100 µl aliquots of K3EDTA-treated whole blood were immediately 
deproteinised in 1ml ice-cold 0.3 M perchloric acid. These tubes were then 
centrifuged and the resulting supernatant was stored at -80°C for later 
fluorometric determination of plasma lactate concentration using the method 
described by Maughan (1982). 
Plasma markers of systemic inflammation 
The remaining K3EDTA-treated whole blood was centrifuged at 1,500 g for 10 
min in a refrigerated centrifuge at 4ºC. The plasma obtained was aliquoted into 
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eppendorf tubes at 0.5 ml/tube and stored at -80ºC for later determination of 
plasma concentrations of interleukin-6 (IL-6), interleukin-10 (IL-10), soluble 
tumour necrosis factor receptor I (sTNF-RI), soluble tumour necrosis factor 
receptor II (sTNF-RII) and C-reactive protein (CRP) by enzyme-linked 
immunosorbent assay (ELISA) as detailed in Section 2.5. 
Neutrophil degranulation 
1 ml of heparinised whole blood was immediately added to an eppendorf tube 
containing 50 µl of 10 mg/ml bacterial extract solution (Stimulant, 84015, 
Sigma-Aldrich, Gillingham, Dorset, UK). The tube was sealed and blood and 
stimulant were mixed by gentle inversion and then incubated for 1 h at 37ºC, 
being gently mixed again after 30 min. After incubation, the mixture was 
centrifuged for 2 min at 12,400 g and the resulting supernatant was stored at -
80ºC prior to analysis. A further 1 ml of heparinised whole blood was 
centrifuged at 1,500 g for 10 min in a refrigerated centrifuge at 4ºC and the 
plasma obtained was stored at -80ºC prior to analysis. Polymorphonuclear 
(PMN) cell elastase concentration was determined in both bacterially-stimulated 
and unstimulated (plasma elastase) samples using a commercially available 
ELISA kit (RD191021100, BioVendor GmbH, Heidelberg, Germany), according 
to the manufacturer’s instructions. Bacterially-stimulated and unstimulated 
samples were pre-diluted 1:1000 and 1:50 in the dilution buffer provided, 
respectively. All samples were assayed in duplicate and all samples from the 
same patient were assayed in the same plate. The inter- and intra-assay 
coefficient of variation (CV) for all elastase ELISAs were 2.3% and 2.9%, 
respectively. Total bacterially-stimulated elastase release was calculated by 
subtracting plasma elastase concentration from the bacterially-stimulated 
elastase concentration. This was then divided by the neutrophil count to obtain 
the bacterially-stimulated elastase release per neutrophil. 
T-lymphocyte and monocyte activation 
200 µl aliquots of heparinised whole blood were cultured in 12 x 75 mm 
polystyrene round bottom tubes with caps (BD Biosciences, Oxford, UK) with no 
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additive (unstimulated condition) or with 1 µg/ml staphylococcal enterotoxin B 
(SEB, S4881, Sigma-Aldrich, Gillingham, Dorset, UK). Triplicate tubes were set 
up for each condition and incubated at 37ºC in a humid 5% CO2 atmosphere for 
20 h. After incubation, the whole blood aliquots were labelled in the respective 
culture tubes with cocktails of fluorochrome conjugated mouse monoclonal 
antibodies against human cell surface markers (all from BD Biosciences, 
Oxford, UK) as follows (one per condition): 1) lymphocyte surface markers: 
FITC conjugated anti-CD4 (555346), PE conjugated anti-CD69 (555531) and 
PE-Cy5 conjugated anti-CD8 (555368); 2) monocyte surface markers: FITC 
conjugated anti-CD14 (555397), PE conjugated anti-CD86 (555658) and PerCP 
conjugated anti-HLA-DR (347402); the remaining tube was left unstained. 
Labelling was carried out on ice for 20 min, and this was followed by erythrocyte 
lysis and leukocyte fixation, achieved by incubating samples for 10 min in the 
dark with FACS Lysing solution (BD Biosciences, Oxford, UK). Leukocytes were 
subsequently washed twice in phosphate-buffered saline (PBS) containing 
0.1% bovine serum albumin (BSA) and 2 mM EDTA and resuspended again in 
the same buffer for immediate flow cytometer acquisition. Samples were 
acquired on a flow cytometer (BD FACSCalibur, Oxford, UK) equipped with 
CellQuest software package (BD Biosciences, Oxford, UK). For samples 
labelled with lymphocyte markers, side scatter (SSC) vs. forward scatter (FSC) 
plots were used to gate on the lymphocyte population by morphology, and 
30,000 lymphocytes were acquired per sample. For samples labelled with 
monocyte markers, 100,000 total cells were acquired per sample. Negative 
unstained control samples were also acquired. Software generated data files 
were stored for later analysis as detailed in Section 2.6. Flow cytometer settings 
were set up at the beginning of the study and kept constant for each patient 
samples. 
Peripheral blood mononuclear cell cytokine production 
Peripheral blood mononuclear cells (PBMCs) were separated from 
approximately 5 ml of heparinised whole blood by density gradient 
centrifugation at 400 g for 30 min on Histopaque 1077 (Sigma-Aldrich, 
Gillingham, Dorset, UK). Cells were subsequently washed twice in sterile 
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isotonic salt solution (HBSS, Invitrogen, Paisley, UK, supplemented with 100 
units/ml penicillin, 100 µg/ml streptomycin and 10 mM HEPES) and 
resuspended in culture medium (RPMI 1640 with 2 mM L-Glutamine, Invitrogen, 
Paisley, UK, supplemented with 10% fetal calf serum (FCS), 100 units/ml 
penicillin, 100 µg/ml streptomycin and 50 mM HEPES). PBMCs were counted 
on a haemocytometer, and cell concentration adjusted to 106 PBMCs/ml. 
Aliquots of cells (200 µl) were cultured in flat bottom 96-well microplates in 
culture medium alone (unstimulated condition) or with 1 µg/ml SEB (S4881, 
Sigma-Aldrich, Gillingham, Dorset, UK). Quadruplicate wells were set up for 
each condition, and incubated at 37°C in a humid 5% CO2 atmosphere for 8 
days. After incubation, the microplates were centrifuged at 300 g for 10 min, 
and the resulting supernatants harvested and stored at -80ºC for later 
determination of IL-6 and IL-10 concentrations by ELISA (detailed in Section 
2.5). SEB-stimulated PBMCs IL-6 and IL-10 production were calculated by 
subtracting the respective unstimulated concentrations from the SEB-stimulated 
concentrations. 
Whole blood cytokine production 
IL-6 concentration was also determined in the stimulated samples obtained as 
described above for the neutrophil degranulation assay by ELISA (using the 
method developed for culture supernatants detailed in Section 2.5). Bacterially-
stimulated whole blood IL-6 production was calculated by subtracting plasma 
IL-6 concentration from the bacterially-stimulated concentration. 
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2.5.  Enzyme-linked immunosorbent assays 
Interleukin-6 and interleukin-10 assays 
ELISAs for detection of IL-6 and IL-10 levels in plasma samples were 
developed and optimised using the capture and detection antibodies included in 
BD OptEIA ELISA sets (IL-6: 555220 and IL-10: 555157, BD Biosciences, 
Oxford, UK), National Institute for Biological Standards and Control (NIBSC) 
standards (IL-6: 89/548 and IL-10: 93/722, NIBSC, Potters Bar, Hertfordshire, 
UK) and an ELISA Amplification System (19589-109, Invitrogen, Paisley, UK). 
96-well ELISA plates (Nunc-Immuno 439454 MaxiSorp) were coated with the 
anti-human IL-6 or IL-10 capture antibody diluted at the lot-specific 
recommended dilution in 0.05 M sodium carbonate buffer at 100 µl/well, sealed 
and incubated overnight at 4ºC. The next day, plates were washed 3 times (at 
300 µl/well) with tris-buffered saline (TBS) with 0.05% Tween 20 (TBS-T) and 
blocked for 1 h at room temperature with 5% BSA (Probumin, Millipore, Illinois, 
USA) in TBS at 200 µl/well. Plates were subsequently washed 3 times with 
TBS-T and duplicates of samples (neat), standards (serially diluted in TBS with 
10% FCS from 200 pg/ml to 0.78 pg/ml) and blank (TBS with 10% FCS) were 
added at 100 µl/well. Plates were again sealed and incubated overnight at 4ºC. 
The following day, plates were washed 6 times with TBS-T and the biotinylated 
anti-human IL-6 or IL-10 detection antibody diluted at the lot-specific 
recommended dilution in TBS-T with 1% BSA was added at 100 µl/well. Plates 
were incubated for 2 h at room temperature and subsequently washed 7 times 
with 30 seconds soaks with TBS-T. Streptavidin (SAv)-alkaline phosphatase 
conjugate (554065, BD Biosciences, Oxford, UK) diluted 1:2000 in TBS with 1% 
BSA was then added at 100 µl/well and plates were incubated for a further 1 h 
at room temperature. After a final wash (7 times with 30 seconds soaks with 
TBS-T), the substrate and amplifier solutions (prepared according to the 
manufacturer’s instructions) were added (at 50 µl/well each) in two subsequent 
steps (incubated for approximately 25 min at 25ºC each). The reaction was 
stopped with 0.3 M sulphuric acid (at 50 µl/well) and the plates were 
immediately read at 490 nm. Samples’ concentrations were determined by 
relation to a standard curve generated by plotting the standards’ absorbances 
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against the log of the standards’ concentrations using a four-parameter logistic 
equation (Graphpad Prism version 5, Graphpad Software, La Jolla, CA, USA). 
All samples from the same patient were assayed on the same plate. Duplicates 
with a CV above 10% were repeated. The inter- and intra-assay CV were 4.4% 
and 3.4% for IL-6 and 5.1% and 3.8% for IL-10, respectively. 
ELISAs for detection of IL-6 and IL-10 levels in culture supernatants were 
developed and optimised using BD OptEIA ELISA sets (IL-6: 555220 and IL-10: 
555157, BD Biosciences, Oxford, UK), which include capture and detection 
antibodies, SAv-horseradish peroxidase (HRP) conjugate and standards. 96-
well ELISA plates (Nunc-Immuno 439454 MaxiSorp) were coated with the anti-
human IL-6 or IL-10 capture antibody diluted at the lot-specific recommended 
dilution in 0.05 M sodium carbonate buffer at 65 µl/well, sealed and incubated 
overnight at 4ºC. The next day, plates were washed 3 times (at 300 µl/well) with 
PBS with 0.05% Tween 20 (PBS-T.05) and blocked for 1 h at room temperature 
with 10% FCS in PBS at 100 µl/well. Plates were subsequently washed 3 times 
with PBS-T.05 and duplicates of samples (neat and diluted 1:5 in PBS for 
unstimulated and SEB-stimulated samples, respectively), standards (serially 
diluted in PBS with 10% FCS from 600 pg/ml to 0.6 pg/ml and 1 ng/ml to 1 
pg/ml for IL-6 and IL-10 assays, respectively) and blank (PBS with 10% FCS) 
were added at 50 µl/well. Plates were again sealed and incubated overnight at 
4ºC. The following day, plates were washed 5 times with PBS-T.05 and the 
working detector (biotinylated anti-human IL-6 or IL-10 detection antibody + 
SAv-HRP, both diluted at the lot-specific recommended dilutions in PBS with 
10% FCS) was added at 50 µl/well. Plates were incubated for 1 h 30 min at 
room temperature and subsequently washed 7 times with 30 seconds soaks 
with PBS-T.05. Tetramethylbenzidine (TMB) substrate (1-Step Ultra TMB-
ELISA, Pierce, Illinois, USA) was then added at 50 µl/well and plates were 
incubated for 30 min in the dark at room temperature. The reaction was stopped 
with 2 M sulphuric acid (50 µl/well) and the plates were immediately read at 450 
nm. Samples’ concentrations were determined by relation to a standard curve 
generated by plotting the log of the standards’ absorbances against the log of 
the standards’ concentrations using a four-parameter logistic equation 
(Graphpad Prism version 5, Graphpad Software, La Jolla, CA, USA). All 
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samples from the same patient were assayed on the same plate. Duplicates 
with a CV above 10% were repeated, as were samples that fell beyond the 
dynamic range of each assay standard curve (adjusting the dilution factor 
accordingly). The inter- and intra-assay CV were 3.8% and 2.5% for IL-6 and 
5.0% and 3.4% for IL-10, respectively. 
Soluble tumour necrosis factor receptors I and II assays 
ELISAs for detection of sTNF-RI and sTNF-RII in plasma samples were 
developed and optimised using the capture and detection antibodies and 
standards included in R&D DuoSet ELISA Development kits (sTNF-RI: DY225 
and sTNF-RII: DY726, R&D Systems, Abingdon, UK). 96-well ELISA plates 
(Nunc-Immuno 439454 MaxiSorp) were coated with the anti-human sTNF-RI or 
sTNF-RII capture antibody (previously reconstituted according to the 
manufacturer’s instructions) diluted 1:200 in 0.05 M sodium carbonate buffer at 
65 µl/well, sealed and incubated overnight at 4ºC. The next day, plates were 
washed 4 times (at 200 µl/well) with PBS with 0.1% Tween 20 (PBS-T.1) and 
blocked for 1 h at room temperature with 1% BSA (Probumin, Millipore, Illinois, 
USA) in PBS at 100 µl/well. Plates were subsequently washed 4 times with 
PBS-T.1 and duplicates of samples (diluted 1:10 in PBS), standards (serially 
diluted in PBS with 1% BSA from 10 ng/ml to 10 pg/ml and 18 ng/ml to 18 pg/ml 
for sTNF-RI and sTNF-RII assays, respectively) and blank (PBS with 1% BSA) 
were added at 50 µl/well. Plates were again sealed and incubated overnight at 
4ºC. The following day, plates were washed 4 times with PBS-T.1 and the 
biotinylated anti-human sTNF-RI or sTNF-RII detection antibody (previously 
reconstituted according to the manufacturer’s instructions) diluted 1:200 in PBS 
was added at 50 µl/well. Plates were incubated for 2 h at room temperature and 
subsequently washed 4 times with PBS-T.1. HRP Avidin D (A-2004, Vector 
Laboratories, Peterborough, UK) diluted 1:2000 in PBS was then added at 50 
µl/well and plates were incubated for a further 1 h at room temperature. After a 
final wash (4 times with PBS-T.1), an OPD substrate solution (S2045, Dako, 
Glostrup, Denmark), prepared according to the manufacturer’s instructions, was 
added at 50 µl/well. Approximately 5 min after or when suitable colour has 
developed, the reaction was stopped with 1 M sulphuric acid (at 75 µl/well) and 
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the plates were immediately read at 490 nm. Samples’ concentrations were 
determined by relation to a standard curve generated by plotting the standards’ 
absorbances against the log of the standards’ concentrations using a four-
parameter logistic equation (Graphpad Prism version 5, Graphpad Software, La 
Jolla, CA, USA). All samples from the same patient were assayed on the same 
plate. Duplicates with a CV above 10% were repeated, as were samples that 
fell beyond the dynamic range of each assay standard curve (adjusting the 
dilution factor accordingly). The inter- and intra-assay CV were 3.6% and 2.6% 
for sTNF-RI and 4.5% and 2.9% for sTNF-RII, respectively. 
C-reactive protein assay 
An ELISA for detection of CRP levels in plasma samples was developed and 
optimised using a method adapted from Pawluczyk et al. (2011). 96-well ELISA 
plates (Nunc-Immuno 439454 MaxiSorp) were coated with anti-human CRP 
rabbit polyclonal antibody (235752, Calbiochem, Merck Chemicals, Nottingham, 
UK) diluted to a final concentration of 5 µg/ml in 0.05 M sodium carbonate 
buffer at 65 µl/well, sealed and incubated overnight at 4ºC. The next day, plates 
were washed 4 times (at 200 µl/well) with PBS-T.1 and blocked for 1 h at room 
temperature with 1% BSA in PBS at 100 µl/well. Plates were subsequently 
washed 4 times with PBS-T.1 and duplicates of samples (diluted 1:100 in PBS), 
CRP standards (85/506, NIBSC, Potters Bar, Hertfordshire, UK, serially diluted 
in PBS with 1% BSA from 1 µg/ml to 1 ng/ml) and blank (PBS with 1% BSA) 
were added at 50 µl/well. Plates were again sealed and incubated overnight at 
4ºC. The following day, plates were washed 4 times with PBS-T.1 and anti-
human CRP mouse monoclonal antibody (ab8279, Abcam, Cambridge, UK) 
diluted 1:750 in PBS was added at 50 µl/well. Plates were incubated for 2 h at 
room temperature and subsequently washed 4 times with PBS-T.1. HRP 
conjugated anti-mouse immunoglobulins rabbit polyclonal antibody (P0260, 
Dako, Glostrup, Denmark) diluted 1:1000 in PBS was then added at 50 µl/well 
and plates were incubated for a further 1 h at room temperature. After a final 
wash (4 times with PBS-T.1), an OPD substrate solution (S2045, Dako, 
Glostrup, Denmark), prepared according to the manufacturer’s instructions, was 
added at 50 µl/well. Approximately 5 min after or when suitable colour has 
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developed, the reaction was stopped with 1 M sulphuric acid (at 75 µl/well) and 
the plates were immediately read at 490 nm. Samples’ concentrations were 
determined by relation to a standard curve generated by plotting the standards’ 
absorbances against the log of the standards’ concentrations using a four-
parameter logistic equation (Graphpad Prism version 5, Graphpad Software, La 
Jolla, CA, USA). All samples from the same patient were assayed on the same 
plate. Duplicates with a CV above 10% were repeated, as were samples that 
fell beyond the dynamic range of each assay standard curve (adjusting the 
dilution factor accordingly). The inter- and intra-assay CV were 3.2% and 2.9%, 
respectively. 
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2.6. Flow cytometry data analysis 
Flow cytometry data analysis was performed using FlowJo version 9 for 
Macintosh (Tree Star, Ashland, OR, USA). All data files from the same patient 
were analysed on the same day. 
T-lymphocyte analysis  
SSC vs. FSC plots of all cells acquired were used to gate on the lymphocyte 
population by morphology (Figure 2.1 a). Subsequent SSC vs. FL1 or FL3 plots 
of the lymphocyte population were used to gate, respectively, on the CD4 
positive population (CD4+, helper T-cells; Figure 2.1 b) or on the CD8 brightly 
positive population (CD8++, cytotoxic T-cells; Figure 2.1 c). This gating strategy 
for cytotoxic T-cells was used because it is known that all lymphocytes that 
express CD8 at high fluorescence intensities also express CD3 and that this 
population forms the majority of the total cytotoxic T-cell blood pool, while on 
the other hand, lymphocytes that express CD8 at low fluorescence intensities 
also include natural killer cells (Simpson et al., 2007; Campbell et al., 2008). 
Absolute numbers of CD4+ and CD8++ lymphocytes were obtained by 
multiplying the percentages of CD4+ and CD8++ lymphocytes by the 
corresponding total lymphocyte count (obtained as described in section 2.4). 
This analysis was carried for both unstimulated and SEB-stimulated samples, 
but as there were no significant differences between both, only SEB-stimulated 
data are presented. Further FL2 vs. FL1 or FL3 plots of CD4+ or CD8++ 
lymphocytes, respectively, were used to determine the percentage the CD4+ 
and CD8++ lymphocytes expressing CD69 and the geometric mean of 
fluorescence intensity (GMFI) of CD69 in these cells (Figure 2.1 d, e, f and g). 
The unstimulated samples were used to define the threshold of positive staining 
and only SEB-stimulated data are reported. 
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a)  
b)   c)  
d)   e)  
f)   g)  
Figure 2.1. T-lymphocyte flow cytometry data analysis. 
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Monocyte analysis 
FL2 vs. FL1 plots of all cells acquired were used to gate on the CD14+CD86+ 
cells (Figure 3.2 a). Subsequent FL3 vs. FL1 plots of the CD14+CD86+ cells 
were used to gate on the CD14+CD86+HLA-DR+ cells (Figure 3.2 b). Backgating 
analysis was then performed to ensure the gated cells fell on the monocyte 
region by morphology on SSC vs. FSC plots (Figure 3.2 c). Further FL2 or FL3 
histogram plots of CD14+CD86+HLA-DR+ monocytes were used to determine, 
respectively, the GMFI of CD86 and HLA-DR in these cells (Figure 3.2 d and f). 
Negative unstained controls were used to define the threshold of positive 
staining. This analysis was carried for both unstimulated and SEB-stimulated 
samples and SEB-stimulated data are reported as a ratio to the unstimulated 
condition. 
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a)   b)  
c)  
d)   e)  
Figure 2.2. Monocyte flow cytometry data analysis. 
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2.7. Statistical analysis 
Statistical analysis was performed using PASW statistics version 18 (SPSS, 
Chicago, IL, USA). All statistical procedures are detailed in each individual 
chapter. 
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2.8. Glossary of key immune and inflammatory variables 
Leukocytes (white blood cells): heterogeneous cells found in the circulation 
and various tissues with diverse functions related to the immune response. 
Neutrophil: granulocyte characterised by its multi-lobed nucleus and granular 
cytoplasm; also called a polymorphonuclear phagocyte; acts non-specifically 
and so forms part of the innate immune system; involved in defence against 
bacteria. 
Lymphocyte: mononuclear immune cell involved in the adaptive immune 
response; subpopulations of lymphocytes include T cells and B cells; NK cells 
are a further example of lymphocytes, but these are involved in the innate 
immune response. 
Monocyte: circulating mononuclear phagocytic leukocyte that can ingest and 
destroy foreign material but also capable of antigen-presentation (initiation of 
the acquired immune response); differentiates into a macrophage upon 
migration into tissue. 
T cells: heterogeneous population of lymphocytes comprising helper T cells 
and cytotoxic/supressor T cells. 
Helper T cell: subset of T cell capable of recognising antigen and producing 
several cytokines that activate other immune cells; expresses the cluster 
designation marker CD4 on its surface. 
Cytotoxic T cell: subset of T cell capable of killing certain tumour and virally 
infected cells; expresses the cluster designation marker CD8 on its surface. 
CD69: lymphoid activation cell surface marker whose rapid expression makes it 
amenable for the early detection of T cell activation and for subset activation 
analysis. 
CD14: cell surface marker that is preferentially expressed on monocytes/ 
macrophages. 
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CD86 (B7-2): cell surface molecule that provides a co-stimulatory signal 
necessary for T cell activation; ligand for CD28 and CTLA-4 on the T cell 
surface. 
HLA-DR: major histocompatibility complex (MHC) class II cell surface molecule; 
MHC molecules are involved in antigen presentation to T cells. Class I MHC 
proteins are present on virtually all nucleated cells, whereas class II MHC 
proteins are expressed on antigen-presenting cells. 
Degranulation: the process by which neutrophils release their cytotoxic 
granules (e.g. elastase) into the phagolysosomal vacuole, formed in 
phagocytosis. 
C-reactive protein (CRP): acute phase protein released in response to 
inflammation and infection to help with tissue repair. 
Acute phase proteins: heterogeneous class of serum glycoproteins that are 
released by liver cells in response to pro-inflammatory cytokines and increase in 
concentration during inflammation and infection. 
Interleukin (IL)-6: pro-inflammatory cytokine. 
Interleukin (IL)-10: anti-inflammatory cytokine. 
Soluble tumour necrosis factor receptors (sTNF-Rs): soluble form of the 
natural occurring inhibitors of tumour necrosis factor (TNF), a pro-inflammatory 
cytokine. 
Cytokine: soluble factor produced by many cells; involved in communication 
between immune cells, and between immune cells and other tissues/organs; 
cytokines include interleukins (IL), tumour necrosis factors (TNF), colony-
stimulating factors (CSF) and interferons (IFN). 
Peripheral blood mononuclear cells (PBMCs): mainly lymphocytes and 
monocytes. 
 
  
 
 
 
 
 
 Chapter 3
Effect of an acute bout of moderate intensity aerobic 
exercise and ex vivo extracellular acidosis on T lymphocyte 
and monocyte activation in healthy volunteers 
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3.1. Abstract 
The initial aim of this study was to pilot, in healthy volunteers, the exercise test protocol 
used in the later studies in patients with chronic kidney disease (CKD). In addition, 
given that metabolic acidosis and immune dysfunction are features of CKD but few 
studies have focused on the effect of extracellular pH on immune function, this study 
aimed to investigate the effect of ex vivo extracellular acidosis on T lymphocyte and 
monocyte activation before and after exercise. 
Ten (5 males and 5 females) recreationally active healthy subjects (age 25 ± 2 yrs; 
body mass 66.8 ± 9.2 kg) ran or walked for 30 min on a motorised treadmill at a 1% 
gradient and at a speed that elicited a rating of perceived exertion in the range of 12-14 
(“somewhat hard”). Venous blood samples were collected before and after exercise. 
Peripheral blood mononuclear cells were cultured in acidotic (pH 7.1) vs. neutral 
medium (pH 7.4) and T lymphocyte subset (CD4+ and CD8+) activation (CD69 
expression) and monocyte (CD14+HLA-DR+) activation (CD86 expression) were 
determined by flow cytometry following 20 h in vitro stimulation by staphylococcal 
enterotoxin B (SEB) and tetanus toxoid plus influenza vaccines (TT+FLU). Data were 
examined using two-factor repeated measures ANOVAs (exercise x medium). 
Fluorescence intensity for a surface antigen was calculated as geometric mean (GMFI) 
of all positive-staining cells and expressed as a ratio to unstimulated cells. 
CD86 expression by CD14+HLA-DR+ monocytes was greater on cells cultured in 
acidotic vs. neutral medium with both stimuli (main effect of medium; SEB: 1.5 ± 0.5 vs. 
1.3 ± 0.3, P < 0.05; TT+FLU: 1.3 ± 0.5 vs. 1.1 ± 0.5, P < 0.01) but there was no 
significant effect of exercise. There were no significant effects of exercise or medium 
on CD69 expression by CD4+ or CD8+ T lymphocytes for both stimuli. 
These findings suggest that ex vivo extracellular acidosis up-regulates CD86 
expression by CD14+HLA-DR+ monocytes yet has negligible effects on CD69 
expression by either CD4+ or CD8+ lymphocytes. In addition, the moderate exercise 
protocol used does not appear to affect T lymphocyte and monocyte activation. 
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3.2. Introduction 
The initial aim of this study was to pilot, in healthy volunteers, the exercise test 
protocol used in the later studies in patients with chronic kidney disease (CKD) 
and to establish the “normal” immune response to this protocol. Specifically, we 
determined the feasibility of achieving the desired rating of perceived exertion 
(RPE) range by manipulating the treadmill speed during the exercise test and 
investigated the effect of this moderate intensity aerobic exercise bout on total 
and differential blood leukocyte counts and T lymphocyte and monocyte 
activation. It was hypothesised that moderate intensity aerobic exercise would 
induce modest alterations in immune cells counts and would exert little 
influence on T lymphocyte and monocyte activation. 
In addition, given that metabolic acidosis (Kopple et al., 2005; Kraut & Kurtz, 
2005) and immune dysfunction (Cohen et al., 1997; Pesanti, 2001) are features 
of CKD and that few studies have focused on the effect of extracellular pH on 
immune cells and their function (Lardner, 2001; Kellum et al., 2004), the present 
study was also designed to investigate the effect of ex vivo extracellular 
acidosis on T lymphocyte and monocyte activation before and after exercise. 
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3.3. Methods 
Subjects 
Ten (5 males and 5 females) recreationally active healthy subjects (mean ± SD: 
age 25 ± 2 years; height 171 ± 8 cm; body mass 66.8 ± 9.2 kg) volunteered to 
participate in the study, which was approved by the Loughborough University 
Ethics Committee. All subjects were informed about the rationale for the study 
and the nature of the experimental procedures to be performed before providing 
written informed consent. Subjects were also required to complete a 
comprehensive health-screening questionnaire before taking part in the study. 
They did not report any symptoms of infection in the previous 4 weeks and 
none were currently on medication. Three of the subjects had received the 
current year immunisation against influenza virus, while none of the others have 
been previously immunised against any strain of the virus. All of the subjects 
had received the tetanus vaccination as part of their immunisation programme. 
Preliminary testing 
Prior to the experimental trial, each subject performed a 30 min familiarisation 
trial on a motorised treadmill (Run Race, TechnoGym UK Ltd, Bracknell, UK) at 
a 1% constant gradient to determine the walking/running speed that elicited a 
RPE in the range of 12-14 (“somewhat hard”). Subjects began walking/running 
at 5 km/h. RPE was recorded every 3 min using the Borg scale (Borg, 1982) 
and the treadmill speed was adjusted accordingly until a RPE in the target 
range was established. Heart rate (HR) was also recorded every 3 min using 
short-range radio telemetry (TechnoGym UK Ltd, Bracknell, UK). 
Experimental trial procedures 
For the main trial, subjects reported to the laboratory between 8:00 and 9:00 
AM following an overnight fast. They were instructed to avoid strenuous 
exercise during the preceding 24 h. On arrival, subjects’ body mass was 
recorded and a resting venous blood sample was obtained whilst seated. 
Subjects then began the exercise test protocol, which consisted of 30 min of 
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walking/running on the same treadmill used above at a 1% constant gradient 
and at the speed determined during the familiarisation trial. RPE and HR were 
recorded every 3 min using the methods described above and the treadmill 
speed was adjusted if necessary. Samples of expired air (1 min) were collected 
into Douglas bags after 12 min of exercise and every 6 min thereafter. An 
O2/CO2 analyser (Servomex 1400B, Crowborough, UK) was used along with a 
dry gas meter (Harvard Apparatus, Edenbridge, UK) for the determination of O2 
uptake ( VO2 ), CO2 production ( VCO2 ) and the respiratory exchange ratio 
(RER). During the trial subjects were given ad libitum access to water and the 
volume ingested was noted. Immediately after exercise, a further venous blood 
sample was obtained with the subject seated before body mass was recorded. 
Laboratory conditions were 24.1 ± 0.7ºC ambient temperature and 32 ± 6% 
relative humidity. 
Blood sampling 
Venous blood samples (20 ml each) were obtained from an antecubital vein 
using a 21 g butterfly needle cannula and syringe, and were dispensed into 
three separate S-Monovette tubes (Sarstedt, Leicester, UK), one containing 
K3EDTA (1.6 mg EDTA/ml blood) and two containing lithium heparin (16 IU 
heparin/ml blood). 
Total and differential leukocyte counts and plasma volume 
Blood collected into the K3EDTA S-Monovette tube (7.5 ml capacity, 5 ml blood) 
was used for haematological analysis, including haemoglobin, haematocrit and 
total and differential leukocyte counts using an automated haematology 
analyser (Ac · T 5diff analyser, Beckman Coulter, UK). Plasma volume changes 
were estimated from the haemoglobin and haematocrit values according to Dill 
& Costill (1974) and cell counts were corrected for plasma volume changes 
relative to the resting blood sample. 
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Cell cultures 
Peripheral blood mononuclear cells (PBMCs) were separated from 15 ml blood 
collected into the two lithium heparin S-Monovette tubes (7.5 ml capacity each) 
by density gradient centrifugation on Histopaque 1077 (Sigma-Aldrich, 
Gillingham, Dorset, UK), washed twice in sterile isotonic salt solution (HBSS, 
Invitrogen, Paisley, UK, supplemented with 100 units/ml penicillin, 100 µg/ml 
streptomycin and 10 mM HEPES) and resuspended at approximately 2 x 106 
PBMCs/ml in culture medium (MEM Gibco 21090, Invitrogen, Paisley, UK, 
supplemented with 2 mM L-Glutamine, 100 units/ml penicillin, 100 µg/ml 
streptomycin and 2% dialysed fetal bovine serum) at different pH: neutral 
(additionally containing 8.3 mM NaHCO3 and 24.8 mM NaCL; pH 7.4) and 
acidotic (additionally containing 6.5 mM HCl and 33.2 mM NaCL; pH 7.1) 
medium. Aliquots of cells (1 ml) were cultured in flat-bottomed 24-well plates in 
each medium alone (Unstim), with 1 µg/ml staphylococcal enterotoxin B (SEB, 
Sigma-Aldrich, Gillingham, Dorset, UK), or with a mixture of adsorbed tetanus 
vaccine BP (Wellcome, London, UK) and influenza vaccine (Influvac sub-unit 
2006/7, Solvay Healthcare, Southampton, UK) both at 1:500 final dilution 
(TT+FLU). Cells were incubated at 37ºC in a humid 5% CO2 atmosphere. 
Staining and flow cytometry 
After 20 h in culture, PBMCs from each culture condition were harvested. The 
cells were pelleted, the supernatant removed and the cells were resuspended in 
ice-cold phosphate-buffered saline containing 0.1% bovine serum albumin and 
2mM EDTA (PBS-BSA-EDTA). Aliquots of cells were labelled with cocktails of 
the following monoclonal antibodies against human cell surface markers (all 
obtained from BD Biosciences, Oxford, UK): lymphocyte surface markers FITC 
anti-CD4, PE-Cy5 anti-CD8, and PE anti-CD69; monocyte surface markers 
FITC anti-CD14, PerCP anti-HLA-DR and PE anti-CD86. Labelling was carried 
out on ice for 20 min and the cells subsequently washed once in PBS-BSA-
EDTA, after which they were fixed with FACS Lyse (BD Biosciences, Oxford, 
UK) and resuspended again in PBS/BSA/EDTA. Samples were analysed on a 
flow cytometer (BD FACSCalibur, Oxford, UK) equipped with the CellQuest 
software package (BD Biosciences, Oxford, UK). For samples labelled with 
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lymphocyte markers, side scatter versus forward scatter plots were used to gate 
on the lymphocyte population by morphology, and 30,000 lymphocyte events 
were acquired per analysis. The percentage of lymphocytes expressing CD4 
and CD8 was derived from histogram analysis of FL1 and FL3, respectively. 
CD4+ and CD8+ cells were gated into separate regions, and FL2 histogram 
plots of the cells in each of these regions were used to determine the 
percentage of the CD4+ and CD8+ cells expressing CD69 and the fluorescence 
intensity of CD69 in these cells. For samples labelled with monocyte markers, 
100,000 cell events in total were acquired per analysis. FL1 and FL3 
histograms were used to gate on CD14+ and HLA-DR+ cells, respectively, and a 
FL2 histogram plot of CD14+HLA-DR+ cells was used to determine the 
fluorescence intensity of CD86. Negative unstained controls were used to 
define the threshold of positive staining for all surface markers. Fluorescence 
intensity for a surface antigen was calculated as geometric mean (GMFI) of all 
positive-staining cells and expressed as a ratio to unstimulated cells.  
Statistical analysis 
All data are presented as mean values and standard deviations (± SD). Data 
were checked for normality and if a data set was not normally distributed, 
statistical analysis was performed on the logarithmic transformation of the data. 
Exercise test data, including RPE, HR, VO2  and RER, were examined using a 
one-factor (time) repeated measures analysis of variance (ANOVA). 
Haematological data, including plasma volume and total and differential 
leukocyte counts were analysed using Student’s paired t-tests (pre- vs. post-
exercise). Flow cytometry data were examined using a two-factor [exercise 
(pre- and post-exercise) x medium (neutral and acidotic)] repeated measures 
ANOVA. For the ANOVAs, assumptions of homogeneity and sphericity in the 
data were checked and appropriate adjustments in the degrees of freedom 
were made according to Atkinson (2001). Any significant F ratios subsequently 
shown were assessed by using Student’s paired t-tests with Bonferroni 
correction for multiple comparisons applied to the unadjusted P value. However, 
for the two-factor ANOVA if there was no significant interaction but significant 
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main effects were found, the main effects only are reported. Statistical 
significance was accepted at P < 0.05. 
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3.4. Results 
Treadmill speed 
The mean treadmill speed obtained from the familiarisation trial and therefore 
the speed at the onset of the main trial exercise test was 8.3 ± 1.7 km/h, 
ranging from 6.0 to 11.0 km/h. Only minor adjustments in the speed were 
required throughout the exercise test to ensure target RPE. Specifically, four of 
the subjects required slight speed increments during the initial stages of the 
exercise test, while speed was reduced for two subjects during the last stages 
of the exercise test. Treadmill speed at 15 and 30 min of exercise was 8.4 ± 1.7 
and 8.3 ± 1.9 km/h, respectively. 
Rating of perceived exertion  
RPE increased with exercise duration (main effect of time: F2,4 = 11.0, P < 
0.001; Figure 3.1), yet significant differences were only found between RPE at 3 
min and at 15, 24, and 27 min (P < 0.05 for all). RPE also tended to be lower at 
3 min than at 18 (P = 0.078), 21 (P = 0.058), and 30 min (P = 0.079).  At 3 and 
6 min, respectively five and three of the subjects were exercising below the 
required target RPE range of 12-14. With the consequent treadmill speed 
adjustments, all subjects were exercising within this range from 9 min until the 
end of the exercise test. 
  
50 
 
Figure 3.1. Subjective rating of perceived exertion (RPE) in response to the exercise test. 
Data are mean ± SD (n=10); main effect of time: P < 0.001, *P < 0.05 vs. 15, 24 and 27 min. 
Heart rate, oxygen uptake and respiratory exchange ratio 
HR increased with exercise duration (main effect of time: F3,5 = 29.4, P < 0.001; 
Figure 3.2). HR at 3, 15, and 30 min was 142 ± 10, 155 ± 12, and 161± 12 
beats/min, respectively. A main effect of time (F1,6 = 5.2, P < 0.05; Table 3.1) 
was also found for VO2  with values increasing as a function of exercise 
duration, yet no significant differences between any time points were found 
(Table 3.1). Additionally, RER was similar throughout the exercise (Table 3.1). 
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Figure 3.2. Heart rate (HR) in response to the exercise test. Data are mean ± SD (n=10); 
main effect of time: P < 0.001. 
Table 3.1. Oxygen uptake mean and respiratory exchange ratio in response to the 
exercise test. Data are mean ± SD (n=10). 
Time (min) 
12 18 24 30 
Oxygen uptake (l/min)*t 
1.86 ± 0.66 1.96 ± 0.73 1.99 ± 0.72 2.05 ± 0.74 
Respiratory exchange ratio 
0.94 ± 0.09 0.93 ± 0.11 0.92 ± 0.07 0.92 ± 0.06 
main effect of time: *t P < 0.05 
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Body mass and plasma volume 
Following exercise, body mass when corrected for fluid intake fell by 0.4 ± 0.2 
kg, varying between 0.2 and 0.7 kg. Likewise, plasma volume fell by 3.9 ± 4.6% 
after exercise (P < 0.05). 
Total and differential blood leukocyte counts 
Total and differential blood leukocyte counts are shown in Table 3.2. After 
exercise, total leukocyte concentration was elevated by 26% above resting 
levels (P < 0.005). Similarly, numbers of circulating neutrophils, lymphocytes 
and monocytes at post-exercise were 22, 35, and 28% respectively, higher than 
at pre-exercise (P < 0.05, P < 0.005 and P < 0.01, respectively).  
Table 3.2. Total and differential leukocyte counts in response to the exercise test. Data 
are mean ± SD (n=10). 
 Pre-exercise Post-exercise 
Leukocytes (x 109/l) 5.0    ± 1.1 6.3 ± 1.6*** 
Neutrophils (x 109/l) 2.4 ± 0.8 2.9 ± 1.3* 
Lymphocytes (x 109/l) 1.8 ± 0.4 2.5 ± 0.5***  
Monocytes (x 109/l) 0.6 ± 0.2 0.7 ± 0.2** 
*P < 0.05, **P < 0.01 and ***P < 0.005 vs. pre-exercise 
T lymphocyte subsets  
There was no significant exercise x medium interaction and no significant main 
effect of medium for the % of CD4+ cells in any condition. However, there was a 
significant main effect of exercise for all conditions  (Unstim: F1,0 = 8.4, P < 0.05; 
SEB: F1,0 = 16.5, P < 0.01; TT+FLU: F1,0 = 17.8, P < 0.005; Table 3.3), with the 
% of CD4+ cells decreasing following exercise (marginal means pre vs. post-
exercise Unstim: 35 ± 8 vs. 31 ± 8%; SEB: 35 ± 6 vs. 30 ± 7; TT+FLU: 34 ± 6 
vs. 29 ± 7%).There was neither significant exercise x medium interaction nor 
significant effects of medium or exercise for the % of CD8+ cells in any condition 
(Table 3.3). 
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Table 3.3. Percentages of CD4+ and CD8+ cells following 20h culture in acidotic vs. 
neutral medium with different stimuli and in response to the exercise test. Data are mean 
± SD (n=10). 
 Pre-exercise Post-exercise 
 Neutral Acidotic Neutral Acidotic 
% CD4+ 
Unstim*e 35 ± 08 35 ± 07 31 ± 09 31 ± 08 
SEB**e 35 ± 06 34 ± 06 30 ± 08 31 ± 08 
TT+FLU***e 34 ± 06 34 ± 07 28 ± 08 29 ± 06 
% CD8+ 
Unstim 28 ± 10 29 ± 09 30 ± 13 30 ± 11 
SEB 29 ± 10 28 ± 10 31 ± 13 29 ± 11 
TT+FLU 32 ± 10 32 ± 11 34 ± 13 32 ± 12 
main effect of exercise: *e P < 0.05, **e P < 0.01 and ***e P < 0.005 
Activation of CD4+ and CD8+ lymphocytes  
There was no significant exercise x medium interaction for the % of CD4+ cells 
expressing CD69 in any condition, yet there was a significant main effect of 
exercise for Unstim (F1,0 = 5.7, P < 0.05; marginal means pre- vs. post-exercise: 
5 ± 4 vs. 4 ± 4%; Table 3.4). There was also a significant main effect of medium 
for Unstim (F1,0 = 7.5, P < 0.05; marginal means neutral vs. acidotic: 5 ± 4 vs. 4 
± 5%; Table 3.4) and TT+FLU (F1,0 = 9.8, P < 0.05; marginal means neutral vs. 
acidotic: 16 ± 8 vs. 13 ± 7%; Table 3.4). No significant interaction between 
exercise and medium or significant main effects of medium or exercise for the 
% of CD8+ cells expressing CD69 were found for any condition (Table 3.4). 
There was no significant exercise x medium interaction or significant effects of 
medium or exercise for CD69 expression (GMFI) on both CD4+ and CD8+ cells 
in any condition (Figures 3.3 and 3.4). 
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Table 3.4. Percentages of CD4+ and CD8+ cells expressing CD69 following 20h culture in 
acidotic vs. neutral medium with different stimuli and in response to the exercise test. 
Data are mean ± SD (n=10). 
 Pre-exercise Post-exercise 
 Neutral Acidotic Neutral Acidotic 
% CD4+CD69+ 
Unstim*e*m 5 ± 05 5 ± 06 4 ± 04 4 ± 05 
SEB 50 ± 22 45 ± 15 47 ± 19 44 ± 19 
TT+FLU*m 15 ± 08 14 ± 07 16 ± 08 12 ± 07 
% CD8+CD69+ 
Unstim 5 ± 05 5 ± 06 4 ± 04 4 ± 05 
SEB 50 ± 22 45 ± 15 47 ± 20 44 ± 19 
TT+FLU 15 ± 08 14 ± 07 16 ± 08 12 ± 07 
main effect of exercise: *e P < 0.05 
 main effect of medium: *m P < 0.05 
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Figure 3.3. CD69 expression (geometric mean fluorescence intensity expressed as a ratio 
to unstimulated cells) on CD4+ cells following 20h culture in acidotic vs. neutral medium 
with a) SEB and b) TT+FLU and in response to the exercise test. Data are mean ± SD 
(n=10). 
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Figure 3.4. CD69 expression (geometric mean fluorescence intensity expressed as a ratio 
to unstimulated cells) on CD8+ cells following 20h culture in acidotic vs. neutral medium 
with a) SEB and b) TT+FLU and in response to the exercise test. Data are mean ± SD 
(n=10). 
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Activation of CD14+HLA-DR+ monocytes 
There was no significant exercise x medium interaction and no significant effect 
of exercise for CD86 expression on CD14+HLA-DR+ cells in any condition. 
However, there was a main effect of medium for both SEB (F1,0 = 6.8, P < 0.05; 
Figure 3.5a) and TT+FLU (F1,0 = 16.0, P < 0.01; Figure 3.5b), with CD86 
expression on CD14+HLA-DR+ cells being up-regulated by acidotic medium 
(marginal means neutral vs. acidotic SEB: 1.3 ± 0.3 vs. 1.5 ± 0.5; TT+FLU: 1.1 
± 0.5 vs. 1.3 ± 0.5). 
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Figure 3.5. CD86 expression (geometric mean fluorescence intensity expressed as a ratio 
to unstimulated cells) on CD14+HLA-DR+ cells following 20h culture in acidotic vs. 
neutral medium with a) SEB (main effect of medium: P < 0.05) and b) TT+FLU (main effect 
of medium: P < 0.01) and in response to the exercise test. Data are mean ± SD (n=10). 
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3.5. Discussion 
The initial aim of this study was to pilot the exercise test protocol used in the 
later studies in patients with CKD. Additionally, in an attempt to mimic the CKD 
patients’ acidotic milieu, T lymphocyte and monocyte activation by different 
stimuli were assessed by flow cytometry in PBMCs isolated from pre- and post-
exercise blood samples and cultured in acidotic vs. neutral media. The main 
findings of the present study were that ex vivo extracellular acidosis up-
regulated CD86 expression by CD14+HLA-DR+ monocytes, yet had negligible 
effects on CD69 expression by either CD4+ or CD8+ T lymphocytes. In addition, 
the moderate exercise protocol used in the present study did not appear to 
have an effect on these activation markers. 
The exercise protocol appears to have successfully induced the required 
response with only some of the subjects requiring minor adjustments of the 
treadmill speed to elicit the target RPE. Moreover, the adjustments made 
appear to be more related with the exercise time, with slight increases 
necessary at the early stages of exercise for some subjects and small 
decreases needed at the late stages for others. However, it is important to 
highlight that in the present study the treadmill speed was previously 
determined in a familiarisation trial and although this would also be ideal with 
the patients it was not possible due to logistical and financial restrictions. 
Therefore, it was decided that in the patients’ studies we should record the RPE 
at smaller time intervals, i.e. every 2 min, to ensure that the required RPE is 
attained as quickly as possible. 
The exercise protocol used in the present study only caused a modest elevation 
in the total number of circulating leukocytes, which in turn reflected similar 
relative increases in the numbers of circulating neutrophils, lymphocytes and 
monocytes. Furthermore, none of the cell counts exceeded the normal ranges.  
This is accordance with Nieman et al. (2005) where only mild and transient 
increases in total and differential leukocyte counts have been reported following 
a similar exercise protocol of 30 min of walking at 60-65% of VO2max . This 
response is not unexpected, since the magnitude of the exercise induced 
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elevation in total and differential leukocyte counts is proportional to the intensity 
and duration of the exercise performed (Nieman et al., 1994; Robson et al., 
1999). One limitation of the present study was that blood samples were not 
taken during the recovery from exercise and therefore we were not able to 
determine how long the cell counts remained elevated above pre-exercise 
levels. It is likely that total and differential leukocyte counts would have returned 
to resting levels within 1 hour following exercise of the intensity and duration 
used, as observed in Nieman et al. (2005). Nevertheless, we concluded that 
this needed to be assessed in the patients’ studies and it was decided that one 
further blood sample should be obtained at 1 h post-exercise. 
The main finding of this study was the higher CD86 expression by CD14+HLA-
DR+ monocytes cultured for 20 h in acidotic (pH 7.1) vs. neutral (pH 7.4) 
medium, with this result being consistent for both SEB and TT+FLU stimulated 
cells. Similar effects were reported by Vermeulen et al. (2004), who observed 
increased expression of CD86 by dendritic cells exposed to pH 6.5 compared 
with pH 7.3. This effect appears to be related to the length of exposure to the 
acidotic condition, because these effects were observed after 4 h and 24 h of 
incubation, but not after 30 min exposure. Interestingly, in CKD defective 
expression of CD86 on monocytes of dialysis but not pre-dialysis patients was 
reported (Girndt et al., 2001b). We might be tempted to suggest that the results 
of the present study indicate that this defective CD86 expression in dialysis 
patients is not caused by acidosis. However, the present findings cannot be 
extrapolated to CKD. It is important to highlight that metabolic acidosis in CKD 
is a chronic condition and in the present study cells were only exposed to ex 
vivo acute acidosis.  
CD86 (B7-2) is a molecule that provides a co-stimulatory signal necessary for T 
cell activation. Activation of T cells requires at least two signals: the primary 
signal occurs through the engagement of the T cell receptor (TCR) by the major 
histocompatibility complex (MHC)-antigen peptide complex on the antigen-
presenting cell (APC) such as monocyte or dendritic cell; the secondary signal 
occurs through the engagement of CD28 on the T cell by B7-1 (CD80) or B7-2 
(CD86) co-stimulatory molecules on the APC (Bretscher, 1999). Both signals 
are required for production of an effective immune response and in the absence 
  
61 
of CD28 co-stimulation, T cell receptor signalling alone results in anergy 
(Sharpe & Freeman, 2002). In the present study CD86 expression was 
assessed on CD14+HLA-DR+ monocytes, i.e. CD14+ monocytes expressing 
MHC class II molecule, and therefore monocytes involved in the activation of 
CD4+ T cells. We might therefore have expected that the up-regulation of the 
co-stimulatory CD86 signal in acidotic medium would have resulted in an 
enhanced CD4+ T cell activation. However, the results of the present study 
were not able to show this and no effect of extracellular acidosis on CD69 
expression (a marker of T cell activation) by CD4+ T cells was observed. In fact, 
the percentage of CD4+ cells expressing CD69 was actually lower in acidotic 
compared with neutral medium for unstimulated and TT+FLU-stimulated cells 
but not for SEB. Although there is no clear explanation for this, it seems 
reasonable to note that the statistical main effects observed take into account 
the pre and post-exercise samples together, which might induce in erroneous 
conclusions about the effect of medium itself since the percentages of CD4+ 
cells decrease considerably following exercise. To address this we have 
investigated the effect of medium independently on the pre-exercise samples 
and have found no differences in the percentages of CD4+CD69+ cells between 
acidotic and neutral medium for any condition (data not shown). This suggests 
that the effects observed here are related to alterations in cell number. 
Furthermore, it should be emphasised that T cell activation involves a far more 
complex signalling cascade than the simplistic description presented above. It is 
interesting to note that cytotoxic T lymphocyte antigen 4 (CTLA-4) competes 
with CD28 for B7 ligands, such as CD86, and in fact it has much higher affinity 
than CD28 for these molecules. B7 engagement of CTLA-4 down-regulates T 
cell activation (Sansom, 2000). Therefore, although in the present study CD86 
was up-regulated by acidotic medium, its higher affinity with CTLA-4 might have 
contributed to a down-regulation of T cell activation. 
The moderate exercise protocol used in the present study had negligible effect 
on CD69 expression by CD4+ and CD8+ cells. Although there was a significant 
main effect of exercise for the percentage of CD4+ cells expressing CD69 in 
unstimulated cells, this is probably just an effect of the decrease in CD4+ cells 
observed following exercise. Previous studies that have determined CD69 
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expression on CD4+ and CD8+ cells following 75 min of cycling at approximately 
75% of VO2max  (Rønsen et al., 2001) or 60 min of treadmill running at 95% of 
ventilatory threshold (Green et al., 2003), have also found no effect of exercise. 
However, decreases in the CD69 expression on both CD4+ and CD8+ cells 
immediately after an incremental treadmill test to exhaustion have also been 
reported (Vider et al., 2001). The present study support the findings of Rønsen 
et al. (2001) and Green et al. (2003). The inconsistent findings reported by 
Vider et al. (2001) are probably due to the nature of the exercise challenge that 
aimed to achieve exhaustion. 
CD86 expression by CD14+HLA-DR+ monocytes was also unaffected by the 
moderate exercise protocol used in the present study. This is in contrast to the 
study of Lancaster et al. (2005), which have reported a decrease of CD86 
expression by CD14+ monocytes following 1.5 h of cycling at 55% of maximal 
work rate at 34ºC. The reasons of this inconsistency may be due to the obvious 
differences in exercise duration and intensity or in the ambient conditions. 
In summary, the findings of the present study suggest that ex vivo extracellular 
acidosis up-regulates CD86 expression by CD14+HLA-DR+ monocytes, yet has 
negligible effects on CD69 expression by either CD4+ or CD8+ T lymphocytes. 
In addition, the moderate exercise protocol used in the present study appears to 
have no effect on T lymphocyte and monocyte activation. However, it is 
important to note that the effects of ex vivo acidosis in healthy participants do 
not necessarily reflect the situation of the in vivo acidotic milieu in CKD. 
 
  
 
 
 
 
 
 Chapter 4
Effect of an acute bout of moderate intensity aerobic 
exercise on immunity and inflammation in chronic kidney 
disease patients 
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4.1. Abstract 
Chronic kidney disease (CKD) is associated with a complex state of immune 
dysfunction characterised by immune depression and immune activation (inducing 
inflammation). In healthy people, acute moderate exercise usually exerts little influence 
on immune and inflammatory responses, but it is not known what effect it may have in 
CKD patients given their compromised immunity and inflammatory status. Therefore, 
this study investigated the effects of an acute bout of moderate intensity aerobic 
exercise on measures of immunity and inflammation in pre-dialysis CKD patients. 
Fifteen (12 males and 3 females) pre-dialysis stage 3-5 CKD patients (age 59 ± 10 yrs; 
BMI 27.1 ± 5.1 kg/m2; eGFR 18.3 ± 7.3 ml/min/1.73 m2) walked for 30 min on a 
motorised treadmill at a 1% gradient and at a speed that elicited a rating of perceived 
exertion in the range of 12-14 (“somewhat hard”). Venous blood samples were 
collected before, immediately after and 1 h after exercise. CD4+ and CD8++ lymphocyte 
activation (CD69 expression) and CD14+CD86+HLA-DR+ monocyte activation (HLA-DR 
and CD86 expression) were determined by flow cytometry following 20 h in vitro 
stimulation by SEB. Elastase release from unstimulated (plasma elastase) and 
bacterially-stimulated neutrophils, and plasma inflammatory markers (IL-6, IL-10, 
sTNF-Rs and CRP) were determined by ELISA. Data were examined using one-factor 
repeated measures ANOVAs and Student’s paired t-tests (Holm-Bonferroni correction). 
Exercise had no effect on CD4+ or CD8++ lymphocyte activation (CD69) and 
CD14+CD86+HLA-DR+ monocyte activation (HLA-DR and CD86). Plasma elastase 
concentration was elevated immediately after exercise, yet values returned to resting 
levels 1 h after exercise. Bacterially-stimulated elastase release per neutrophil did not 
change immediately after exercise but increased by 1 h after exercise. In addition, 
exercise induced elevations in the plasma concentrations of IL-6 (peaked immediately 
after), IL-10 (peaked 1 h after) and sTNF-RII (only elevated 1 h after) but had no effect 
on sTNF-RI and CRP levels. 
These findings indicate that acute moderate aerobic exercise in pre-dialysis CKD 
patients seems to be safe from an immune and inflammatory perspective and it 
appears to improve immunosurveillance as well as to exert anti-inflammatory effects. 
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4.2. Introduction 
Chronic kidney disease (CKD) is associated with profound alterations in the 
innate and adaptive immunity as described in Chapter 1. This leads to a 
complex state of immune dysfunction, in which signs of immune depression and 
immune activation paradoxically coexist (Descamps-Latscha et al., 2002; 
Eleftheriadis et al., 2007; Kato et al., 2008). While functional immune cell 
deficiencies predispose patients with CKD to infectious complications, 
persistent immune cell activation contributes to a state of chronic inflammation 
that is associated with increased cardiovascular disease risk among these 
patients. Remarkably, infection and cardiovascular disease are leading causes 
of morbidity and mortality in CKD (Naqvi & Collins, 2006; Dalrymple & Go, 
2008; Saran & DuBose, 2008; Stenvinkel, 2010). 
In healthy people, acute moderate exercise usually exerts little influence on 
immune and inflammatory responses, but acute strenuous exercise (intensive 
and/or prolonged) exerts a temporary depression on many aspects of the 
immune function and induces an inflammatory response (Gleeson, 2007; Walsh 
et al., 2011). However, little is known about the effects of acute exercise on 
immune and inflammatory measures in immunocompromised individuals and/or 
persons with a chronic inflammatory condition. 
To our knowledge, no previous research has addressed the effects of acute 
exercise on immune and inflammatory parameters in patients with CKD. This is 
somewhat surprising because if we are to advocate exercise into the routine 
clinical care of patients with CKD, it seems paramount to determine if exercise 
is safe to their underlying compromised immunity and inflammatory status. In 
addition, examining the effects of acute exercise may elucidate some of the 
mechanisms behind the benefits that regular exercise participation may confer. 
Therefore, the aim of this study was to investigate the effects of an acute bout 
of moderate intensity aerobic exercise on measures of immunity and 
inflammation in pre-dialysis CKD patients. 
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4.3. Methods 
Patients 
Patients that completed the 1-month study (n=25) were eligible for this study, 
i.e. blood samples were obtained following the baseline exercise test. However, 
patients on PD (n=4) and patients on immunosuppressive therapy (n=5) were 
excluded. In addition, 1 further patient was excluded because blood samples 
were not obtained following exercise. Therefore, a total of 15 pre-dialysis 
patients were included in this analysis and their characteristics are shown in 
Table 4.1. 
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Table 4.1. Patients’ characteristics (n=15). 
Gender (n males / n females) 12 / 3 
Age* (years) 59 ± 10 
Weight* (kg) 80 ± 15 
Height* (cm) 172 ± 10 
BMI* (kg/m2) 27.1 ± 5.1 
eGFR* (ml/min/1.73 m2) 18.3 ± 7.3 
CKD stage# a)   
Stage 3 
Stage 4 
Stage 5 
1 
8 
6 
(7%) 
(53%) 
(40%) 
Primary renal disease# b)   
Renal Vascular Disease 
Cystic/poly 
Glomerulonephritis 
Diabetes 
Pyelonephritis 
Uncertain 
2 
2 
3 
2 
2 
4 
(13%) 
(13%) 
(20%) 
(13%) 
(13%) 
(27%) 
Number of comorbidities#   
1 
2 
3 
4 
5 
6 
1 
3 
(33%) 
(40%) 
(7%) 
(20%) 
BMI: body mass index 
eGFR: estimated glomerular filtration rate 
CKD: chronic kidney disease 
a) based on eGFR 
Data are *mean ± SD or #n (%) 
b) grouped according to UK Renal Registry (2010) 
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Experimental and analytical procedures 
All patients performed an exercise test as described in Section 2.2. Venous 
blood samples were obtained at rest (pre-exercise), immediately after the 
exercise test (post-exercise) and 1 h into the recovery period (1 h post-
exercise). All analytical procedures are detailed in Chapter 2. 
Statistical analysis  
Data are presented as mean ± standard deviation (SD) unless otherwise stated. 
Data were inspected for normality using the Shapiro-Wilk test. If a data set was 
not normally distributed, statistical analysis was performed on the logarithmic 
transformation of the data, but data were back transformed for presentation. 
Outliers were defined as values deviating more than 3 SDs from the mean and 
were excluded from analysis. Data were examined using a one-factor (time: 
pre-exercise, post-exercise, 1 h post-exercise) analysis of variance (ANOVA) 
with repeated measures design. For any significant unadjusted F values 
subsequently shown, sphericity of the data were determined using the 
Mauchly’s test and appropriate adjustments in the degrees of freedom were 
made according to Atkinson (2001), i.e. Greenhouse-Geisser correction applied 
when Greenhouse-Geisser epsilson < 0.75 or Huynh-Feldt correction used for 
less severe asphericity. A priori planned Student’s paired t-tests with Holm-
Bonferroni correction for multiple comparisons applied to the unadjusted P 
value were then performed between specific time points (post-exercise vs. pre-
exercise and 1 h post-exercise vs. pre-exercise) and effect sizes for these 
comparisons were calculated according to Cohen (1988) with correction for 
sample size (Hedges, 1981), by dividing the difference between means by the 
pooled SD. Statistical significance was accepted at P < 0.05. 
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4.4. Results 
Exercise test outcomes 
The average RPE response to exercise was 13 ± 1, and this was achieved at 
an average walking speed of 4.4 ± 1.5 km/h (range 2.1 to 8.1 km/h). The RPE 
response to exercise at 2 min intervals is illustrated in Figure 4.1. Walking 
speed at 2, 16 and 30 min was 2.9 ± 0.9, 4.6 ± 1.6 and 4.7 ± 1.8 km/h, 
respectively. There was an effect of exercise on plasma lactate concentration 
(Figure 4.2; F1,1 = 17.2, P = 0.001). Plasma lactate concentration was elevated 
above pre-exercise levels at post-exercise (P = 0.006, ES = 1.36) but it had 
returned to pre-exercise levels by 1 h post-exercise. 
 
 
Figure 4.1. Rating of perceived exertion (RPE) response to exercise. Data are mean ± SD 
(n=15). 
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
6
8
10
12
14
16
18
20
time (min)
R
PE
  
70 
 
Figure 4.2. Plasma lactate response to exercise. Data are mean and individual values 
(n=13). 
Total and differential blood leukocyte counts 
Total and differential blood leukocyte counts in response to exercise are shown 
in Table 4.2. Exercise induced an increase in total leukocyte concentration (F1,8 
= 10.3, P = 0.001), which was more pronounced at post-exercise (P = 0.0001, 
ES = 0.44) but still observable at 1 h post-exercise (P = 0.010, ES = 0.27). 
These effects were mainly attributable to the observed effects of exercise on 
the numbers of circulating neutrophils (F1,4 = 10.7, P = 0.002) and lymphocytes 
(F2,0 = 13.0, P < 0.0005), as there was no effect of exercise on monocyte count. 
Neutrophil concentration was elevated above pre-exercise levels at post-
exercise (P = 0.0004, ES = 0.35) and to a greater extent at 1 h post-exercise (P 
= 0.002, ES = 0.47). Lymphocyte concentration was also elevated at post-
exercise (P = 0.005, ES = 0.53) but it had returned to pre-exercise levels by 1 h 
post-exercise. 
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Table 4.2. Total and differential blood leukocyte counts in response to exercise. 
 Pre-ex Post-ex 1 h post-ex 
Leukocytes (x 109/l) 6.6 ± 1.9 7.5 ± 1.9* 7.2 ± 2.2* 
Neutrophils (x 109/l) 4.1 ± 1.4 4.6 ± 1.4* 4.9 ± 1.7* 
Lymphocytes (x 109/l) 1.6 ± 0.6 1.9 ± 0.6* 1.5 ± 0.6 
Monocytes (x 109/l) 0.6 ± 0.2 0.6 ± 0.1 0.5 ± 0.2 
Data are mean ± SD (n=15) 
*P < 0.05 vs. pre-ex 
T lymphocyte subsets 
Exercise induced alterations in the T lymphocyte subsets relative distribution, 
i.e. CD4+/CD8++ ratio (Table 4.3; F2,0 = 18.1, P < 0.0005), which in comparison 
with pre-exercise was lower at post-exercise (P = 0.005, ES = 0.26) and higher 
at 1 h post-ex (P = 0.035, ES = 0.21). This effect was mostly due to the 
observed effect of exercise on CD8++ lymphocyte count (Table 4.3; F2,0 = 19.6, 
P < 0.0005), which was elevated at post-exercise (P = 0.001, ES = 0.24) but fell 
slightly below pre-exercise count at 1 h post-exercise (P = 0.040, ES = 0.16). 
There was no effect of exercise on CD4+ lymphocyte count (Table 4.3). 
Activation of CD4+ and CD8++ lymphocytes 
Exercise had no effect on the percentages of CD4+ or CD8++ lymphocytes 
expressing CD69 following 20 h in vitro SEB stimulation (Table 4.3). There were 
also no effects of exercise on the SEB-stimulated CD69 expression (GMFI) by 
either CD4+CD69+ or CD8++CD69+ lymphocytes (Table 4.3). 
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Table 4.3. CD4+ and CD8++ lymphocyte counts and CD4+/CD8++ ratio, percentages of CD4+ 
and CD8++ lymphocytes expressing CD69 and CD69 expression by CD4+CD69+ and 
CD8++CD69+ lymphocytes after 20 h in vitro stimulation with staphylococcal enterotoxin 
B (SEB) in response to exercise. 
 Pre-ex Post-ex 1 h post-ex 
T lymphocyte subsets 
   CD4+ (x 109/l) 0.5 ± 0.3 0.6 ± 0.3 0.5 ± 0.3 
   CD8++ # (x 109/l) 0.4 ± 0.3 0.5 ± 0.4* 0.3 ± 0.2* 
   CD4+/CD8++ #  1.9 ± 1.2 1.7 ± 1.2* 2.2 ± 1.4* 
CD69+ cells (%) 
   CD4+ 23 ± 10 23 ± 11 23 ± 11 
   CD8++ 24 ± 11 26 ± 14 24 ± 11 
CD69 (GMFI) 
   CD4+CD69+ 141 ± 49 132 ± 42 143 ± 53 
   CD8++CD69+ # 106 ± 51 101 ± 55 109 ± 60 
GMFI: geometric mean of fluorescence intensity 
#Statistical analysis performed on log-transformed data  
Data are mean ± SD (n=15)  
*P < 0.05 vs. pre-ex 
Activation of CD14+CD86+HLA-DR+ monocytes  
CD86 and HLA-DR expression (GMFI) by CD14+CD86+HLA-DR+ monocytes 
following 20 h in vitro SEB stimulation (expressed as a ratio to unstimulated 
condition) were also not affected by exercise (Table 4.4). 
Table 4.4. CD86 and HLA-DR expression by CD14+CD86+HLA-DR+ monocytes after 20 h 
in vitro stimulation with staphylococcal enterotoxin B (SEB) in response to exercise. 
 Pre-ex Post-ex 1 h post-ex 
CD86 (GMFI*) 1.9 ± 0.9 1.8 ± 0.8 1.9 ± 0.8 
HLA-DR (GMFI*) 2.2 ± 1.0 2.2 ± 0.9 2.2 ± 0.9 
GMFI: geometric mean of fluorescence intensity  
*Ratio to unstimulated condition 
Data are mean ± SD (n=15) 
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Neutrophil degranulation (elastase release) 
There was an effect of exercise on plasma elastase concentration, i.e. 
unstimulated elastase release (Table 4.5; F1,2 = 7.9, P = 0.015). Plasma 
elastase concentration was elevated above pre-exercise levels at post-exercise 
(P = 0.030, ES = 0.73), yet it had returned to pre-exercise levels by 1 h post-
exercise. Total elastase release following 1 h in vitro stimulation with bacterial 
extract was also elevated following exercise (Table 4.5; F1,8 = 8.9, P = 0.003) 
and while a trend was already observed at post-exercise (P = 0.054, ES = 0.22) 
this was only evident at 1 h post-exercise (P = 0.007, ES = 0.54). When these 
data were corrected for changes in numbers of circulating neutrophils (i.e. 
expressed as bacterially-stimulated elastase release per cell), values were also 
elevated in response to exercise (Table 4.5; F1,3 = 6.6, P = 0.003), however this 
was only observed at 1 h post-exercise (P = 0.035, ES = 0.41). 
Table 4.5. Plasma elastase (unstimulated elastase release) and total and per neutrophil 
elastase release following 1 h in vitro stimulation with bacterial extract in response to 
exercise. 
 Pre-ex Post-ex 1 h post-ex 
Plasma elastase (µg/l) 
 54 ± 19 74 ± 34* 52 ± 16 
Total bacterially-stimulated elastase release (µg/l) 
 3398 ± 1489 3765 ± 1867 4359 ± 2033* 
Bacterially-stimulated elastase release per neutrophil (fg/cell) 
 510 ± 180 516 ± 206 598 ± 245* 
Data are mean ± SD (n=15) 
*P < 0.05 vs. pre-ex 
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Plasma markers of systemic inflammation 
Exercise induced an increase in plasma IL-6 levels (Figure 4.3; F2,0 = 13.3, P < 
0.0005), which was more evident at post-exercise (P = 0.0004, ES = 0.33) but 
still noticeable at 1 h post-exercise (P = 0.004, ES = 0.25). Plasma IL-10 
concentration was also elevated in response to exercise (Figure 4.4; F1,8 = 12.1, 
P < 0.0005), and although an increase was already apparent at post-exercise 
(P = 0.006, ES = 0.58) it was further increased by 1 h post-exercise (P = 0.001, 
ES = 1.12). Exercise also induced an elevation in plasma sTNF-RII levels 
(Figure 4.6; F2,0 = 4.3, P = 0.024), which was only evident at 1 h post-exercise 
(P = 0.027, ES = 0.30). There were no effects of exercise on plasma sTNF-RI 
(Figure 4.5) and CRP (Figure 4.7) concentrations. 
 
 
Figure 4.3. Plasma interleukin-6 (IL-6) response to exercise. Data are mean and individual 
values (n=15); statistical analysis performed on log-transformed data. 
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Figure 4.4. Plasma interleukin-10 (IL-10) response to exercise. Data are mean and 
individual values (n=13). 
 
 
Figure 4.5. Plasma soluble tumour necrosis factor receptor I (sTNF-RI) response to 
exercise. Data are mean and individual values (n=15). 
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Figure 4.6. Plasma soluble tumour necrosis factor receptor II (sTNF-RII) response to 
exercise. Data are mean and individual values (n=15). 
 
 
Figure 4.7. Plasma C-reactive protein (CRP) response to exercise. Data are mean and 
individual values (n=15); statistical analysis performed on log-transformed data. 
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4.5. Discussion 
This study investigated the effects of an acute bout of moderate intensity 
aerobic exercise on measures of immunity and inflammation in pre-dialysis CKD 
patients. We found that exercise enhanced neutrophil responsiveness to a 
bacterial challenge, yet did not affect T lymphocyte and monocyte activation. In 
addition, exercise induced a systemic anti-inflammatory environment. Overall, 
exercise induced an immune and inflammatory response that is comparable to 
that observed in healthy individuals. 
Exercise induced a modest increase in the peripheral blood leukocyte count, 
which peaked immediately after exercise reflecting the concomitant elevations 
in circulating neutrophil and lymphocyte numbers. However, 1 h after exercise 
cessation leukocyte concentration was still elevated, mostly due to a further 
increase in circulating neutrophils, as lymphocytes had already returned to pre-
exercise values. On the other hand, circulating monocyte count does not 
appear to have been affected. Exercise-induced leukocytosis is a well 
established phenomenon (McCarthy & Dale, 1988; Walsh et al., 2011). It has 
been suggested that the leukocytosis observed immediately after exercise is 
likely to be produced by demargination of neutrophils and lymphocytes from the 
blood vessels due to increased shear stress and catecholamines, whereas the 
delayed leukocytosis is mainly attributable to a release of neutrophils from the 
bone marrow induced by elevated cortisol levels (McCarthy & Dale, 1988; 
McCarthy et al., 1991; Walsh et al., 2011). The magnitude of these changes is, 
however, related to the intensity and the duration of the exercise performed 
(Nieman et al., 1994; Robson et al., 1999; Walsh et al., 2011).  
In contrast to the marked alterations induced by strenuous exercise (intensive 
or prolonged), Nieman et al. (2005) reported mild and transient increases in 
total and differential leukocyte counts following 30 min walking at 60-65% of 
VO2max   in healthy women, whereas Markovitch et al. (2008) reported no effect 
of 30 min walking at 50% of VO2max  in middle-aged healthy men. Our results are 
in agreement with Nieman et al. (2005) and the lack of effect observed by 
Markovitch et al. (2008) is likely to be intensity-related. Although we have not 
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measured VO2 during exercise, the average RPE response to exercise reported 
by Nieman et al. (2005) was identical to our study. Furthermore, the exercise 
protocol used in the present study was previously piloted in healthy volunteers 
and elicited similar alterations in total and differential leukocyte counts (Chapter 
3). The neutrophilia observed 1 h after exercise might also be partially related to 
the circadian variation in circulating neutrophils, which are known to increase 
throughout the morning hours (Haus & Smolensky, 1999). In agreement with 
this, Nieman et al. (2005) reported that neutrophil concentration 1 h after 
exercise, albeit elevated in relation to pre- and post-exercise, did not differ 
significantly from a control sitting condition at this time point. As we did not 
include a resting trial, we may only speculate that the effects of exercise and 
circadian variation are likely to superimpose to each other. Most importantly, 
and given that neutrophilia, monocytosis and lymphocytopenia are common 
features of CKD (Eleftheriadis et al., 2007; Agarwal & Light, 2011), our data 
suggest that an acute bout of moderate intensity aerobic exercise in pre-dialysis 
CKD patients does not elicit abnormal alterations in total and differential 
leukocyte counts. 
Exercise had little effect on the distribution of T lymphocyte subsets, which 
mainly reflected the small biphasic changes on the numbers of circulating 
CD8++ lymphocytes – elevated immediately after exercise and falling below pre-
exercise levels by 1 h into the recovery period. This pattern of mobilisation has 
been widely reported for T lymphocytes and its subpopulations (Gleeson & 
Bishop, 2005; Walsh et al., 2011) and appears to be largely dependent on the 
exercise intensity (Nieman et al., 1994). As expected for moderate intensity 
exercise, the effects on T lymphocyte subset counts reported in the present 
study were small and only CD8++ lymphocytes appear to have been affected. 
CD8+ lymphocytes have higher density of β2-adrenergic receptors than CD4+ 
lymphocytes and the density of these receptors increases with both exercise 
and exposure to catecholamines (Landmann, 1992; Shephard, 2003). Hence, 
the recruitment of CD8+ lymphocytes during exercise into the circulation is 
usually greater than that for CD4+ lymphocytes (Nieman et al., 1994; Gleeson & 
Bishop, 2005), which in the light of the exercise intensity used in the present 
study perhaps explains the lack of effect on CD4+ lymphocytes. Again, our 
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results indicate that alterations in the circulating numbers of T lymphocyte 
subsets in response to an acute bout of moderate intensity aerobic exercise in 
pre-dialysis CKD patients follow the normal pattern. 
SEB-stimulated activation of CD4+ and CD8++ lymphocytes, assessed by CD69 
expression, was unaffected by exercise. This is in agreement with our 
preliminary findings in healthy volunteers using the same exercise protocol 
(Chapter 3). Two other studies in well-trained men have found that the in vivo 
and mitogen-stimulated expression of CD69 on CD4+ and CD8+ lymphocytes 
did not significantly alter in response to 75 min of cycling at 75% of VO2max  
(Rønsen et al., 2001) or 60 min of treadmill running at 95% of ventilatory 
threshold (Green et al., 2003). However, decreases in the CD69 expression on 
both CD4+ and CD8+ cells immediately after an incremental treadmill test to 
exhaustion have also been reported in well-trained men (Vider et al., 2001) yet 
the nature of the exercise challenge is likely to explain this inconsistency. SEB-
stimulated activation of CD14+CD86+HLA-DR+ monocytes, assessed by the 
expression of CD86 and HLA-DR molecules, was also unaffected by exercise. 
This is again consistent with our pilot work in healthy subjects (Chapter 3). 
Disturbances in T lymphocytes and monocytes have been implicated in the 
immune dysfunction state that accompanies CKD, in which signs of immune 
depression and activation coexist (Eleftheriadis et al., 2007; Kato et al., 2008). 
Our study suggests that an acute bout of moderate intensity aerobic exercise in 
pre-dialysis CKD patients does not hinder T lymphocyte and monocyte immune 
competence nor it seems to aggravate the “pre-activated” state of these cells. 
Plasma elastase concentration was elevated above pre-exercise levels 
immediately after exercise, indicating that exercise induced a spontaneous 
neutrophil activation (degranulation in vivo). This is not unexpected because 
elevated plasma elastase levels have been consistently reported following 
various exercise protocols (Robson et al., 1999; Peake, 2002; Walsh et al., 
2011). Even moderate intensity exercise bouts, such as 60 min of cycling at 
approximately 70% of maximal heart rate (Smith et al., 1996) or 30 min of 
cycling at 70% of VO2max  (Blannin et al., 1996) have been shown to elevate the 
plasma concentration of elastase in healthy volunteers. Nevertheless, within 1 h 
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after exercise plasma elastase had returned to resting levels. Considering that 
neutrophils from patients with CKD are known to be primed (Sela et al., 2005), 
this observation is particularly important as it suggests that the exercise-induced 
neutrophil activation was only transient. The effects of repetitive exercise, 
however, require further investigation.  
Total bacterially-stimulated elastase release increased in response to exercise, 
however this most likely reflects the parallel neutrophilia (i.e. more cells, more 
elastase is released). When adjusted to take numbers of circulating neutrophils 
into account, bacterially-stimulated elastase release per neutrophil was 
unaltered immediately after exercise, but was increased 1 h after exercise, 
indicating enhanced neutrophil responsiveness to a bacterial challenge in the 
post-exercise period. This is in contrast to the reported reductions in stimulated 
neutrophil degranulation following numerous exercise protocols (Robson et al., 
1999; Peake, 2002; Walsh et al., 2011). In fact, stimulated neutrophil 
degranulation has even been shown to be diminished 2.5 h after 30 min of 
cycling at 70% of VO2max  in healthy subjects (Blannin et al., 1996) and therefore, 
exercise intensity is unlikely to explain this difference.  
In healthy people, the decreased functional capacity of the neutrophils following 
acute exercise has been, at least in part, attributed to the cortisol-induced 
release of less mature neutrophils from the bone marrow (Pyne, 1994; Peake, 
2002). However, as neutrophil function is known to be impaired in CKD 
(Chonchol, 2006), in the current study this  influx of “fresh” neutrophils may 
actually have contributed to the mobilisation of more functional neutrophils into 
the circulation. Although speculative this is perhaps supported by the fact that 
the increase in bacterially-stimulated elastase release per neutrophil coincided 
with the delayed neutrophilia (i.e. at 1 h post-exercise). Nonetheless, our results 
indicate improved ability of the neutrophils to respond to a bacterial challenge 
following an acute bout of moderate intensity aerobic exercise in pre-dialysis 
CKD patients. Given that neutrophil dysfunction is believed to increase the 
susceptibility to infections in CKD (Cohen et al., 1997; Chonchol, 2006), a 
potential protective effect of exercise is encouraging. Having said this, we do 
not know the duration of any protective effect. 
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Plasma IL-6 concentration was moderately elevated in response to exercise, 
with peak levels occurring immediately after exercise and, albeit still elevated, 
appeared to be returning towards resting levels by 1 h after exercise 
termination. Exercise also induced an increase in plasma IL-10 concentration, 
and although levels were already elevated immediately after exercise, peak 
values were reached 1 h after the end of exercise. At this time, there was also a 
small increase in plasma sTNF-RII levels, while the plasma concentrations of 
sTNF-RI and CRP appeared to have been unaffected by exercise. It has been 
consistently reported that plasma IL-6 levels increase during exercise, with a 
magnitude that is determined by the combination of mode, intensity and 
duration of the exercise performed (Fischer, 2006; Pedersen & Febbraio, 2008). 
Two studies in disease-free subjects have investigated the IL-6 response to the 
same exercise mode and duration used in the current study and have provided 
conflicting findings – in agreement with our results, Nieman et al. (2005) 
reported an increase following 30 min walking at 60-65% of VO2max , while in 
contrast Markovitch et al. (2008) reported no effect of 30 min walking at 50% of 
VO2max . Although differences in subject characteristics (such as gender, age or 
fitness) may also be a factor to consider, it is more likely that exercise intensity 
explains this discrepancy. In agreement, 40 min of cycling at approximately 
80% of maximal heart rate (RPE - “somewhat hard”) led to an increase in 
plasma IL-6 levels, while 40 min of cycling at approximately 60% of maximal 
heart rate (RPE - “fairly light”) did not, in middle-aged sedentary overweight 
men (Mendham et al., 2011). 
In CKD, circulating plasma IL-6 levels are chronically elevated and have been 
associated with atherosclerosis and other uraemic complications (Stenvinkel et 
al., 2002b; 2005). In fact, IL-6 appears to be the strongest predictor of outcome 
in CKD (Barreto et al., 2010). This raises the question about the safety of an 
exercise-induced increase in plasma IL-6 levels in patients with CKD. However, 
it is now clear that contracting skeletal muscle is the main source of the IL-6 in 
circulation in response to exercise (Steensberg et al., 2000; Toft et al., 2011) 
and muscle-derived IL-6, the first so-called “myokine” described (Pedersen et 
al., 2003), appears to mediate metabolic and anti-inflammatory effects, both 
locally and systemically in an hormone-like fashion (Petersen & Pedersen, 
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2005; Pedersen & Febbraio, 2008). In contrast to the cytokine cascade in 
sepsis, where IL-6 appearance is preceded by the pro-inflammatory TNF-α and 
IL-1β, in response to exercise IL-6 is typically the first cytokine present in the 
circulation, which is followed by the cytokine inhibitors IL-1ra and sTNF-Rs as 
well as the anti-inflammatory IL-10 (Petersen & Pedersen, 2005; Pedersen & 
Febbraio, 2008). The kinetics of the cytokine response to exercise observed in 
the present study are consistent with this. The greatest increase in plasma IL-6 
levels observed immediately after exercise was followed by a marked increase 
in plasma IL-10 levels 1 h after exercise, and although plasma IL-6 
concentration was still elevated at this time, it seemed to be returning towards 
resting values. Furthermore, a small increase in plasma sTNF-RII levels was 
also detected at this time. Given the moderate intensity of the exercise 
performed only mild increases in sTNF-Rs were expected, because even after 
strenuous exercise the increases in sTNF-Rs have been shown to be 
considerably lower than the marked increases in IL-6 and IL-10 (Ostrowski et 
al., 1999). However, the abnormally high resting levels of sTNF-Rs observed in 
our patients might have underestimated the observed effect of exercise on 
sTNF-RII as well as masked a possible effect on sTNF-RI.  
On the other hand, plasma CRP concentration was clearly unaffected by 
exercise. This is somewhat expected since CRP levels only appear to be 
modestly elevated immediately following strenuous physical exertion (Kasapis & 
Thompson, 2005; Plaisance & Grandjean, 2006). However, we should 
acknowledge that our study is limited by the fact that we have only collected 
blood samples until 1 h after exercise and alterations in CRP levels are often 
not seen until a few hours or even the day after exercise (Kasapis & Thompson, 
2005; Plaisance & Grandjean, 2006). In agreement, an increase in plasma CRP 
levels was reported 24 h after 40 min of cycling at approximately 80% of 
maximal heart rate in middle-aged sedentary overweight men, while no 
alterations were detected immediately or 3 h after exercise (Mendham et al., 
2011).  
A recent systematic review has highlighted a major gap in our knowledge 
regarding the effects of acute exercise on inflammatory markers in patients with 
a chronic inflammatory disease (Ploeger et al., 2009). To our knowledge this is 
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the first study to address this question in CKD and our results indicate that an 
acute bout of moderate intensity exercise in pre-dialysis CKD patients induces 
an anti-inflammatory environment and does not appear to exacerbate their 
underlying inflammatory status. An obvious limitation of our study is that we 
have not measured classical pro-inflammatory cytokines such as TNF-α and IL-
1β. However, there is convincing evidence from the literature to suggest that 
their levels would remain unaltered: it has been demonstrated that IL-6 infusion 
in humans enhances plasma IL-1ra, IL-10 and sTNF-RI but not TNF-α and IL-
1β (Tilg et al., 1994; Steensberg et al., 2003). In addition, exercise and IL-6 
infusion have been shown to inhibit the endotoxin-induced increase in 
circulating levels of TNF-α in healthy humans (Starkie et al., 2003). 
In summary, exercise enhanced neutrophil responsiveness to a bacterial 
challenge, while it did not affect T lymphocyte and monocyte activation. In 
addition, exercise induced a systemic anti-inflammatory environment. These 
findings suggest that an acute bout of moderate intensity aerobic exercise in 
pre-dialysis CKD patients seems to be safe from an immune and inflammatory 
perspective and it appears to improve immunosurveillance as well as to exert 
anti-inflammatory effects. However, it is not known whether these effects 
translate into a longer lasting state of immune and inflammatory protection. 
 
  
 
 
 
 
 
 Chapter 5
Effect of 1-month of regular moderate intensity aerobic 
exercise on immunity and inflammation in chronic kidney 
disease patients  
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5.1. Abstract 
Chronic kidney disease (CKD) is associated with a complex state of immune 
dysfunction characterised by immune depression, which predisposes CKD patients to 
infections, and by immune activation resulting in inflammation, which is associated with 
cardiovascular disease among these patients. It has been suggested that regular 
moderate exercise may enhance immune function and exert anti-inflammatory effects. 
However, such effects have been poorly investigated in CKD. Therefore, this study 
investigated the effects of 1-month of regular moderate intensity aerobic exercise on 
measures of immunity and inflammation in pre-dialysis CKD patients. 
Twenty-one (16 males and 5 females) pre-dialysis stage 3-5 CKD patients (age 58 ± 11 
yrs; BMI 27.7 ± 4.6 kg/m2; eGFR 21.5 ± 8.3 ml/min/1.73 m2) exercised for 30 min, 5 
times/week, for 1-month. The exercise programme consisted of brisk walking at a 
rating of perceived exertion (RPE) in the range of 12-14 (“somewhat hard”). At baseline 
and 1-month, patients performed a standard 30 min treadmill exercise test. Resting 
venous blood samples were collected on both occasions. SEB-stimulated CD4+ and 
CD8++ lymphocyte (CD69 expression) and CD14+CD86+HLA-DR+ monocyte activation 
(HLA-DR and CD86 expression) were determined by flow cytometry. Elastase release 
from unstimulated (plasma elastase) and bacterially-stimulated neutrophils, plasma 
inflammatory markers (IL-6, IL-10, sTNF-Rs and CRP), and cytokine levels in SEB-
stimulated PBMCs and bacterially-stimulated whole blood cultures were measured by 
ELISA. Data were examined using Student’s paired t-tests. 
RPE response to the exercise test at 1 month was lower than at baseline. After 1-
month, CD86 expression by CD14+CD86+HLA-DR+ monocytes was down-regulated, 
while HLA-DR expression, albeit showing a similar trend, did not change significantly. 
CD4+ and CD8++ lymphocyte activation (CD69) and neutrophil degranulation responses 
also remained unaltered. Plasma IL-6 levels were reduced, while plasma IL-10 levels 
were increased, resulting in a decreased IL-6/IL-10 ratio. Plasma sTNF-Rs levels were 
also reduced, while plasma CRP levels remained unchanged. IL-6 levels in SEB-
stimulated PBMCs and bacterially-stimulated whole blood cultures were also reduced. 
These findings indicate that regular moderate aerobic exercise in pre-dialysis CKD 
patients seems to be safe from an immune and inflammatory perspective and it 
appears to exert anti-inflammatory effects, most likely mediated by a down-regulation 
of monocyte activation. Longer duration and controlled trials are needed to confirm 
these potential effects.  
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5.2. Introduction 
The profound alterations in innate and adaptive immunity associated with 
chronic kidney disease (CKD) lead to a complex state of immune dysfunction, in 
which signs of immune depression and immune activation paradoxically coexist 
(as described in Chapter 1). Immune cell suppression predisposes patients with 
CKD to infections (Cohen et al., 1997; Descamps-Latscha et al., 2002; 
Eleftheriadis et al., 2007; Kato et al., 2008), yet persistent immune cell 
activation contributes to a state of chronic inflammation, evidenced by 
elevations in circulating levels of inflammatory mediators such as tumour 
necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 and IL-8 (Pereira et al., 
1994; Descamps-Latscha et al., 1995; Stenvinkel et al., 2005; Carrero et al., 
2008; 2009). These are associated with increased cardiovascular disease risk 
among these patients, with infection and cardiovascular disease the leading 
causes of morbidity and mortality in CKD (Naqvi & Collins, 2006; Dalrymple & 
Go, 2008; Saran & DuBose, 2008; Stenvinkel, 2010). 
It has been suggested that regular participation in moderate intensity exercise 
may enhance certain aspects of immune function and may exert anti-
inflammatory effects (Petersen & Pedersen, 2005; Senchina & Kohut, 2007; 
Haaland et al., 2008; Beavers et al., 2010; Gleeson et al., 2011; Nieman, 2011). 
These are believed to contribute, at least in part, to the lower risk of infection 
and cardiovascular disease that is observed in physically active individuals in 
comparison with their sedentary counterparts (Gleeson et al., 2011; Nieman, 
2011). However, the impact of regular exercise on immune and inflammatory 
parameters in patients with CKD is still unclear. The majority of the limited 
literature in this area has been focused on the effects of exercise in 
haemodialysis patients (Bronas, 2009), with little attention given to pre-dialysis 
CKD patients.  
Therefore, the aim of this study was to investigate the effects of 1-month of 
regular moderate intensity aerobic exercise on measures of immunity and 
inflammation in pre-dialysis CKD patients. 
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5.3. Methods 
Patients 
Thirty-three CKD patients (26 pre-dialysis patients and 7 patients on PD) were 
recruited for the 1-month study. A total of 25 patients, including 4 patients on 
PD, completed the study, while the other 8 patients dropped out. However, 
patients on PD were excluded from the analysis. Therefore, the present study 
includes a total of 21 pre-dialysis patients and their characteristics at baseline 
are shown in Table 5.1. 
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Table 5.1. Patients’ characteristics at baseline (n=21). 
Gender (n males / n females) 16 / 5 
Age* (years) 58 ± 11 
Weight* (kg) 82 ± 15 
Height* (cm) 172 ± 9 
BMI* (kg/m2) 27.7 ± 4.6 
eGFR* (ml/min/1.73 m2) 21.5 ± 8.3 
CKD stage# a)   
Stage 3 
Stage 4 
Stage 5 
5 
10 
6 
(24%) 
(48%) 
(29%) 
Primary renal disease# b)   
Renal Vascular Disease 
Cystic/poly 
Glomerulonephritis 
Diabetes 
Pyelonephritis 
Uncertain 
Other 
4 
2 
4 
2 
2 
5 
2 
(19%) 
(10%) 
(19%) 
(10%) 
(10%) 
(24%) 
(10%) 
Number of comorbidities#   
1 
2 
3 
4 
8 
7 
2 
4 
(38%) 
(33%) 
(10%) 
(19%) 
Immunosuppressive therapy# c) 5 (24%) 
BMI: body mass index 
eGFR: estimated glomerular filtration rate 
CKD: chronic kidney disease 
a) based on eGFR 
Data are *mean ± SD or #n (%) 
b) grouped according to UK Renal Registry (2010) 
c) excluded from the analysis of immune and inflammatory parameters 
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Experimental and analytical procedures 
All patients were prescribed a home-based exercise programme as described in 
Section 2.3. At baseline and after 1-month of regular exercise, all patients 
performed an exercise test as described in Section 2.2. Resting venous blood 
samples were obtained on both occasions. All analytical procedures are 
detailed in Chapter 2. 
Statistical analysis  
Data are presented as mean ± standard deviation (SD) unless otherwise stated. 
Data were inspected for normality using the Shapiro-Wilk test. If a data set was 
not normally distributed, statistical analysis was performed on the logarithmic 
transformation of the data, but data were back transformed for presentation. 
Outliers were defined as values deviating more than 3 SDs from the mean and 
were excluded from analysis. Data were examined using Student’s paired t-
tests (baseline vs. 1-month).  Effect sizes were calculated according to Cohen 
(1988) with correction for sample size (Hedges, 1981), by dividing the difference 
between means by the pooled SD. Statistical significance was accepted at P < 
0.05. 
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5.4. Results 
Exercise test outcomes 
The average walking speed during both exercise tests was 4.3 ± 1.3 km/h 
(range 2.1 to 8.1 km/h). The RPE response to baseline and 1-month exercise 
tests is illustrated in Figure 5.1. At 1-month, the RPE response to exercise was 
lower than at baseline (Table 5.2; ES = 1.78 and ES = 1.74 for average and 
area under curve, respectively). Likewise, the plasma lactate response to the 1-
month exercise test was lower than at baseline (Table 5.2; ES = 0.95). 
 
 
Figure 5.1. Rating of perceived exertion (RPE) response to baseline and 1-month 
exercise tests. Data are mean ± SD (n=21). 
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Table 5.2. Exercise test outcomes at baseline and 1-month. 
 Baseline 1-month P 
RPE (average) 13 ± 1 11 ± 1 0.00001 
RPE (area under curve) 183 ± 21 138 ± 31 0.00002 
Δ plasma lactate (mmol/l) 1.2 ± 1.1 0.4 ± 0.4 0.008 
RPE: rating of perceived exertion 
Δ = post-ex – pre-ex 
Data are mean ± SD (n=21) 
Body composition 
After 1-month of regular exercise there was a negligible decrease in body 
weight (Table 5.3; ES = 0.07), which led to a minor reduction in BMI (Table 5.3; 
ES = 0.08). 
Total and differential blood leukocyte counts 
The exercise intervention had no effect on the total and differential numbers of 
circulating leukocytes (Table 5.3). Haematocrit, haemoglobin and plasma 
volume were also unaltered (Table 5.3). 
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Table 5.3. Body composition, general haematology and total and differential blood 
leukocyte counts at baseline and 1-month. 
 Baseline 1-month P 
Body composition* 
Weight (kg) 82.6 ± 15.7 81.5 ± 15.1 0.011 
BMI (kg/m2) 27.8 ± 4.7 27.4 ± 4.6 0.013 
General haematology* 
Haematocrit (%) 36.5 ± 4.5 36.7 ± 4.4 0.807 
Haemoglobin (g/dl) 13.4 ± 1.6 13.3 ± 1.8 0.710 
Plasma volume (%) 63.5 ± 4.5 63.4 ± 4.4 0.810 
Total and differential blood leukocyte counts# 
Leukocytes (x 109/l) 6.9 ± 2.2 6.7 ± 2.2 0.561 
Neutrophils (x 109/l 4.3 ± 1.5 4.0 ± 1.5 0.192 
Lymphocytes (x 109/l) 1.7 ± 0.7 1.8 ± 0.8 0.312 
Monocytes (x 109/l) 0.6 ± 0.2 0.6 ± 0.2 0.612 
BMI: body mass index Data are mean ± SD (*n=21 or #n=16) 
T lymphocyte subsets 
There were no effects of the exercise intervention on the numbers of CD4+ and 
CD8++ lymphocytes (Table 5.4). Consequently, the CD4+/CD8++ ratio also 
remained unchanged (Table 5.4). 
Activation of CD4+ and CD8++ lymphocytes 
The percentages of CD4+ and CD8++ lymphocytes expressing CD69 following 
20 h in vitro SEB stimulation were unaffected by the exercise programme (Table 
5.4). Similarly, SEB-stimulated CD69 expression (GMFI) by either CD4+CD69+ 
or CD8++CD69+ lymphocytes was also unaltered (Table 5.4). 
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Table 5.4. CD4+ and CD8++ lymphocyte counts and CD4+/CD8++ ratio, percentages of CD4+ 
and CD8++ lymphocytes expressing CD69 and CD69 expression by CD4+CD69+ and 
CD8++CD69+ lymphocytes after 20 h in vitro stimulation with staphylococcal enterotoxin 
B (SEB) at baseline and 1-month. 
 Baseline 1-month P 
T lymphocyte subsets 
CD4+ (x 109/l) 0.6 ± 0.3 0.6 ± 0.3 0.989 
CD8++ (x 109/l) 0.5 ± 0.3 0.5 ± 0.3 0.876 
CD4+/CD8++  1.7 ± 0.7 1.6 ± 0.5 0.519 
CD69+ cells (%) 
CD4+ 25 ± 10 24 ± 14 0.727 
CD8++ 27 ± 11 25 ± 12 0.412 
CD69 (GMFI) 
CD4+CD69+ 135 ± 32 132 ± 34 0.845 
CD8++CD69+ 92 ± 30 95 ± 39 0.813 
GMFI: geometric mean of fluorescence intensity Data are mean ± SD (n=16) 
Activation of CD14+CD86+HLA-DR+ monocytes 
CD86 expression (GMFI) by CD14+CD86+HLA-DR+ monocytes following 20 h in 
vitro SEB stimulation (expressed as a ratio to unstimulated condition) was 
down-regulated after the exercise intervention (Table 5.5; ES = 0.49), while 
HLA-DR expression by the same cells did not change significantly (Table 5.5).  
Table 5.5. CD86 and HLA-DR expression by CD14+CD86+HLA-DR+ monocytes after 20 h 
in vitro stimulation with staphylococcal enterotoxin B (SEB) at baseline and 1-month. 
 Baseline 1-month P* 
CD86 (GMFI#) 1.9 ± 0.8 1.6 ± 0.9 0.029 
HLA-DR (GMFI#) 2.0 ± 0.6 1.7 ± 0.6 0.224 
GMFI: geometric mean of fluorescence intensity  
#Ratio to unstimulated condition 
*Statistical analysis performed on log-transformed data 
Data are mean ± SD (n=16)  
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Neutrophil degranulation (elastase release) 
The exercise intervention had no effect on plasma elastase concentration 
(unstimulated elastase release) nor on the total and per neutrophil elastase 
release following 1 h in vitro stimulation with bacterial extract (Table 5.6). 
Table 5.6. Plasma elastase (unstimulated elastase release) and total and per neutrophil 
elastase release following 1 h in vitro stimulation with bacterial extract at baseline and 1-
month. 
 Baseline 1-month P 
Plasma elastase (µg/l) 
 66 ± 22 67 ± 27 0.910 
Total bacterially-stimulated elastase release (µg/l) 
 3274 ± 1617 3296 ± 1416 0.931 
Bacterially-stimulated elastase release per neutrophil* (fg/cell) 
 498 ± 147 541 ± 284 0.833 
*Statistical analysis performed on log-transformed data Data are mean ± SD (n=16) 
Plasma markers of systemic inflammation 
Following 1-month of regular exercise, plasma IL-6 concentration was 
decreased below baseline levels (Figure 5.2; ES = 0.41), while plasma IL-10 
concentration was increased (Figure 5.3; ES = 0.78). Consequently, there was 
a decline in the plasma IL-6/IL-10 ratio (Figure 5.4; ES = 0.61). Plasma sTNF-RI 
(Figure 5.5) and sTNF-RII (Figure 5.6) levels were also reduced following the 
exercise intervention (ES = 0.44 and ES = 0.62, respectively), while plasma 
CRP levels remained unchanged (Figure 5.7). 
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Figure 5.2. Plasma interleukin-6 (IL-6) at baseline and 1-month. Data are mean and 
individual values (n=16); statistical analysis performed on log-transformed data. 
 
 
Figure 5.3. Plasma interleukin-10 (IL-10) at baseline and 1-month. Data are mean and 
individual values (n=14). 
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Figure 5.4. Plasma interleukin-6 to interleukin-10 (IL-6/IL-10) ratio at baseline and 1-
month. Data are mean and individual values (n=16); statistical analysis performed on log-
transformed data. 
 
 
Figure 5.5. Plasma soluble tumour necrosis factor receptor I (sTNF-RI) at baseline and 1-
month. Data are mean and individual values (n=16). 
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Figure 5.6. Plasma soluble tumour necrosis factor receptor II (sTNF-RII) at baseline and 
1-month. Data are mean and individual values (n=16). 
 
 
Figure 5.7. Plasma C-reactive protein (CRP) at baseline and 1-month. Data are mean and 
individual values (n=16); statistical analysis performed on log-transformed data. 
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PBMCs cytokine production 
IL-6 production by PBMCs following 8 days in vitro SEB stimulation was 
decreased following the exercise intervention (Table 5.7; ES = 0.95), while 
SEB-stimulated PBMCs IL-10 production remained unchanged (Table 5.7). 
Accordingly, the ratio of IL-6 to IL-10 production by SEB-stimulated PBMCs at 
1-month was lower than at baseline (Table 5.7; ES = 1.36). 
Whole blood cytokine production 
Whole blood IL-6 production following 1 h in vitro stimulation with bacterial 
extract was also lowered following 1-month of regular exercise (Table 5.7; 
ES=0.60). 
Table 5.7. Peripheral blood mononuclear cells (PBMCs) cytokine production following 8 
days in vitro stimulation with staphylococcal enterotoxin B (SEB) and whole blood 
cytokine production following 1 h in vitro stimulation with bacterial extract at baseline 
and 1-month. 
 Baseline 1-month P* 
SEB-stimulated PBMCs cytokine production 
IL-6 (ng/l) 1.8 ± 1.7 1.1 ± 1.9 0.004 
IL-10 (ng/l) 1.1 ± 0.7 1.1 ± 0.8 0.355 
IL-6/IL-10 ratio 2.2 ± 2.0 0.7 ± 0.7 0.007 
Bacterially-stimulated whole blood cytokine production 
IL-6 (pg/l) 19.9 ± 12.1 14.2 ± 7.8 0.041 
IL: interleukin 
*Statistical analysis performed on log-transformed data 
Data are mean ± SD (n=16) 
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Effect of additional bicarbonate therapy 
Ten of the patients that participated in this study were randomised to receive 
sufficient additional oral bicarbonate to raise plasma bicarbonate to 
approximately 29 mmol/l, while the remaining patients continued with their usual 
bicarbonate therapy (target plasma bicarbonate 24 mmol/l).  
To investigate the effects of the additional bicarbonate therapy data were 
examined using an ANOVA with mixed design: within-subjects (time: baseline 
vs. 1-month) x between-subjects (treatment: standard vs. bicarbonate). 
As expected, there was an effect of the additional bicarbonate therapy on 
plasma bicarbonate concentration (F = 10.9, P = 0.005). At 1-month, plasma 
bicarbonate levels were elevated above baseline levels in the bicarbonate 
group (1-month: 26.8 ± 2.6 mmol/l vs. baseline: 22.6 ± 3.2 mmol/l, P = 0.006) 
but remained unaltered in the standard group (1-month: 22.3 ± 3.4 mmol/l vs. 
baseline: 22.6 ± 2.7 mmol/l, P = 0.813). 
However, there were no effects of the additional bicarbonate therapy on any of 
the immune and inflammatory parameters studied. 
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5.5. Discussion 
This study investigated the effects of 1-month of regular moderate intensity 
aerobic exercise on measures of immunity and inflammation in pre-dialysis CKD 
patients. We found that the exercise intervention down-regulated monocyte 
activation, while it did not affect T lymphocyte activation or neutrophil 
degranulation responses. In addition, the exercise intervention exerted anti-
inflammatory effects at the systemic level and in PBMC and whole blood 
cultures. 
After 1-month of regular exercise, the RPE response to a standardised exercise 
test was lower than at baseline: patients’ perception of the same absolute 
exercise load dropped, in average, from “somewhat hard” to “fairly light”. In 
agreement, the plasma lactate response to the acute exercise test was also 
reduced after 1-month. Previous studies have shown that aerobic exercise 
training can improve exercise tolerance and capacity in pre-dialysis CKD 
patients (Clyne et al., 1991; Eidemak et al., 1997; Boyce et al., 1997; Leehey et 
al., 2009; Toyama et al., 2010; Mustata et al., 2010). Our data confirm and 
extend these findings by showing that even 1-month of regular exercise 
appears to be sufficient to bring about significant improvements in exercise 
tolerance in pre-dialysis CKD. It may be argued that our study is limited by the 
lack of determination of peak exercise capacity. However, such measurements 
may not necessarily reflect the patients’ capacity to perform daily living 
activities, which are more likely to demand sustained effort at submaximal levels 
(Koufaki & Kouidi, 2010). Therefore, the observed improvements in submaximal 
exercise tolerance are arguably even more clinically relevant. 
Circulating total and differential blood leukocyte counts were not affected by 
regular exercise. This is consistent with previous research in healthy elderly 
adults (Haaland et al., 2008). However, a recent study has shown that 
leukocyte, neutrophil and monocyte counts were reduced following 6-weeks of 
moderate aerobic exercise training in overweight women with coronary risk 
factors (Michishita et al., 2010). In addition, the reported decreases in monocyte 
and neutrophil counts were related to the decreases in fasting triglyceride and 
BMI and the increases in insulin sensitivity and exercise capacity (Michishita et 
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al., 2010). Hence, although our study failed to detect this, it is possible that 
regular exercise participation may reduce neutrophil and monocyte counts in 
those with a chronic inflammatory condition. On the other hand, we have 
previously reported that an acute bout of moderate intensity aerobic exercise in 
pre-dialysis CKD patients elicits modest alterations in total and differential blood 
leukocyte counts (Chapter 4). Given that disturbances in total and differential 
blood leukocytes are common in CKD (Eleftheriadis et al., 2007; Agarwal & 
Light, 2011), it is important to highlight that regular exercise appears to be safe 
in this regard. 
Regular exercise had no effect on the in vivo and in vitro neutrophil 
degranulation responses, as indicated by the unaltered plasma elastase levels 
and bacterially-stimulated elastase release after 1-month of regular exercise. 
Little is known about the effects of moderate exercise training on neutrophil 
function (Walsh et al., 2011) but there is cross-sectional evidence suggesting 
that long-term physical activity may counteract the age-associated decline in 
neutrophil function. Yan et al. (2001) reported that physically active older men 
(who exercised at least twice a week for a minimum of 1 hour for more than 3 
years) had higher neutrophil phagocytic activity than their sedentary 
counterparts and that this function was preserved at the level of a group of 
younger subjects. Hence, it is conceivable that exercise interventions of longer 
duration than the one used in the present study are required for beneficial 
effects of exercise on neutrophil function to become apparent. On the other 
hand, given that plasma elastase levels are elevated in CKD (Costa et al., 
2008; Caimi et al., 2009; Polańska et al., 2010) and that primed neutrophils 
have been implicated in the chronic state of systemic inflammation and 
oxidative stress that accompanies CKD (Sela et al., 2005), it is important to note 
that the present findings indicate that regular exercise in pre-dialysis CKD 
patients does not appear to exacerbate their resting neutrophils’ activation 
state, even though transient spontaneous neutrophil activation might occur 
during each acute exercise bout (Chapter 4). In addition, although the current 
study does not show that the enhanced neutrophil responsiveness to an in vitro 
bacterial challenge observed following an acute bout of exercise (Chapter 4) 
translates into a chronic adaptation, it should also be highlighted that regular 
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exercise does not appear to be detrimental to the neutrophil function of pre-
dialysis CKD patients, which is particularly important considering that neutrophil 
function is impaired in CKD (Chonchol, 2006) 
T lymphocyte subset counts and their relative distribution also remained 
unaltered following the exercise programme, which is again in agreement with 
several reports in healthy older adults (Haaland et al., 2008; Simpson & Guy, 
2010). A single study in a group of CKD patients on haemodialysis has also 
reported no alterations in the circulating CD4+ and CD8+ lymphocyte counts or 
the CD4+/CD8+ ratio following 6-months of exercise training (Daniilidis et al., 
2004). In CKD, although lymphocytopenia is commonly described, cell numbers 
are usually in the lower normal range and the CD4+/CD8+ ratio also remains 
within normal levels (Girndt et al., 2001a; Eleftheriadis et al., 2007). Our data 
are consistent with this. 
Regular exercise had no effect on the SEB-stimulated activation of CD4+ and 
CD8++ lymphocytes, assessed by the early activation marker CD69. There is 
limited information concerning the effects of exercise training on T lymphocyte 
activation. Only two studies to date have addressed this question using the 
CD69 marker. Phytohemagglutinin (PHA)–stimulated CD69 expression by CD4+ 
and CD8+ cells remained unaltered following 10-months of moderate aerobic 
exercise training in older adults (Lee et al., 2004). Likewise, 12-months of 
resistance training had no effect on the percentages of CD3+, CD4+ or CD8+ 
cells expressing CD69 in elderly women (Raso et al., 2007). Interestingly, in the 
first study PHA-induced T lymphocyte proliferation and CD25 (IL-2 receptor α) 
expression were increased following the exercise intervention (Kohut & 
Senchina, 2004; Lee et al., 2004), whereas in the latter the percentages of 
CD3+, CD4+ or CD8+ cells expressing CD25 or HLA-DR did not change, as did 
not numbers of CD4+ or CD8+ cells expressing the co-stimulatory molecule 
CD28 nor did PHA-stimulated T lymphocyte proliferation (Raso et al., 2007). In 
fact, studies that have used other markers of T lymphocyte activation have 
yielded conflicting results. Kapasi et al. (2003) found no effect of 8-months of a 
mixed endurance and resistance exercise training programme in frail elderly 
nursing home residents on the percentages of CD3+, CD4+ or CD8+ cells 
expressing CD28 or CD25 and the percentages of CD3+ and CD8+ cells 
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expressing HLA-DR. Of note, PHA-stimulated T lymphocyte proliferation was 
also unaffected. In contrast, increased numbers and percentages of CD4+ cells 
expressing CD28 were reported after 6-months of moderate aerobic exercise 
training in a group of elderly males and females (Shimizu et al., 2008) and 
increased percentages of PHA-stimulated CD4+ cells expressing CD25 were 
reported during 12-months of moderate aerobic exercise training in older men 
but not older women (Broadbent & Gass, 2008). It can be argued that when 
studying T lymphocyte activation, the assessment of activation markers 
following in vitro activation by appropriate stimuli is more relevant than the ex 
vivo spontaneous levels of these markers. However, obvious differences 
between the studies described above, including the length of the intervention, 
the exercise regimen (mode, intensity and duration) and subjects’ 
characteristics, make comparisons difficult. Nevertheless, although 
inconclusive, the available evidence points towards some favourable effects of 
regular, particularly aerobic exercise, on several aspects of T lymphocyte 
function but it appears that long-term interventions (> 6-months) are required 
(Kohut & Senchina, 2004; Haaland et al., 2008; Simpson & Guy, 2010). The 
fact that most cross-sectional studies have consistently reported enhanced T 
lymphocyte function in physically active older adults (probably for longer periods 
than what is commonly used in exercise intervention studies) compared with 
their sedentary counterparts (Kohut & Senchina, 2004; Simpson & Guy, 2010) 
also supports the idea that long-term regular exercise participation is needed for 
the benefits to occur. Therefore, although it appears from the current findings 
that T lymphocyte activation is not affected by regular exercise in pre-dialysis 
CKD patients, longer duration trials are warranted to fully elucidate this.  
On the other hand, it is important to highlight that the majority of the research 
described above was conducted in sedentary but otherwise healthy older 
adults, and little is known about the effects of regular exercise on 
immunocompromised individuals, such as CKD patients. T lymphocyte 
deficiencies have been widely reported in CKD (Girndt et al., 2001a; 
Eleftheriadis et al., 2007; Kato et al., 2008). Of particular interest is the fact that 
despite reduced T lymphocyte proliferative activity, an increased number of 
CD3+ cells expressing CD69 (assessed ex vivo and after PHA and anti-CD3 
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stimulation) has been described in pre-dialysis and haemodialysis patients 
(albeit to a greater extent in the latter group), as compared to healthy controls 
(Meier et al., 2002). Given that higher percentages of CD3+ or CD3+CD69+ cells 
expressing anexin V or CD95 (apoptosis markers) were also described in 
patients vs. controls, it is believed that in patients with CKD a significant 
proportion of activated T cells ultimately do not proliferate but become apoptotic 
(Meier et al., 2002). The present study indicates that regular moderate aerobic 
exercise does not influence CD69 expression by T lymphocytes and therefore it 
does not appear to aggravate their activated state. Nevertheless, our study is 
limited by its short-duration and the lack of a control group. As mentioned 
above, chronic T lymphocyte function adaptations only appear to occur after 
longer periods of exercise engagement. In addition, CD69 expression by T 
lymphocytes has been reported to increase overtime in a group of CKD patients 
on haemodialysis (Meier et al., 2000), so similar findings could be anticipated in 
pre-dialysis patients. Therefore, longer duration and controlled trials are needed 
to establish the impact of regular exercise on T lymphocyte activation in pre-
dialysis CKD patients. 
CD86 expression by CD14+CD86+HLA-DR+ monocytes following in vitro SEB-
stimulation was down-regulated after the exercise intervention, whereas HLA-
DR expression by the same cells, although apparently showing a similar trend, 
did not change significantly. These results suggest that regular exercise may 
reduce monocyte activation in pre-dialysis CKD patients. To our knowledge no 
previous research has investigated the effects of chronic exercise on these 
monocyte cell surface molecules, while a single study has reported that CD86 
and HLA-DR expression by CD14+ monocytes were down-regulated following 
acute prolonged exercise (Lancaster et al., 2005). However, there is emerging 
evidence that exercise training and increased physical activity levels down-
regulate Toll-like receptor (TLR) 4 expression by CD14+ monocytes (McFarlin et 
al., 2004; Stewart et al., 2005; McFarlin et al., 2006), which is a recognised 
potential mechanism for the anti-inflammatory role of exercise (Gleeson et al., 
2006; Flynn & McFarlin, 2006; Gleeson et al., 2011). Our results are in 
agreement with these findings because activation of TLRs up-regulates major 
histocompatibility complex (MHC) class II (HLA-DR) and co-stimulatory 
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molecule expression (CD80/86) on the antigen processing cell (APC) such as 
the monocyte or dendritic cell (Takeda et al., 2003) and therefore it is possible 
that the down-regulation of CD86 and possibly HLA-DR were mediated by a 
down-regulation of TLR 4. Although we have not used the conventional TLR 4 
ligand, that is, lipopolysaccharide, as a stimuli in our in vitro activation assays, it 
should be noted that SEB has already been shown to up-regulate TLR 4 in 
human monocytes (Hopkins et al., 2005). 
Another explanation for the observed down-regulation of monocyte activation 
may lie in a reduced proportion of circulating CD16+ monocytes. The recently 
updated classification of monocyte heterogeneity acknowledges the existence 
of three monocyte subsets: classical (CD14++CD16-), intermediate 
(CD14++CD16+) and non-classical (CD14+CD16++) (Ziegler-Heitbrock et al., 
2010). However, in earlier studies the latter two subsets were often denoted as 
(CD14+)CD16+ monocytes, which have traditionally been labelled pro-
inflammatory monocytes and are elevated in various inflammatory conditions, 
including CKD (Ziegler-Heitbrock, 2007). Interestingly, CD16+ monocytes 
express higher levels of CD86 and HLA-DR in comparison with classical 
monocytes (Gordon & Taylor, 2005; Ziegler-Heitbrock, 2007; Zawada et al., 
2011) and therefore a reduction in the proportion of these cells in the circulation 
following the exercise intervention could also explain our findings. In fact, 
evidence exists that regular exercise appears to reduce the proportion of pro-
inflammatory monocytes in the blood compartment (Timmerman et al., 2008), 
which is proposed as another mechanism whereby exercise exerts its anti-
inflammatory effects (Gleeson et al., 2011). Of note, pro-inflammatory, 
specifically CD14++CD16+ monocytes, have been recently shown to be 
independently associated with cardiovascular outcome in both dialysis (Heine et 
al., 2008) and pre-dialysis (Rogacev et al., 2011) patients. Hence, research 
addressing the impact of regular exercise on the different monocyte subsets in 
CKD patients seems highly warranted. 
On the other hand, we have to acknowledge the possible detrimental role of a 
down-regulation of monocyte activation in the orchestration of the adaptive 
immune response.  T cell activation requires at least two signals. The 
interaction between MHC-antigen peptide complex on the APC with the T cell 
  
106 
receptor provides the first signal, while the second signal occurs through the 
interaction between co-stimulatory cell surface molecules (CD80/86) on the 
APC and CD28 on the T cell membrane. Importantly, in the absence of co-
stimulatory signalling, T cells fail to respond effectively and are rendered 
anergic (Sharpe & Freeman, 2002).  
In CKD, T lymphocyte function is clearly impaired and it is currently 
acknowledged that this can be attributed to the defective interaction between 
the APC and the T lymphocyte (Girndt et al., 2001a; Eleftheriadis et al., 2007; 
Kato et al., 2008). Several aspects of this interaction have been shown to be 
impaired, although it should be noted that most of this evidence comes from 
studies conducted on haemodialysis patients (Eleftheriadis et al., 2007). Of 
particular interest is a study by Girndt et al. (2001b), which has shown that ex 
vivo monocyte CD86 expression was reduced in haemodialysis patients (also 
confirmed after in vitro stimulation with either interferon-ɣ or cyclic adenosine 
monophosphate), while HLA-DR expression was not affected. Furthermore, the 
defective CD86 expression was associated with the clinical immune defect 
(lower levels in non-responders than responders to hepatitis B vaccination), as 
well as with the in vitro lymphocyte proliferative response (Girndt et al., 2001b). 
However, this defect was not observed in pre-dialysis patients, suggesting a 
possible role for the dialysis procedure itself and/or the severity of the renal 
function impairment (Girndt et al., 2001b). It is also important to highlight that 
while Girndt et al. (2001b) reported that monocyte HLA-DR expression was 
normal, this was only assessed ex vivo and a previous study has shown that 
although monocytes recently isolated from haemodialysis patients do not 
express less HLA-DR than those from healthy individuals, their HLA-DR 
expression is impaired after in vitro stimulation with hepatitis B surface antigen 
(Stachowski et al., 1994). Nevertheless, from the evidence above it is not clear 
whether or not CD86 and HLA-DR expression are compromised in pre-dialysis 
patients.  
However, there is emerging evidence implicating CKD-associated TLR 
disturbances in the APC dysfunction (Kato et al., 2008). As mentioned above, 
activation of TLRs up-regulates CD86 and HLA-DR expression (Takeda et al., 
2003), and therefore it is possible that the defective expression of these 
  
107 
molecules are mediated through TLR deficiencies. Indeed, evidence of a down-
regulation of TLR 4 expression exists for both pre-dialysis (Ando et al., 2006; 
Koc et al., 2011) and haemodialysis (Kuroki et al., 2007; Koc et al., 2011) 
patients, while two conflicting studies in haemodialysis patients have reported 
an up-regulation of TLR 4 expression (Gollapudi et al., 2010; Kim et al., 2011). 
As previously discussed it is plausible that the exercise-induced down-
regulation of monocyte activation observed in the present study was mediated 
through a down-regulation of TLR 4 expression. Hence, it is possible that the 
anti-inflammatory effects of exercise in CKD might be accompanied by some 
degree of impairment of the adaptive immune response.  
In the present study we have used SEB as the stimuli for the in vitro activation 
assays. In contrast to conventional antigens, SEB does not require processing 
and presentation and acts through cross-linking the MHC on the APC with the 
Vβ domain of the TCR, resulting in the stimulation of a large proportion of T 
cells that is CD4-independent and therefore both CD4+ and CD8+ cells are 
stimulated (Bueno et al., 2007). Importantly, proliferation of T lymphocytes after 
SEB stimulation also requires co-stimulation (Krummel et al., 1996; Mittrücker et 
al., 1996). Therefore, it could be argued that the exercise-induced down-
regulation of monocyte activation observed in the present study did not impair T 
lymphocyte function because SEB-stimulated activation of CD4+ and CD8++ 
lymphocytes was maintained after the exercise intervention. However, we have 
to acknowledge that the use of CD69 expression as an indicator of maintained 
T lymphocyte function is limited in CKD. Indeed, as noted above, an increased 
number of CD69+ T lymphocytes is actually associated with lower T lymphocyte 
proliferative capacity (Meier et al., 2002; 2005). In addition, stimulation of T cells 
by SEB in the absence of co-stimulation (CD28-deficient mice) does not appear 
to influence the early events of T cell activation, such as CD69 expression 
(Mittrücker et al., 1996). Therefore, we cannot refute the possibility that a down-
regulation of monocyte activation could be associated with reduced T 
lymphocyte responsiveness and future research should address the impact of 
regular exercise on other aspects of the T lymphocyte function of CKD patients. 
On the other hand, it has been demonstrated that monocytes from CKD 
patients are “pre-activated” and overproduce pro-inflammatory cytokines (Girndt 
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et al., 2001a; Descamps-Latscha et al., 2002; Eleftheriadis et al., 2007), 
typically by assessing the concentration of pro-inflammatory cytokines, such as 
TNF-α, IL-1β, IL-6 and IL-8, in supernatants from LPS-stimulated PBMC 
cultures (Girndt et al., 1995; Higuchi et al., 1997; Morita et al., 1997; 
Sardenberg et al., 2004)  but also in supernatants from LPS-stimulated whole 
blood cultures (Gollapudi et al., 2010) or through intracellular staining following 
LPS stimulation by flow cytometry (Girndt et al., 1998). Haemodialysis treatment 
is an obvious candidate to explain such findings, but studies that have included 
pre-dialysis patients have also shown that pro-inflammatory cytokine production 
is increased, albeit to a smaller extent than in haemodialysis patients (Higuchi 
et al., 1997; Sardenberg et al., 2004; Mantuano et al., 2007), indicating that 
uraemia per se also plays a role. In the present study, we found that IL-6 
production by PBMCs following SEB stimulation was reduced after the exercise 
intervention, while IL-10 production by the same cells was maintained, resulting 
in a marked reduction in the ratio of IL-6 to IL-10 production. In addition, the 
exercise-induced reduction in IL-6 production was confirmed in bacterially-
stimulated whole blood cultures. These findings are in agreement with mounting 
evidence indicating that regular exercise can improve the PBMC cytokine profile 
after in vitro stimulation through reductions in pro-inflammatory and/or increases 
in anti-inflammatory cytokine production (Smith et al., 1999; Stewart et al., 
2005; Sloan et al., 2007; Timmerman et al., 2008; Phillips et al., 2010; Ortega et 
al., 2010), and provide the first evidence of similar effects in pre-dialysis CKD 
patients. Importantly, the reduced production of pro-inflammatory cytokines by 
PBMCs has been proposed as another possible mechanism mediating the anti-
inflammatory effects of exercise (Nicklas & Brinkley, 2009). Hence, it seems 
that the apparent exercise-induced down-regulation of the immune response 
(discussed above) might be a small price to pay for the anti-inflammatory 
effects. Interestingly, the production of IL-6, TNF-α and IL-10 by LPS-stimulated 
PBMCs from haemodialysis patients have also been associated with the clinical 
immune defect – non-responders to hepatitis B vaccination produced higher 
levels of IL-6 and TNF-α, while responders produced normal levels of these 
cytokines but higher levels of IL-10 (Girndt et al., 1995). Undoubtedly, immune 
system dysfunction in CKD is a multifactorial process, where at the immune cell 
level signs of functional deficiency coexist with signs of activation. It makes 
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intuitive sense that persistent cellular activation will further impair the functional 
defects. This perhaps also explains the apparently conflicting findings from a 
recent study, which has reported that monocytes from infection prone pre-
dialysis CKD patients exhibited significantly reduced synthesis of TNF-α, IL-1β, 
IL-6 and IL-8 in response to LPS challenge compared with those from control 
subjects (Ando et al., 2006). Nevertheless, seeming paradoxical it can be 
argued that in pre-dialysis CKD patients a down-regulation of the 
immune/inflammatory response through exercise training may contribute to an 
enhanced immune function in the longer term. 
The potential anti-inflammatory effects of regular exercise were confirmed at the 
systemic level. Plasma IL-6 concentration was reduced after 1-month of regular 
exercise, while plasma IL-10 concentration was increased, resulting in a 
decreased ratio of IL-6 to IL-10 in the circulation (a proposed indicator of the 
overall inflammatory status). Plasma sTNF-Rs levels were also reduced, while 
plasma CRP levels remained unaltered. These findings are very promising 
because the persistent inflammation that accompanies CKD is associated with 
cardiovascular disease (the leading cause of death in CKD) and other uraemic 
complications (Carrero & Stenvinkel, 2010). The cytokine network is clearly 
altered in CKD (Stenvinkel et al., 2005; Carrero et al., 2008). Plasma IL-6 levels 
are elevated and have consistently been shown to predict all cause and 
cardiovascular mortality in CKD (Stenvinkel et al., 2002b; 2005). Of interest, the 
predictive value of plasma IL-6 has been recently confirmed in pre-dialysis CKD 
patients (Barreto et al., 2010). IL-10 has been regarded as one of the most 
important anti-inflammatory immune-regulating cytokines (Moore et al., 2001). 
Hence, as a result of the underlying persistent inflammation, it is not surprising 
that plasma IL-10 levels are usually found to be elevated in CKD (Morita et al., 
1997; Moser et al., 2003; Sardenberg et al., 2004). On the other hand, 
haemodialysis patients with lower levels of plasma IL-10 appear to be at a 
higher risk for atherosclerosis (Seyrek et al., 2005). In agreement, 
haemodialysis patients genetically predisposed to produce higher levels of IL-
10 show better immune balance (Girndt et al., 2001c) and are at lower risk of 
cardiovascular events (Girndt et al., 2002). In this context, it can be argued that 
the balance between IL-6 and IL-10 might be a more valid parameter to draw 
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conclusions about the overall inflammatory status. The sTNF-Rs, which are the 
extracellular form of the natural occurring inhibitors of TNF but also likely 
“footprints” of its activity (Brockhaus, 1997), are also elevated in CKD (Pereira 
et al., 1994; Descamps-Latscha et al., 1995; Ankersmit et al., 2001). Altogether 
the evidence presented above clearly illustrates the significance of our findings.  
However, in contrast to the favourable effects on plasma cytokines we have 
failed to detect an effect of regular exercise on plasma CRP. There is no 
obvious explanation for this. Although it is also well established that CRP levels 
are elevated and predict all cause and cardiovascular mortality in CKD (Lacson 
& Levin, 2004; Wanner et al., 2009), CRP is a rather non-specific marker and 
therefore it might be difficult to detect changes in small patient cohorts. In 
addition, CRP is currently thought to be a simple marker rather than a causal 
factor for cardiovascular disease (Zhang et al., 2007; Zacho et al., 2008) and 
therefore it can be argued that an effect of exercise may be detectable in the 
longer-term. Notwithstanding, it is noteworthy that IL-6 has been consistently 
reported to be a stronger predictor of all cause and cardiovascular outcome in 
CKD, than any other inflammatory marker, including CRP (Tripepi et al., 2005; 
Honda et al., 2006; Zoccali et al., 2006; Pachaly et al., 2008; Wetmore et al., 
2008; Barreto et al., 2010). 
Previous studies reporting effects of regular exercise on systemic inflammatory 
markers in CKD patients have yielded conflicting results (Załuska et al., 2002; 
Castaneda et al., 2004; Nindl et al., 2004; Cheema et al., 2007a; 2007b; Kopple 
et al., 2007; Toussaint et al., 2008; Leehey et al., 2009; Wilund et al., 2010; 
Afshar et al., 2010; 2011; Cheema et al., 2011). It is noteworthy that in most of 
these studies systemic inflammatory markers have been secondary study 
outcomes and therefore it is not surprising that the widely used inflammatory 
marker CRP is reported in all of them. Exercise training reduced CRP levels in 6 
studies (Załuska et al., 2002; Castaneda et al., 2004; Nindl et al., 2004; 
Cheema et al., 2007a; 2007b; Afshar et al., 2010; 2011; Cheema et al., 2011), 
while the other 4 reports have found no effect (Kopple et al., 2007; Toussaint et 
al., 2008; Leehey et al., 2009; Wilund et al., 2010). It is important to highlight 
that only 2 of these studies have focused on pre-dialysis patients (Castaneda et 
al., 2004; Leehey et al., 2009). Castaneda et al. (2004) reported that 12-weeks 
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of resistance exercise training reduced CRP and IL-6 levels, while Leehey et al. 
(2009) reported that 24-weeks of aerobic exercise training had no effect on 
CRP levels. On the other hand, data from cytokine measurements is only 
available in 3 other studies in haemodialysis patients (Kopple et al., 2007; 
Wilund et al., 2010; Cheema et al., 2011). Besides the lack of effect on CRP 
levels, Kopple et al. (2007) reported no effect of approximately 21-weeks of 
aerobic (intradialytic) or resistance (before dialysis) training or both on IL-6 and 
TNF-α levels, whilst Wilund et al. (2010) also reported no effect of 4-months of 
intradialytic aerobic exercise on IL-6 levels. It is worth mentioning that in the 
study of Kopple et al. (2007) a trend for a reduction in CRP and IL-6 levels was 
apparent following aerobic exercise training but not after resistance exercise 
training or a combination of both regimens. Intriguingly, Cheema et al. (2011) 
have recently reported that 12-weeks of intradialytic progressive resistance 
training had no effect on TNF-α, IL-1β, IL-6, IL-8, IL-10 and IL-12 levels, while a 
reduction in CRP levels had been previously reported (Cheema et al., 2007a). 
Altogether the available literature indicates that the effect of regular exercise on 
the inflammatory status of CKD patients is still unresolved. The present study 
points towards a strong anti-inflammatory role of moderate aerobic exercise in 
pre-dialysis CKD patients. While our study is limited by its short duration and 
uncontrolled design, it is strengthened by the simultaneous measurement of 
several immune and inflammatory parameters and therefore provides novel 
insights into the anti-inflammatory role of exercise in CKD. 
Some of the mechanisms whereby exercise might have exerted its anti-
inflammatory effects have already been noted above. In addition, it has been 
proposed that the anti-inflammatory effects of regular exercise may be 
mediated by the induction of an anti-inflammatory environment with each bout 
of exercise (Petersen & Pedersen, 2005; Gleeson et al., 2011). We have 
previously demonstrated that exercise of the same mode, intensity and duration 
as prescribed in the present study is capable of such effect in pre-dialysis CKD 
patients (Chapter 4). Another mechanism possibly mediating the anti-
inflammatory effects of exercise is the reduction of visceral fat mass, with a 
subsequent decreased release of adipokines, following exercise training 
(Pedersen, 2009; Gleeson et al., 2011). In the present study, there were minor, 
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yet statistically significant, reductions in body weight and BMI. Of note, exercise 
can reduce visceral fat even in the absence of any weight loss (Ross & 
Bradshaw, 2009). In a separate arm of this study full body dual energy x-ray 
absorptiometry scans revealed that there was an increase in lean body mass 
(baseline: 49.4± 2.2 kg vs. 1-month: 50.1 ± 2.3 kg) and a reduction in fat mass 
(baseline: 28.1 ± 2.4 kg vs. 1-month: 27.5 ± 2.4 kg) following the exercise 
intervention (Clapp, 2010). These findings are suggestive of a possible 
involvement of the adipocytes in the anti-inflammatory effects of exercise 
observed in the present study. 
In summary, these findings suggest that regular moderate intensity aerobic 
exercise in pre-dialysis CKD patients seems to be safe from an immune and 
inflammatory perspective. Further, a 1-month home-based exercise programme 
appears to exert anti-inflammatory effects, most likely mediated by a down-
regulation of monocyte activation. Longer duration and controlled trials are 
needed to confirm these potential effects. 
 
  
 
 
 
 
 
 Chapter 6
Effect of 6-months of regular moderate intensity aerobic 
exercise on immunity and inflammation in chronic kidney 
disease patients 
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6.1. Abstract 
We have previously reported that a 1-month exercise intervention in pre-dialysis CKD 
patients exerted anti-inflammatory effects, likely mediated by the observed down-
regulation of monocyte activation, yet did not affect T lymphocyte activation and 
neutrophil degranulation responses. However, the study was limited by its short-
duration and lack of control. Therefore, the present study investigated the effects of 6-
months of regular moderate intensity aerobic exercise on measures of immunity and 
inflammation in pre-dialysis CKD patients using a controlled design. 
Eighteen (11 M, 7 F) pre-dialysis stage 3-5 CKD patients (age 62 ± 8 yrs; eGFR 25.3 ± 
7.9 ml/min/1.73 m2) exercised for 30 min, 5 times/week, for 6-months. The exercise 
programme consisted of brisk walking at a rating of perceived exertion (RPE) in the 
range of 12-14. A further 14 (8M, 6F) pre-dialysis stage 3-5 CKD patients (age 56 ± 15 
yrs; eGFR 29.3 ± 5.6 ml/min/1.73 m2) acted as non-exercise controls. Resting venous 
blood samples were collected at baseline and after 6-months. SEB-stimulated CD4+ 
and CD8++ lymphocyte (CD69 expression) and CD14+CD86+HLA-DR+ monocyte 
activation (HLA-DR and CD86 expression) were determined by flow cytometry. 
Elastase release from unstimulated (plasma elastase) and bacterially-stimulated 
neutrophils, and plasma inflammatory markers (IL-6, IL-10, sTNF-Rs and CRP) were 
measured by ELISA. Data were examined using ANOVAs with mixed design and 
Student’s t-tests (Holm-Bonferroni correction). 
Average RPE response to a standardised 30 min treadmill walking exercise test after 
the training period was lower than at baseline in exercisers only. After 6-months, CD86 
and HLA-DR expression by CD14+CD86+HLA-DR+ monocytes was down-regulated in 
exercisers, but up-regulated in controls. Expression of CD69 by both CD4+CD69+ and 
CD8++CD69+ lymphocytes was down-regulated in exercisers, but did not change in 
controls. Plasma IL-6 showed a tendency to reduction and IL-10 to increase in 
exercisers but was unaltered in controls. Plasma IL-6/IL-10 ratio, reflecting overall 
inflammatory status, was reduced in exercisers, but unchanged in controls. Plasma 
sTNF-RI were reduced and sTNF-RII tended to be reduced in exercisers but unaltered 
in controls. Plasma CRP levels and neutrophil degranulation responses were not 
affected by the exercise intervention. 
These findings confirm that regular walking exercise is safe from an immune and 
inflammatory perspective and has the potential to be an effective anti-inflammatory 
therapy in pre-dialysis CKD patients.  
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6.2. Introduction 
Previous work presented in this thesis suggests that a 1-month home-based 
exercise programme in pre-dialysis CKD patients is associated with an anti-
inflammatory effect, as evidenced by lower inflammatory cytokine levels in the 
circulation and released from stimulated cell cultures, and most likely related to 
the observed down-regulation of monocyte activation (Chapter 5). This is 
important given the chronically inflamed state of patients with CKD and the 
strong association between chronic systemic inflammation and cardiovascular 
disease; the major cause of mortality in these patients (Stenvinkel, 2010). On 
the other hand, 1-month of regular exercise had no effect had on T lymphocyte 
activation and neutrophil degranulation responses (Chapter 5).  
While these findings are encouraging the study was of short duration and had 
an uncontrolled design. It is interesting to note that the available evidence from 
exercise intervention studies assessing immune, particularly T lymphocyte 
function in healthy individuals is suggestive that longer interventions are 
required for alterations to occur (Kohut & Senchina, 2004). Furthermore, the 
fact that the evidence from cross-sectional studies between physically active 
and sedentary individuals is much more compelling regarding immune and 
inflammatory measures compared with data from exercise interventions, further 
support the idea that long-term regular exercise participation might be needed 
for stronger effects to occur (Kohut & Senchina, 2004; Beavers et al., 2010). 
Therefore, the aim of this study was to investigate the effects of 6-months of 
regular moderate intensity aerobic exercise on measures of immunity and 
inflammation in pre-dialysis CKD patients using a controlled design. 
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6.3. Methods 
Patients 
Forty CKD pre-dialysis patients were recruited. The first 20 patients recruited 
were assigned to an exercise programme of 6-months duration, while the other 
20 patients continued with their habitual physical activity (control group). Fifteen 
of the patients in the exercise group were carried into this study from the 1-
month study (Chapter 5) and engaged in an additional period of 5-months of 
exercise training. For this reason randomisation was not possible. 
Experimental and analytical procedures 
Patients in the exercise group were prescribed a home-based exercise 
programme as described in Section 2.3. All patients performed an exercise test 
as described in Section 2.2 at baseline and after 6-months. Resting venous 
blood samples were obtained on both occasions. All analytical procedures are 
detailed in Chapter 2. 
Statistical analysis  
Data are presented as mean ± standard deviation (SD) unless otherwise stated. 
Data were inspected for normality using the Shapiro-Wilk test. If a data set was 
not normally distributed, statistical analysis was performed on the logarithmic 
transformation of the data, but data were back transformed for presentation. 
Outliers were defined as values deviating more than 3 SDs from the mean and 
were excluded from analysis. Baseline data were initially screened using 
Student’s independent t-tests (exercise vs. control). All data was then examined 
using an analysis of variance (ANOVA) with mixed design: within-subjects (time: 
baseline vs. 6-months) x between-subjects (group: exercise vs. control). 
Assumption of homogeneity was checked using Levene’s test. Where 
significant time x group interactions were observed, data were further examined 
using a priori planned Student’s t-tests with Holm-Bonferroni correction as 
follows: paired (baseline vs. 6-months) for each group and independent 
(exercise vs. control) for 6-months data. Effect sizes for these comparisons 
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were calculated according to Cohen (1988) with correction for sample size 
(Hedges, 1981), by dividing the difference between means by the pooled SD. 
Where significant differences between groups were observed at baseline and 
for other related variables, data were further examined by computing the 
absolute (6-months – baseline) or relative (percentage of difference from 
baseline) changes over 6-months for each group and using Student’s 
independent t-tests (exercise vs. control). Statistical significance was accepted 
at P < 0.05. 
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6.4. Results 
Patients’ characteristics at baseline 
Eighteen patients in the exercise group and 14 non-exercise controls completed 
the study. Reasons for dropping out were progression to dialysis (n=2), change 
in personal circumstances (n=2), and lack of motivation (n=4). Baseline 
characteristics of patients that completed the study are shown in Table 6.1. 
There was a similar distribution by gender among the groups (exercise: 61% 
males and 39% females vs. control: 57% males and 43% females) and the 
groups did not differ in terms of age (P = 0.201) and anthropometric 
characteristics (weight: P = 0.271, height: P = 0.619, BMI: P = 0.327). Kidney 
function was also comparable between groups (eGFR: P = 0.533). The majority 
of the patients on each group were in stages 3 and 4 of CKD. 
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Table 6.1. Patients’ characteristics at baseline for each group. 
 
Exercise group 
(n=18) 
Control group 
(n=14) 
Gender (n males / n females) 11 / 7 8 / 6 
Age* (years) 62 ± 8 56 ± 15 
Weight* (kg) 80.2 ± 15.2 87.7 ± 20.9 
Height* (cm) 171 ± 11 173 ± 12 
BMI* (kg/m2) 27.5 ± 4.4 29.3 ± 5.5 
eGFR* (ml/min/1.73 m2) 25.3 ± 7.9 29.3 ± 5.5 
CKD stage# a)     
Stage 3 
Stage 4 
Stage 5 
7 
8 
3 
(39%) 
(44%) 
(17%) 
6 
7 
1 
(43%) 
(50%) 
(7%) 
Primary renal disease# b)     
Renal Vascular Disease 
Cystic/poly 
Glomerulonephritis 
Diabetes 
Pyelonephritis 
Interstitial 
Uncertain 
Other 
3 
2 
3 
1 
2 
0 
4 
3 
(17%) 
(11%) 
(17%) 
(6%) 
(11%) 
 
(22%) 
(17%) 
0 
1 
4 
1 
0 
1 
6 
1 
 
(7%) 
(29%) 
(7%) 
 
(7%) 
(43%) 
(7%) 
Number of comorbidities#     
0 
1 
2 
3 
4 
0 
8 
5 
2 
3 
 
(44%) 
(28%) 
(11%) 
(17%) 
2 
6 
2 
3 
1 
(14%) 
(43%) 
(14%) 
(21%) 
(7%) 
Immunosuppressive therapy# c) 5 (28%) 3 (21%) 
BMI: body mass index 
eGFR: estimated glomerular filtration rate 
CKD: chronic kidney disease 
Data are *mean ± SD or #n (%) 
a) based on eGFR 
b) grouped according to UK Renal Registry (2010) 
c) excluded from the analysis of immune and inflammatory parameters 
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Exercise test outcomes 
The average walking speed during both exercise tests did not differ between 
groups (exercise: 4.3 ± 1.3 km/h vs. control: 4.0 ± 1.2 km/h, P = 0.479). The 
RPE response to both exercise tests for each group is illustrated in Figure 6.1. 
RPE response did not differ between groups at baseline (Table 6.2; P = 0.693 
and P = 0.759 for average and area under curve, respectively) but it was 
affected by the exercise intervention (Table 6.2; time x group interaction for 
average: F = 5.5, P = 0.026 and area under curve: F = 5.0, P = 0.034). At 6-
months, the RPE response in the exercise group was lower than at baseline 
(Table 6.2; average: P = 0.0003, ES = 1.75 and area under curve: P = 0.00004, 
ES = 1.72), and also lower than the control group at that time (Table 6.2; 
average: P = 0.029, ES = 0.84 and area under curve: P = 0.032, ES = 0.83). In 
contrast, RPE response did not change in the control group (Table 6.2; 
average: P = 0.141, ES = 0.56 and area under curve: P = 0.124, ES = 0.61). 
Plasma lactate response to exercise did not differ between groups at baseline 
(Table 6.2; P = 0.586) and it was unaffected by the exercise intervention (Table 
6.2).  
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Figure 6.1. Rating of perceived exertion (RPE) response to baseline and 6-months 
exercise tests for a) exercise group and b) control group. Data are mean ± SD (n=18 ex; 
n=14 ctrl). 
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Table 6.2. Exercise test outcomes at baseline and 6-months for each group. 
 Exercise group Control group 
 Baseline 6-months Baseline 6-months 
RPE 
 (average) 12.4 ± 0.6 10.4 ± 1.5*
 # 12.3 ± 0.7 11.6 ± 1.5 
RPE  
 (area under curve) 180 ± 18 124 ± 43*
 # 178 ± 18 159 ± 41 
Δ plasma lactate 
 (mmol/l) 1.0 ± 1.1 0.6 ± 0.9 0.8 ± 0.7 0.8 ± 0.7 
RPE: rating of perceived exertion 
Δ = post-ex – pre-ex 
Data are mean ± SD (n=18 ex; n=14 ctrl) 
*P < 0.05 vs. baseline 
#P < 0.05 vs. control  
Body composition 
The exercise intervention did not affect weight or BMI (Table 6.3). However, 
weight and consequently BMI were lower at 6-months in comparison with 
baseline (Table 6.3; main effects of time for weight: F = 8.3, P = 0.007 and BMI: 
F = 9.9, P = 0.004). 
Total and differential blood leukocyte counts 
Total and differential blood leukocyte counts at baseline and 6-months for each 
group are given in Table 6.3. At baseline, there were no differences between 
groups in numbers of circulating leukocytes (P = 0.562), neutrophils (P = 
0.556), lymphocytes (P = 0.973) or monocytes (P = 0.659) and neither of these 
parameters were affected by the exercise intervention. There were also no time 
x group interactions nor main effects of time for haematocrit, haemoglobin or 
plasma volume (Table 6.3). 
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Table 6.3. Body composition, general haematology and total and differential blood 
leukocyte counts at baseline and 6-months for each group. 
 Exercise group Control group 
 Baseline 6-months Baseline 6-months 
Body composition* 
Weight (kg) 80.2 ± 15.2 78.5 ± 15.1 87.7 ± 20.9 85.9 ± 19.5 
BMI (kg/m2) 27.5 ± 4.4 27.0 ± 4.5 29.3 ± 5.5 28.6 ± 4.9 
General haematology* 
Haematocrit 
(%) 36.9 ± 4.5 37.4 ± 3.7 36.3 ± 3.2 35.6 ± 3.8 
Haemoglobin 
(g/dl) 13.6 ± 1.7 13.4 ± 1.4 13.5 ± 1.8 12.6 ± 2.5 
Plasma volume 
(%) 63.1 ± 4.5 62.6 ± 3.7 63.7 ± 3.2 64.4 ± 3.8 
Total and differential blood leukocyte counts# 
Leukocytes 
(x 109/l) 6.7 ± 2.4 6.6 ± 2.1 6.2 ± 1.5 5.9 ± 1.6 
Neutrophils 
(x 109/l 4.3 ± 1.8 4.2 ± 1.6 3.9 ± 1.3 3.6 ± 1.2 
Lymphocytes 
(x 109/l) 1.5 ± 0.6 1.6 ± 0.6 1.5 ± 0.3 1.6 ± 0.5 
Monocytes 
(x 109/l) 0.6 ± 0.2 0.5 ± 0.2 0.5 ± 0.2 0.4 ± 0.2 
BMI: body mass index Data are mean ± SD 
(*n=18 or #n=13 ex; *n=14 or #n=11 ctrl) 
T lymphocyte subsets 
T lymphocyte subset counts are shown in Table 6.4. At baseline, there were no 
differences among groups in the numbers of CD4+ (P = 0.652) and CD8++ (P = 
0.785) lymphocytes. Therefore, the CD4+/CD8++ ratio was also comparable 
between groups (Table 6.4; P = 0.491). There were no time x group interactions 
for any of these measures (Table 6.4). 
 
  
124 
Activation of CD4+ and CD8++ lymphocytes 
The percentages of CD4+ and CD8++ lymphocytes expressing CD69 following 
20 h in vitro SEB stimulation did not differ between groups at baseline (Table 
6.4; P = 0.645 and P = 0.790, respectively) and were also unaffected by the 
exercise intervention (Table 6.4). However, there were main effects of time for 
both CD4+ (F = 21.5, P < 0.0005) and CD8++ (F = 7.4, P = 0.013) percentage of 
positive cells for CD69, which were lower at 6-months in comparison with 
baseline (Table 6.4). SEB-stimulated CD69 expression (GMFI) by either 
CD4+CD69+ or CD8++CD69+ lymphocytes at baseline tended to be higher in the 
exercise group in comparison with the control group (Table 6.4; P = 0.056 and 
P = 0.053, respectively). There was a time x group interaction (F = 6.1, P = 
0.024) and a main effect of time (F = 6.9, P = 0.017) for CD69 expression by 
CD4+CD69+ lymphocytes (Table 6.4), which was down-regulated following the 
exercise intervention in the exercise group (Table 6.4; P = 0.017, ES = 0.59) 
while it did not change in the control group (Table 6.4; P = 0.912). Likewise, a 
time x group interaction (F = 13.0, P = 0.002) and a main effect of time (F = 4.6, 
P = 0.046) were also found for CD69 expression by CD8++CD69+ lymphocytes 
(Table 6.4), which was also down-regulated after 6-months in the exercise 
group (Table 6.4; P = 0.010, ES = 0.65) but remained unaltered in the control 
group (Table 6.4; P = 0.266). Comparisons of the relative changes over 6-
months (i.e. percentage of difference from baseline) between groups in SEB-
stimulated CD69 expression (GMFI) by either CD4+CD69+ (Figure 6.2) or 
CD8++CD69+ (Figure 6.3) lymphocytes confirmed these effects (ES = 1.09 and 
ES = 1.70, respectively). 
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Table 6.4. CD4+ and CD8++ lymphocyte counts and CD4+/CD8++ ratio, percentages of CD4+ 
and CD8++ lymphocytes expressing CD69 and CD69 expression by CD4+CD69+ and 
CD8++CD69+ lymphocytes after 20 h in vitro stimulation with staphylococcal enterotoxin 
B (SEB) at baseline and 6-months for each group. 
 Exercise group Control group 
 Baseline 6-months Baseline 6-months 
T lymphocyte subsets 
CD4+ (x 109/l) 0.6 ± 0.2 0.6 ± 0.2 0.7 ± 0.2 0.7 ± 0.3 
CD8++ # (x 109/l) 0.4 ± 0.3 0.4 ± 0.3 0.3 ± 0.1 0.3 ± 0.1 
CD4+/CD8++ #  2.2 ± 1.6 2.4 ± 2.0 2.3 ± 1.0 2.4 ± 1.0 
CD69+ cells (%) 
CD4+ 24 ± 10 20 ± 8 26 ± 8 22 ± 8 
CD8++ 30 ± 15 24 ± 10 31 ± 10 28 ± 8 
CD69 (GMFI) 
CD4+CD69+ 175 ± 55 143 ± 53* 131 ± 41 130 ± 42 
CD8++CD69+ 110 ± 44 85 ± 32* 77 ± 23 82 ± 23 
GMFI: geometric mean of fluorescence intensity 
#Statistical analysis performed on log-transformed data 
Data are mean ± SD  
(n=10 ex; n=10 ctrl) 
*P < 0.05 vs. baseline 
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Figure 6.2. Relative changes over 6-months in SEB-stimulated CD69 expression (GMFI) 
by CD4+CD69+ lymphocytes for each group. Data are mean and individual values (n=10 ex; 
n=10 ctrl). 
 
Figure 6.3. Relative changes over 6-months in SEB-stimulated CD69 expression (GMFI) 
by CD8++CD69+ lymphocytes for each group. Data are mean and individual values (n=10 ex; 
n=10 ctrl). 
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Activation of CD14+CD86+HLA-DR+ monocytes 
CD86 expression (GMFI) by CD14+CD86+HLA-DR+ monocytes following 20 h in 
vitro SEB stimulation (expressed as a ratio to unstimulated condition) at 
baseline was higher in the exercise group in comparison with the control group 
(Table 6.5; P = 0.015), while HLA-DR expression by the same cells did not 
differ significantly (Table 6.5; P = 0.108). There was a time x group interaction 
for CD86 expression by CD14+CD86+HLA-DR+ monocytes (Table 6.5; F = 24.8, 
P < 0.0005), which was down-regulated following the exercise intervention in 
the exercise group (Table 6.5; P = 0.004, ES = 1.27) but in contrast it was up-
regulated in the control group (Table 6.5; P = 0.018, ES = 0.76). Similarly, a 
time x group interaction was also found for HLA-DR expression by 
CD14+CD86+HLA-DR+ monocytes (Table 6.5; F = 0.6, P = 0.006), which was 
also down-regulated after 6-months in the exercise group (Table 6.5; P = 0.037, 
ES = 0.72) and up-regulated in the control group (Table 6.5; P = 0.043, ES = 
0.51). Comparisons of the relative changes over 6-months (i.e. percentage of 
difference from baseline) between groups in SEB-stimulated CD86 (Figure 6.4) 
and HLA-DR (Figure 6.5) expression (GMFI expressed as a ratio to 
unstimulated condition) by CD14+CD86+HLA-DR+ monocytes confirmed these 
effects (ES = 2.12 and ES = 1.17, respectively). 
Table 6.5. CD86 and HLA-DR expression by CD14+CD86+HLA-DR+ monocytes after 20 h 
in vitro stimulation with staphylococcal enterotoxin B (SEB) at baseline and 6-months for 
each group. 
 Exercise group Control group 
 Baseline 6-months Baseline 6-months 
CD86 (GMFIa)) 2.1 ± 0.8# 1.3 ± 0.3* 1.3 ± 0.5 1.7 ± 0.6* 
HLA-DR (GMFIa)) 3.0 ± 1.7 2.0 ± 0.7* 1.9 ± 0.5 2.3 ± 0.9* 
GMFI: geometric mean of fluorescence intensity  
a)Ratio to unstimulated condition 
Statistical analysis performed on log-transformed data 
Data are mean ± SD 
(n=11 ex; n=10 ctrl) 
*P < 0.05 vs. baseline 
#P < 0.05 vs. control 
  
128 
 
Figure 6.4. Relative changes over 6-months in SEB-stimulated CD86 expression (GMFI 
expressed as a ratio to unstimulated condition) by CD14+CD86+HLA-DR+ monocytes for 
each group. Data are mean and individual values (n=11 ex; n=10 ctrl). 
 
Figure 6.5. Relative changes over 6-months in SEB-stimulated HLA-DR expression (GMFI 
expressed as a ratio to unstimulated condition) by CD14+CD86+HLA-DR+ monocytes for 
each group. Data are mean and individual values (n=11 ex; n=10 ctrl). 
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Neutrophil degranulation (elastase release) 
At baseline, there were no differences between groups for plasma elastase 
concentration, i.e. unstimulated elastase release (P = 0.833) or total and per 
neutrophil elastase release following 1 h in vitro stimulation with bacterial 
extract (P = 0.667 and P = 0.992, respectively) and the exercise intervention 
had no effect on any of these measures (Table 6.6). 
Table 6.6. Plasma elastase (unstimulated elastase release) and total and per neutrophil 
elastase release following 1 h in vitro stimulation with bacterial extract at baseline and 6-
months for each group. 
 Exercise group Control group 
 Baseline 6-months Baseline 6-months 
Plasma elastase (µg /l) 
 68 ± 22 63 ± 22 70 ± 18 62 ± 9 
Total bacterially-stimulated elastase release* (µg /l) 
 3703 ± 1892 3586 ± 2107 3150 ± 1636 2837 ± 1134 
Bacterially-stimulated elastase release per neutrophil* (fg /cell) 
 522 ± 121 539 ± 174 530 ± 144 535 ± 141 
*Statistical analysis performed on log-transformed data Data are mean ± SD  
(n=13 ex; n=11 ctrl) 
Plasma markers of systemic inflammation 
At baseline, there were no differences between groups for plasma IL-6 (Figure 
6.6; P = 0.632), IL-10 (Figure 6.7; P = 0.148), IL-6/IL-10 ratio (Figure 6.8; P = 
0.318), sTNF-RII (Figure 6.10; P = 0.556) and CRP (Figure 6.11; P = 0.897) but 
plasma sTNF-RI concentration was higher in the exercise group in comparison 
with the control group (Figure 6.9; P = 0.009). There were time x group 
interactions for plasma IL-10 (Figure 6.7; F = 4.8, P = 0.043), IL-6/IL-10 ratio 
(Figure 6.8; F = 9.3, P = 0.006) and sTNF-RI (Figure 6.9; F = 7.5, P = 0.013). 
Plasma IL-10 levels tended to be increased after 6-months in the exercise 
group (Figure 6.7; P = 0.074, ES = 0.66) but did not change in the control group 
(Figure 6.7; P = 0.333).  Plasma IL-6/IL-10 ratio was reduced following the 
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exercise intervention in the exercise group (Figure 6.8; P = 0.024; ES = 0.65) 
while it remained unchanged in the control group (Figure 6.8; P = 0.117). 
Plasma sTNF-RI concentration also decreased in the exercise group (Figure 
6.9; P = 0.044, ES = 0.20) and remained unaltered in the control group (Figure 
6.9; P = 0.134). In addition, there was a main effect of group for plasma sTNF-
RI concentration (Figure 6.9; F = 6.3, P = 0.020) with higher overall values 
observed in the exercise group. Trends for time x group interactions were also 
observed for plasma levels of IL-6 (Figure 6.6; F = 4.2, P = 0.054) and sTNF-RII 
(Figure 6.10; F = 3.4, P = 0.082), which tended to be reduced after 6-months in 
the exercise group (Figure 6.6; P = 0.060, ES = 0.40 and Figure 6.10; P = 
0.064, ES = 0.25, respectively) but remained unaltered in the control group 
(Figure 6.6; P = 0.429 and Figure 6.10; P = 0.504, respectively). There was no 
time x group interaction for plasma CRP concentration (Figure 6.11). 
Comparisons of the absolute changes over 6-months (i.e. absolute difference 
from baseline) between groups confirmed the statistical outcomes of the time x 
group interactions but are useful in the interpretation of the observed effects 
and trends as the absolute changes observed for each marker were in opposite 
directions  (Table 6.7). Absolute changes over 6-months were different between 
groups for plasma IL-10, IL-6/IL-10 and sTNF-RI (ES = 0.93, ES = 1.27 and ES 
= 1.15, respectively) and tend to differ for plasma IL-6 and sTNF-RII (ES = 0.88 
and ES = 0.78, respectively), while absolute changes over 6-months in plasma 
CRP did not differ between groups (ES = 0.40). 
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Figure 6.6. Plasma interleukin-6 (IL-6) at baseline and 6-months for each group. Data are 
mean and individual values (n=12 ex; n=10 ctrl); statistical analysis performed on log-
transformed data; time x group interaction (trend): P = 0.054. 
 
Figure 6.7. Plasma interleukin-10 (IL-10) at baseline and 6-months for each group. Data 
are mean and individual values (n=10 ex; n=9 ctrl); statistical analysis performed on log-
transformed data; time x group interaction: P = 0.043. 
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Figure 6.8. Plasma interleukin-6 to interleukin-10 (IL-6/IL-10) ratio at baseline and 6-
months for each group. Data are mean and individual values (n=12 ex; n=11 ctrl); statistical 
analysis performed on log-transformed data; time x group interaction: P = 0.006; *P < 0.05 
vs. baseline. 
 
Figure 6.9. Plasma soluble tumour necrosis factor receptor I (sTNF-RI) at baseline and 6-
months for each group. Data are mean and individual values (n=13 ex; n=10 ctrl); statistical 
analysis performed on log-transformed data; time x group interaction: P = 0.013; *P < 0.05 
vs. baseline; #P < 0.05 vs. control. 
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Figure 6.10. Plasma soluble tumour necrosis factor receptor II (sTNF-RII) at baseline and 
6-months for exercise and control groups. Data are mean and individual values (n=12 ex; 
n=10 ctrl); statistical analysis performed on log-transformed data; time x group interaction 
(trend): P = 0.082. 
 
Figure 6.11. Plasma C-reactive protein (CRP) at baseline and 6-months for exercise and 
control groups. Data are mean and individual values (n=13 ex; n=9 ctrl); statistical analysis 
performed on log-transformed data. 
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Table 6.7. Absolute changes over 6-months in plasma markers of systemic inflammation 
for each group. 
 Exercise group Control group P* 
Δ IL-6 (pg/ml) -2.2 ± 3.6 0.4 ± 2.1 0.054 
Δ IL-10 (pg/ml) 1.5 ± 2.3 -0.5 ± 1.7 0.043 
Δ IL-6/IL-10 ratio -1.0 ± 1.2 0.2 ± 0.6 0.006 
Δ sTNF-RI (ng/ml) -0.5 ± 0.7 0.3 ± 0.7 0.013 
Δ sTNF-RII (ng/ml) -1.7 ± 3.2 1.1 ± 3.9 0.082 
Δ CRP (µg/ml) -0.9 ± 2.2 0.6 ± 2.2 0.370 
IL: interleukin 
sTNF-R: soluble tumour necrosis factor receptor 
CRP: C-reactive protein 
Δ = 6-months – baseline 
*Statistical analysis performed on log-transformed data 
Data are mean ± SD 
(n=see corresponding figure) 
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Effect of additional bicarbonate therapy 
Ten of the 20 patients initially recruited for each group were randomised to 
receive additional oral bicarbonate (target plasma bicarbonate 29 mmol/l) or to 
continue with their usual bicarbonate therapy (target plasma bicarbonate 24 
mmol/l).  
Eight of the 18 patients in the exercise group who completed the study, and 6 of 
the 14 patients in the control group who completed the study received additional 
bicarbonate therapy. 
To investigate the effects of the additional bicarbonate therapy on the exercise 
group data were examined using an ANOVA with mixed design: within-subjects 
(time: baseline vs. 6-months) x between-subjects (treatment: standard vs. 
bicarbonate). 
As expected, there was an effect of the additional bicarbonate therapy on 
plasma bicarbonate concentration (F = 7.0, P = 0.017). At 6-months, plasma 
bicarbonate levels were elevated above baseline levels in the bicarbonate 
group (6-months: 27.4 ± 1.3 mmol/l vs. baseline: 23.1 ± 3.2 mmol/l, P = 0.009) 
but remained unchanged in the standard group (6-months: 25.0 ± 2.5 mmol/l vs. 
baseline: 23.9 ± 2.6 mmol/l, P = 0.137). 
However, there were no effects of the additional bicarbonate therapy on any of 
the immune and inflammatory parameters studied. 
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6.5. Discussion 
This study investigated the effects of 6-months of regular moderate intensity 
aerobic exercise on measures of immunity and inflammation in pre-dialysis CKD 
patients. We found that the exercise intervention down-regulated T-lymphocyte 
and monocyte activation and that these effects were accompanied by 
improvements in the systemic inflammatory status. In contrast, the exercise 
intervention had no effect on the neutrophil degranulation responses. 
The exercise intervention improved exercise tolerance in the exercise group 
only, as indicated by the markedly lower RPE response to the exercise test at 
6-months than at baseline, an effect that was not observable in the control 
group. This confirms the findings from our previous 1-month uncontrolled study 
(Chapter 5) and adds to previous evidence that aerobic exercise training can 
improve exercise tolerance and capacity in pre-dialysis CKD patients (Clyne et 
al., 1991; Eidemak et al., 1997; Boyce et al., 1997; Leehey et al., 2009; Toyama 
et al., 2010; Mustata et al., 2010). CKD is associated with an accelerated 
decline in physical function, reaching levels that significantly impact on clinical 
outcomes, such as morbidity, quality of life and, ultimately, survival 
(Kosmadakis et al., 2010). Here, we provide evidence that a home-based 
intervention involving walking exercise can bring about significant 
improvements in the pre-dialysis CKD patients’ ability to perform sustained 
effort at submaximal levels; an intensity likely to reflect their capacity to perform 
daily living activities. 
In contrast with the findings from our previous 1-month uncontrolled study 
(Chapter 5), the plasma lactate response to the acute exercise test was 
unaffected by the exercise intervention. Despite not reaching statistical 
significance it should be noted, however, that the acute lactate response was 
nearly halved in the exercise group at 6-months while it remained absolutely 
unaltered in the control group. As expected with moderate intensity exercise, 
the exercise-induced rise in plasma lactate levels was only small, which 
perhaps makes it difficult to detect statistical significant changes. In addition, it 
is noteworthy that a separate part of this study has suggested that the expected 
training effect on the lactate response to acute exercise appears to be 
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augmented by the administration of additional bicarbonate (Clapp, 2010). This 
appears to be because a significant reduction in the lactate response was 
observed at 6-months in the group of patients from the exercise group that 
received additional bicarbonate therapy. Although we have continuously 
monitored heart rate (HR) during exercise testing, it was concluded that the HR 
response to the acute exercise test was an unreliable measure of exercise 
tolerance. The reason for this is that there were changes in the patients’ 
prescription of anti-hypertensive medication dosages throughout the study, 
which, in addition, differed between the exercise and control groups 
(Kosmadakis et al., 2011). Hence, HR data is not presented here. 
Total and differential blood leukocyte counts were not affected by the exercise 
intervention, confirming the findings from our previous 1-month uncontrolled 
study (Chapter 5). Disturbances in total and differential blood leukocytes are 
often reported in CKD (Eleftheriadis et al., 2007; Agarwal & Light, 2011). We 
have previously reported that acute exercise of the same mode, intensity and 
duration as prescribed here elicits alterations in total and differential blood 
leukocyte counts after exercise (Chapter 4). In this context, the present findings 
primarily indicate that the exercise regimen used is safe, as there is no 
indication that the acute changes that might occur with each bout of exercise 
affect the resting cell counts from pre-dialysis CKD patients when such exercise 
is performed on a regular basis. 
The exercise intervention had no effect on the in vivo and in vitro neutrophil 
degranulation responses, which is again in agreement with our previous 
findings (Chapter 5). In CKD, neutrophils are known to be in a primed state, 
which is associated with the state of systemic inflammation and oxidative stress 
that accompanies the disease (Sela et al., 2005). We have previously reported 
that acute exercise of the same mode, intensity and duration as prescribed here 
induces spontaneous neutrophil activation after exercise in pre-dialysis CKD 
patients (Chapter 4). The present data confirm that when such exercise is 
performed regularly, it does not aggravate the activation state of neutrophils 
from pre-dialysis CKD patients. Furthermore, neutrophil function is impaired in 
CKD, which is believed to contribute to the high incidence of infections 
(Chonchol, 2006). We have previously shown that improved neutrophil 
  
138 
responsiveness to an in vitro bacterial challenge is observed following an acute 
bout of exercise in pre-dialysis CKD patients (Chapter 4). The present findings 
confirm that such an effect does not appear to translate into improved resting 
neutrophil function when patients engage in regular exercise, but as 
importantly, confirm that regular exercise does not appear to hinder neutrophil 
immune competence in pre-dialysis CKD patients. On the other hand, given that 
data from the control patients are not suggestive of altered in vivo and in vitro 
neutrophil degranulation responses over the 6-months study period, it remains 
to be determined if engagement in regular exercise may confer protection 
against a progressive exacerbation of neutrophil activation and a progressive 
decline in neutrophil function over the longer term. The cross-sectional 
evidence that long-term physical activity may counteract the age-associated 
decline in neutrophil function (Yan et al., 2001) is certainly supportive of 
potential benefits. 
In agreement with our previous findings (Chapter 5) and a previous study in 
haemodialysis patients (Daniilidis et al., 2004), T lymphocyte subset counts and 
their relative distribution, i.e. CD4+/CD8++ ratio, were also unaffected by the 
exercise intervention. The percentages of CD4+ and CD8++ lymphocytes 
expressing CD69 following in vitro SEB stimulation were not affected by the 
exercise intervention, however CD69 expression (GMFI) by these cells was 
down-regulated in the exercise group, while it remained unaltered in the 
controls. These results suggest that regular exercise reduces T lymphocyte 
activation in pre-dialysis CKD patients. This is a very promising effect 
considering that it has been consistently demonstrated that T lymphocytes are 
chronically activated in CKD (Descamps-Latscha et al., 1995; Meier et al., 2002; 
Moser et al., 2003; Litjens et al., 2006).  
Given that T lymphocyte “pre-activation” in CKD patients is associated with 
premature apoptosis and impaired proliferation of these cells (Ankersmit et al., 
2001; Meier et al., 2002; Moser et al., 2003; Meier et al., 2005; 2007), it may be 
speculated that the down-regulation of T lymphocyte activation through regular 
exercise is actually enhanced positive effect for the function of these cells. Of 
interest, TNF-RI is a well known cell death-inducing receptor (Ashkenazi & Dixit, 
1998; Naudé et al., 2011) and previous studies have used the concentrations of 
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plasma sTNF-RI as an indicator of the susceptibility of T cells to undergo 
increased activation-induced cell death in CKD patients (Ankersmit et al., 2001; 
Moser et al., 2003). In the present study, plasma sTNF-RI levels were reduced 
in the exercise group and remained unaltered in the control group. These 
findings match the T lymphocyte activation data and suggest, albeit indirectly, 
that a down-regulation of T lymphocyte activation following the exercise 
intervention was accompanied by reduced apoptosis of these cells. Clearly, the 
impact of regular exercise on T lymphocyte apoptosis and function in CKD 
patients warrants further investigation. 
The exercise intervention also affected monocyte activation. CD86 and HLA-DR 
expression (GMFI) by CD14+CD86+HLA-DR+ monocytes following in vitro SEB-
stimulation were down-regulated in the exercise group, but up-regulated in the 
control group. These results confirm our previous work (Chapter 5) indicating 
that regular exercise reduces monocyte activation in pre-dialysis CKD patients. 
It is likely that this down-regulation of monocyte activation have contributed, at 
least in part, to the observed effects on T lymphocyte activation, as this occurs 
through interactions between the monocyte and the T cell. On the other hand, 
we can only attribute the up-regulation of monocyte activation that was 
observed in the control group to a progressive state of monocyte activation that 
accompanies CKD progression (Descamps-Latscha et al., 1995). 
Possible mechanisms mediating the down-regulation of monocyte activation 
following exercise training have been discussed in Chapter 5. Briefly, given that 
exercise training down-regulates monocyte Toll-like receptor (TLR) 4 
expression (Gleeson et al., 2006; Flynn & McFarlin, 2006) and that activation of 
TLRs up-regulates monocyte expression of HLA-DR and CD86 (Takeda et al., 
2003), it is conceivable that the down-regulation of CD86 and HLA-DR 
observed in the present study was mediated by a down-regulation of TLR 4. An 
alternative explanation proposed was that the down-regulation of monocyte 
activation following regular exercise may be related to a reduced proportion of 
circulating CD16+ monocytes, which are known to express higher levels of 
CD86 and HLA-DR in comparison with classical monocytes (Takeda et al., 
2003). It is interesting to note that IL-10 production is low-to-absent in CD16+ 
monocytes (Ziegler-Heitbrock, 2007). Although we did not perform direct 
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measurements of monocyte production of IL-10 in the present study, we did 
observe a trend for increased systemic levels of IL-10 in the exercise group, 
which may provide some indirect support for a possible shift into a subset of 
circulating monocytes that are able to produce IL-10 following the exercise 
intervention. With these initial findings in mind, the effects of regular exercise on 
the different monocyte subsets and their cytokine production profiles in CKD 
patients certainly deserve further research. 
The effects of regular exercise on systemic markers of inflammation are in 
agreement with our previous findings (Chapter 5). In the exercise group, plasma 
IL-6 concentration tended to be reduced after 6-months, while plasma IL-10 
concentration tended to be increased, resulting in a significantly decreased ratio 
of IL-6 to IL-10 in the circulation. Plasma sTNF-RI and sTNF-RII levels were 
and tended to be reduced, respectively. In contrast, CRP levels remained 
unaltered. None of these markers were, however, altered in the control group 
over the 6-months study period. Although it may be argued that these effects 
were not as statistically sound as desired because of the limited sample size, 
they certainly provide evidence of the potential anti-inflammatory role of regular 
exercise engagement in pre-dialysis CKD patients. This is further strengthened 
by the accompanying anti-inflammatory effects that were observed at the cell 
level. The significance and the underlying mechanisms of these anti-
inflammatory effects of regular exercise in pre-dialysis CKD patients have 
already been thoroughly discussed (Chapter 5). 
An obvious limitation of our study is its non-randomised design and therefore 
the intervention group might have included the patients who where wiling to 
exercise whereas the control group might have included those who where 
unwilling. However, this research project had a pragmatic design and when we 
had some difficulties in recruiting patients to the 1-month pilot study we opted to 
invite them to carry on to the 6-month trial and therefore making randomisation 
unviable. Notwithstanding, we were also concerned to minimize the risk of 
“contamination”, i.e. that patients in the study who met during their regular 
clinical care as well as for study sessions may influence each others’ exercise 
patterns. In this small study, such contamination could have been a significant 
confounder. Given that we have used a sequential design (i.e. only exercisers, 
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and later non-exercisers, were involved in the study at any one time) such 
potential confounder was avoided. 
In summary, these findings confirm that regular moderate intensity aerobic 
exercise in pre-dialysis CKD patients is safe from an immune and inflammatory 
perspective. The 6-months home-based exercise programme exerted anti-
inflammatory effects at both systemic and cell level. These findings suggest that 
regular walking exercise has the potential to be an effective anti-inflammatory 
therapy in pre-dialysis CKD patients. 
 
  
 
 
 
 
 
 Chapter 7
General Discussion 
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The studies reported in this thesis provide compelling evidence that walking 
exercise is safe from an immune and inflammatory perspective and has the 
potential to be an effective anti-inflammatory therapy in pre-dialysis CKD 
patients. 
In Chapter 4, it was demonstrated that a single bout of walking exercise 
induced an overall immune and inflammatory response that was comparable to 
that observed in healthy individuals, with no indication of harmful effects to 
patients’ underlying state of immune dysfunction. Acute exercise induced a 
normal pattern of mobilisation of immune cells. Concerning immune cell 
function, acute exercise had no effect on T lymphocyte and monocyte 
activation, while it actually improved neutrophil responsiveness to a bacterial 
challenge in the recovery period. In addition, acute exercise induced a systemic 
anti-inflammatory environment, evidenced by the marked elevation in circulating 
levels of plasma IL-10 following exercise, which was most likely mediated by the 
observed increase in plasma IL-6 levels. 
In Chapters 5 and 6, it was demonstrated that regular walking exercise exerted 
anti-inflammatory effects, with no apparent detrimental effects to patients’ 
immune and inflammatory status. Regular exercise led to improvements in the 
systemic inflammatory status (ratio of pro-inflammatory IL-6 to anti-inflammatory 
IL-10 cytokine levels) that were accompanied, and most likely mediated, by a 
down-regulation of T lymphocyte (only evident after 6-months) and monocyte 
activation. In addition, a reduction in IL-6 production in PBMC and whole blood 
cultures was also observed, though this was only assessed in the 1-month 
study. On the other hand, regular exercise had no effect on circulating immune 
cell numbers and neutrophil degranulation responses. 
Considering the well-known immune deficient and inflammatory state that 
accompanies CKD (Kato et al., 2008; Carrero & Stenvinkel, 2010), it is 
somewhat surprising that this was the first investigation on the impact of acute 
exercise on measures of immunity and inflammation in CKD patients. 
Nevertheless, it is reassuring that no detrimental effects of acute exercise on 
these measures were observed. In fact, acute exercise appeared to improve 
neutrophil immune competence in the recovery period. Although it was later 
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found that when patients engaged in regular exercise such effect did not 
translate into improved resting neutrophil function, it is still possible that there is 
a window of protection following each exercise bout. Because we have only 
collected blood samples up to 1 h after exercise it would be interesting that 
future studies determine the duration of this effect beyond this time point. In 
addition, it would be relevant to investigate if this improvement in neutrophil 
responsiveness still occurs when patients become accustomed to exercise, i.e. 
if acute exercise confers a temporary protective effect when patients are 
engaged in regular exercise. 
Although acute exercise induced an increase in plasma IL-6 levels, this is likely 
to be originated from the contracting skeletal muscle during exercise and 
unlikely to be preceded by elevations in pro-inflammatory cytokines. In contrast 
to the cytokine cascade in sepsis, where IL-6 appearance is preceded by the 
pro-inflammatory TNF-α and IL-1β, in response to exercise IL-6 is typically the 
first cytokine present in the circulation (Petersen & Pedersen, 2005; Pedersen & 
Febbraio, 2008). In fact, the increase in plasma IL-6 levels is the most likely 
cause of the subsequent elevations in plasma IL-10 and sTNF-Rs levels, and 
therefore the key mediator of the exercise-induced anti-inflammatory 
environment. Given that this is one of the postulated mechanisms for the anti-
inflammatory effects of regular exercise (Petersen & Pedersen, 2005; Gleeson 
et al., 2011), which we have observed in the later studies of this thesis, it would 
be relevant that future studies attempt to determine the exercise intensity that 
elicit the greatest acute anti-inflammatory effects in pre-dialysis CKD patients, 
without obviously compromising their underlying inflammatory state. An ideal 
study would examine the effects of different exercise intensities on the time 
course of changes in circulating cytokines (dose-response study design). Of 
interest, a recent study in healthy volunteers has suggested that compared with 
55% and 65% of , 60 min of treadmill running at 75% of  results in 
a greater increase in circulating IL-6 and IL-1ra but not TNF-α levels (Scott et 
al., 2011). On the other hand, the cytokine response to acute exercise should 
also be assessed at different time points during a regular exercise programme 
to ensure that the anti-inflammatory effects are still occurring when patients 
become adapted to exercise. 
VO2max VO2max
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It can be argued that the observed down-regulation of T lymphocyte and 
monocyte activation are signs of a detrimental effect of regular exercise on the 
orchestration of the adaptive immune response. T lymphocyte function is clearly 
impaired in CKD and it is currently acknowledged that this can be attributed to 
the defective interaction between the APC and the T lymphocyte (Girndt et al., 
2001a; Eleftheriadis et al., 2007; Kato et al., 2008). In fact, defective monocyte 
CD86 expression has been reported in haemodialysis patients (Girndt et al., 
2001b). Although this defect was not observed in pre-dialysis patients, evidence 
of a down-regulation of TLR 4 expression exists for both pre-dialysis (Ando et 
al., 2006; Koc et al., 2011) and haemodialysis (Kuroki et al., 2007; Koc et al., 
2011) patients. Given that exercise training in healthy individuals down-
regulates monocyte TLR 4 expression (Gleeson et al., 2006; Flynn & McFarlin, 
2006) and that activation of TLRs up-regulates monocyte expression of HLA-
DR and CD86 (Takeda et al., 2003) it is possible that the observed down-
regulation of CD86 and HLA-DR was mediated by a down-regulation of TLR 4. 
Although the impact of regular exercise on monocyte TLR expression in CKD 
patients needs to be determined in future studies, it appears that the anti-
inflammatory effects of regular exercise in CKD might be accompanied by some 
degree of impairment of the adaptive immune response. 
However, it is important to recall that the complex state of immune dysfunction 
that accompanies CKD is characterised by immune depression as well as by 
immune activation. Monocytes from CKD patients are “pre-activated” and 
overproduce pro-inflammatory cytokines (Girndt et al., 1995; Higuchi et al., 
1997; Morita et al., 1997; Girndt et al., 1998; Sardenberg et al., 2004). Likewise, 
T lymphocytes from CKD patients show increased expression of early activation 
markers and heightened apoptotic turnover (Stachowski et al., 1991; Meier et 
al., 2000; Ankersmit et al., 2001; Meier et al., 2002; Moser et al., 2003; Meier et 
al., 2005; Litjens et al., 2006; Meier et al., 2007; 2008). Of note, data from non-
exercise control patients in our study indicates a progressive state of monocyte 
activation over the study period. Hence, in the light of our findings it seems that 
the apparent exercise-induced down-regulation of the immune response might 
be a small price to pay for the anti-inflammatory effects. On the other hand, 
seeming paradoxical, besides contributing to reduce inflammation, a down-
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regulation of the “pre-activated” state of immune cells might actually contribute 
to improved immune response in the longer term. The present findings certainly 
indicate that the down-regulation of T lymphocyte and monocyte activation is 
associated with reduced inflammation, evidenced at the systemic level and in 
stimulated cell cultures, but if this is associated with improved immune response 
remains unknown. 
Taken together, our findings do not support that regular exercise can enhance 
immune function in CKD patients. Apart from the complexities associated with 
interpreting T lymphocyte and monocyte activation data in this regard, it was 
observed that regular exercise had no effect on the numbers of circulating 
immune cells and neutrophil function. However, given that these measures also 
remained unaltered in the non-exercise control patients over the study period, it 
is possible that regular exercise might still confer benefits over the longer term. 
Clearly, future studies should investigate the effects of longer exercise 
interventions on other functional aspects of the immune cells, preferably 
measures that are less likely to reflect their activated state. 
Given the strong links between inflammation and cardiovascular disease, the 
leading cause of death in CKD (Stenvinkel, 2010), the present findings are of 
major clinical relevance and further support the incorporation of exercise in the 
routine clinical care of patients with CKD. It is important to highlight that 
exercise rehabilitation in CKD is far behind other chronic disease conditions and 
although current guidelines state that patients with CKD should be encouraged 
to exercise (National Collaborating Centre for Chronic Conditions, 2008), there 
are no specific exercise guidelines for this population. On the other hand, 
although there is mounting evidence of the beneficial effects of exercise in 
CKD, it should be noted that the vast majority of exercise research in CKD has 
been conducted in ESRD, particularly haemodialysis patients (Johansen, 2005; 
Cheema & Singh, 2005; Painter, 2005; Johansen, 2007; 2008; Cheema, 2008; 
Segura-Ortí, 2010; Segura-Ortí & Johansen, 2010; Smart & Steele, 2011). 
While there is no doubt that exercise rehabilitation is important for the ESRD 
population, the potential benefits of incorporating exercise therapy at earlier 
stages of the disease are arguably even greater because there are more pre-
dialysis patients and they have a far greater likelihood of cardiovascular death 
  
147 
than progression to ESRD (Drey et al., 2003; Keith et al., 2004; John et al., 
2004; Go et al., 2004; Foley et al., 2005). Our findings provide evidence that a 
home-based regular walking programme has the potential to reduce the high 
risk of cardiovascular disease in pre-dialysis CKD patients.  
It should be noted that although we have asked the patients to fill in exercise 
diaries, there was no way to quantify exactly how much exercise the patients 
actually performed, which might have led to some inter-individual variability in 
the outcomes. Future studies should use a more accurate and objective method 
of assessing exercise training compliance, such as an accelerometer. 
Obviously the anti-inflammatory effects of regular exercise reported in the 
present thesis need to be confirmed in larger cohorts of pre-dialysis CKD 
patients. In addition, given the close links between wasting, inflammation and 
atherosclerosis in CKD (Stenvinkel et al., 1999; 2002b), future studies should 
also address the impact of resistance exercise. There is initial evidence that 
regular resistance exercise can also induce anti-inflammatory effects in pre-
dialysis CKD patients (Castaneda et al., 2004), but a more in-depth study of 
such effects is warranted. Ideally, investigating both exercise modes alone and 
in combination in representative groups of patients at different CKD stages 
would definitely help tailoring future exercise guidelines for this population. 
In conclusion, this thesis provides convincing evidence that exercise has the 
potential to be an effective anti-inflammatory therapy in pre-dialysis CKD 
patients and may in this way reduce the high risk of cardiovascular disease in 
these very vulnerable patients. However, more research is needed to fully 
elucidate the impact of exercise on the complex state of immune dysfunction 
that accompanies CKD. 
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